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Chapter 1 
A HISTORICAL REVIEW 
In 1971 the JOURNAL of the AMERICAN MEDICAL ASSOCIATION (March) 
and CANCER (December) both published the first results of the Health Insur-
ance Plan trial, which had started in Greater New York (USA) in December 
1963. l 2 The purpose of the trial was to find out whether periodic breast 
cancer screening with mammography and physical examination could reduce 
breast cancer mortality. The study compared a random sample of 31,000 
women, aged 40-64, to whom screening examination were offered, with a simi-
larly constituted control group. In the period available for follow-up there 
were 31 breast cancer deaths in the study group, as opposed to 52 in the 
control group. The effect on mortality was most noticeable in women aged 
50-59 at diagnosis, and relatively weak in the younger age-group. As the 
investigators said in 1971, it would take at least 10 years of follow-up to see 
whether the reduction of mortality by screening would remain evident. And in 
further follow-up studies the positive effect has remained manifest.3 
Meanwhile there have been developments in almost every area of oncology 
with respect to (early) diagnosis in symptomatic patients. It has been 
attempted to apply some of these diagnostic tests as screening tests to asymp-
tomatic persons, e.g. the use of the Papanicolaou smear in early detection of 
cervix carcinoma. In the Netherlands, in February 1972, the Minister of Pub-
lic Health and Environmental Affairs requested the Chairman of the Health 
Council to examine the following issue." "Which tests for early diagnosis of 
malignant diseases are suitable for application on a large scale? For an answer 
to this question the following aspects should be considered: 
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1 . sensitivity and reliability of the test; 
2 . the question whether early detection will in effect bring about a signifi-
cant improvement in the prognosis of the malignant disease; 
3 . feasibility in connection with laboratory capacity, man-power, and costs." 
The Committee on Early Diagnosis of Malignant Diseases, appointed to study 
these problems, published its report in July 1974.* According to this report 
the cytological test of the Papanicolaou cervix smear had already been devel-
oped into a method suitable for mass screening. However, regular screening 
of women above age 30 would present organizational diff iculties. Furthermore, 
it was pointed out in this report that radiological methods can be used for 
early detection of breast cancer. On the basis of the above-mentioned results 
of the HIP study the Committee concluded "that the technique of 
mammography is applicable in early diagnosis of breast cancer by means of 
mass screening, provided that mammography methods with a very low 
radiation dose are used." Although the Committee was aware that a number 
of carcinomas (not specified in the report) are induced by exposure to ioniz-
ing radiation of mammography, it was confident ( in 1974) that soon methods 
with a low radiation dose would become available. 
A year before, in 1973, the Ministry of Public Health and the Netherlands 
Prevention Fund had awarded Utrecht a grant for a screening programme with 
xero-radiography among women aged 50-64. 5 With a later grant , awarded for 
the early diagnosis of cervix carcinoma, the Preventicon Institute was founded 
in Utrecht and in December 1974 the breast cancer screening programme was 
officially started there. 
In 1973 Nijmegen applied to the Prevention Fund for a grant for research 
on an optimal screening technique, involving the specific choice between xero-
radiography and f i lm-radiography. With this technique mass screening of a 
larger target population would then be started than the one in Utrecht, v iz . 
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one including women of age 35-49 and 65+. For although the HIP study 
showed a significant effect in women above age 50 only, it must be possible, 
with modern mammography, to achieve a strong effect on mortality in younger 
women too. In Nijmegen the population screening programme with film-screen 
mammography officially started in January 1975. ' 
In 1977 the Secretary of Public Health and Environmental Affairs appealed 
to the Chairman of the Health Council requesting him to compare the current 
views on early detection of breast cancer with those in the 1974-report. Fur-
ther he asked for recommendations dealing directly with the question whether 
population screening for breast cancer would be desirable and acceptable, 
taking into account the experiences within the Utrecht and Nijmegen screening 
projects. Advice on the following concrete issues was asked f o r . 7 
1 . To what extent have the latest developments in the area of mammography 
contributed to the detection of breast cancer in its earliest possible dis-
ease stage? 
2. Is the radiation dose current ly used such that it will not have any 
adverse effects on the population to be examined? 
3. What sensitivity and specificity do early detection techniques have, nota-
bly physical examination, current mammography, and possible other tech-
niques? 
4. To what extent could early diagnosis improve prognosis considering 
today's methods of treatment for breast cancer? 
5. Can it be indicated which age-groups or h igh-r isk groups qualify for 
screening examinations and at what intervals these examinations should 
take place? 
6. On what conditions could a population screening programme be carried out 
considering the number of radiologists and other experts needed, and are 
special training facilities required? 
- 3 -
7. To what extent should screening projects be restricted to centres where 
adequate equipment and man-power are available? 
8. To what extent and in which way can directives be given for proper 
information to the population which creates reasonable expectations about 
the significance of mass screening? 
At the end of 1981 the Committee on Early Detection of Breast Cancer pre­
sented preliminary answers to the 8 questions in a so-called Interim-Advice.7 
This Inter im-Advice quickly dispensed with question 4, on the improvement in 
prognosis by early detection, by referring to the favourable results of the 
American HIP study. 
In 1976 BAILAR had made critical remarks concerning side-effects inherent 
to mass screening with mammography to the effect that "the possible benefits 
of mammography have received more emphasis in the clinical literature than 
have its defects," and that "no satisfactory investigations of associated radia­
tion hazards have been published." * But, as the Committee put it in its 
answer to the second question, "the actual radiation-load in modern mammog­
raphy is very small. Therefore the probability that this radiation-load induces 
breast cancer is also very small. Compared with risks generally considered 
acceptable or inevitable, like accidents in traffic, households, and industry, 
the risk of breast cancer induction may be considered negligible." Other side-
effects of mass screening were touched upon in the report. The specificity of 
the mammography screening test is assumed to be 99%. This means that on the 
mammograms of 1% of women without breast cancer something suspect is per­
ceived which necessitates a diagnostic test, e.g. a biopsy. The excess num­
ber of this kind of histological examinations is directly caused by the intro­
duction of screening. A different and subtler aspect of overdiagnosis 
concerns the se ree η-detected tumours or, rather, the (small) processes about 
the histological aspects and biological behaviour of which not enough is 
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known.' ' " 1 1 It is a separate issue whether "carcinoma" in situ invariably 
develops into infiltrating carcinoma or whether it stops or even regresses. An 
unknown percentage of cases with this kind of process will be diagnosed as 
having breast cancer, so that treatments like mastectomy or a breast saving 
operation will be decided upon. In this way mass screening leads to possible 
over-treatment. With regard to question 5 about an optimal screening policy, 
involving among other things the frequency of screening and the target popu-
lation with respect to age, the Interim-Advice proposed waiting for the 
results of the screening projects in Nijmegen and Utrecht. 
And this brings us round to the present situation. The following 
evaluation does not attempt to deal with each of the 8 questions in the 
Interim-Advice, but it will aim to establish the impact of biennial screening 
with modern mammography on breast cancer mortality. Some attention will be 
paid to the side-effects of screening. Not until the extent of a decline in 
breast cancer mortality has been established and all side-effects have been 
charted can decisions be made about a national mass screening programme. 
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Chapter 2 
LITERATURE ON SCREENING FOR 
BREAST CANCER 
By way of introduction to the description and evaluation of the Nijmegen 
breast cancer screening programme, this chapter contains f i r s t of all a l itera­
t u r e review focussing on the reasons why (experimental) population screening 
for breast cancer has been and continues to be set up. Next, the sometimes 
preliminary results of several screening projects will be described. Finally, 
some notes will be made on the phenomenon of breast cancer screening. 
Mortality is an important index for public health monitoring and planning. 
Explaining mortality rates in terms of age, birth cohort, and calendar period 
is an important tool for determining the impact of new therapies or earl ier 
diagnosis and for predicting f u t u r e mortality f igures. 
In Western Europe and North America today cancer of the breast is a major 
cause of death among women. It accounts for one-fifth of all female deaths 
from cancer. I t is the second cause of death in women aged 25-34, after acci­
dents and suicide; the leading cause of death in women aged 35-54; and sec­
ond only to cardiovascular diseases in older women. 1 Table 2.1 gives an 
impression of the magnitude of breast cancer mortality and its geographical 
s p r e a d . 2 The accuracy of assignment of cause of death in each country will 
not be discussed. It presents the age-adjusted mortality rates per 100,000 
female population, with the world population as standard. The rank order of 
the mortality rates in the series of 48 countries is indicated in parentheses. 
Since the 1950s the breast cancer mortality rates in high-rate countries 
have f u r t h e r increased b y an average of 0 . 5 - 1 per cent per calendar y e a r , 
mainly as a result of increasing rates among postmenopausal women. 1 э * s 
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Table 2.1 Breast cancer mortality around the world 1978-79. Age-adjus-
ted mortality rate per 100,000 population per year in 48 countries2 
Country 
United States 
Argentina* 
Australia 
Austria 
Barbados** 
Bulgaria 
Canada* 
Chile 
Cuba* 
Denmark 
Dominican Republic* 
Ecuador* 
Egypt* 
England & Wales 
Fiji* 
Finland* 
France* 
Germany, FR 
Greece 
Guatemala* 
Hong Kong 
Hungary 
Iceland 
Source of Data: World 
* 1978 only; ** 1979 
Morta 
rate 
27.1 
24.7 
23.2 
23.2 
27.4 
15.8 
27.8 
14.1 
9.9 
17.9 
30.6 
4.1 
6.0 
3.4 
33.8 
7.9 
17.6 
21.9 
25.3 
16.2 
2.7 
10.7 
24.6 
27.2 
Health 
only 
lity 
(rank) 
(14) 
(16) 
(20) 
(20) 
(12) 
(30) 
(U) 
(35) 
(38) 
(25) 
( 6) 
(44) 
(42) 
(45) 
( 1) 
(40) 
(26) 
(24) 
(15) 
(29) 
(46) 
(37) 
(17) 
(13) 
Statist 
Country 
Ireland* 
Israel 
Italy 
Japan 
Luxembourg 
Mauritius 
Netherlands 
New Zealand 
Nicaragua* 
Northern Ireland* 
Norway 
Poland 
Portugal 
Puerto Rico** 
Romania* 
Scotland 
Singapore 
Spain* 
Sweden 
Switzerland 
Thailand 
Uruguay* 
Venezuelan-
Yugoslavia* 
ics Annual, 1980-82 
Morta 
rate 
32.1 
28.3 
22.3 
6.0 
24.4 
6.6 
31.9 
30.0 
0.0 
32.5 
23.6 
16.6 
17.6 
9.2 
14.2 
33.2 
15.5 
15.8 
22.9 
29.5 
1.2 
29.2 
11.5 
14.5 
lity 
(rank) 
( 4) 
(10) 
(23) 
(42) 
(18) 
(41) 
( 5) 
( 7) 
(48) 
( 3) 
(19) 
(28) 
(26) 
(39) 
(34) 
( 2) 
(32) 
(30) 
(22) 
( 8) 
(47) 
( 9) 
(36) 
(33) 
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Mortality is the reflection of prognostic factors i .e . of the attributes of indi-
viduals and environment that affect the outcome of breast cancer disease. 
The environmental factors include medical care and therapy, which influence 
disease progress. With respect to screening the question is whether early 
detection of breast cancer will increase the cure rate and hence decrease the 
mortality rate. The cure rate (survival rate) of breast cancer patients is p r i -
marily dependent upon the spread of the disease process at diagnosis. The 
5-year survival percentages according to stage among breast cancer patients 
diagnosed in Upstate New York in 1967-72 (N=1499), were 75% for the 
localized group, 45% for the regional group, whereas none of the distant 
group reached a 5-year surv iva l . 6 "Localized" means that the tumour is con-
fined to the orginal site, whereas "regional" means spread through direct 
extension to neighbouring tissue or involvement of regional lymph nodes. 
These survival percentages according to disease stage are of the same magni-
tude as was found in other USA areas in the 1940s, 1950s, and early 1960s.7 
Earlier diagnosis may have gradually improved the 5-year survival chances for 
the whole group. The latest data from the USA come from the Surveillance 
Epidemiology and End Results Programme of the National Cancer Ins t i tu te . ' In 
this programme the cancer patient survival experience is continually monitored 
for almost 10% of the US population. The 5-year survival rate (1973-79) based 
on 46,959 patients is 63%, disease stage ignored. When adjusted for normal 
mortality expectation, the relative survival rate is 72%. 
In the therapeutical area no fur ther improvements are expected. 9 There-
fore, it is argued, the only way to reduce breast cancer mortality fur ther is 
to prevent the detection of stage I I , I I I , and IV carcinomas (U1CC classifica-
t ion) . This could be effected by breast self examination or physical examina-
tion by the general practit ioner, by diminishing doctor's and patient's delay, 
and by population screening. The possibility of lowering mortality from breast 
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cancer by detecting the condition in a preclinical stage (without signs and 
symptoms) through mammography was brought up in the USA in the early 
1960s.1 0 1 I Before that time the technique of soft tissue X - r a y examination of 
the breast had been investigated as a possible adjunct to the differential 
diagnosis of clinical breast cancer. Nonpalpable carcinomas of the breast were 
detectable by this technique, and a high degree of reproducibility in the 
interpretation of mammograms was achieved (roughly 85% agreement, 
depending on the underlying lesions) . 1 2 However, certain types of breast 
cancer that are palpable are missed by mammography. Nevertheless, the suc-
cesses in differential diagnosis stimulated a gradual shift in emphasis towards 
the use of this technique for screening asymptomatic women. If this transition 
had taken place unnoted, it might have led to mammography becoming an 
accepted screening technique, like cervical cytology, without ever having 
undergone a test of effectiveness.1 3 In the USA SHIMKIN recognized that the 
climate and time were ripe for a controlled field trial of mammography. l* The 
remaining obstacle was money. It was clear that an adequate trial would be a 
costly enterprise. At that time, research contracts had to be approved by a 
National Cancer Institute Committee. The thought of having millions of women 
screened in radiologists' offices with a test of undocumented effectiveness 
seemed unacceptable to the N C I , and it was able to find the money. 
The tr ial of the Health Insurance Plan 
In 1963 a randomised study was set up involving women from most of the 
medical groups in the Health Insurance Plan of Greater New York . The women 
were stratif ied according to age, size of insured family, and employment 
group through which the family joined the H IP . Then 2 random samples of 
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women aged 40-64 were drawn. The total number of women in each sample was 
31,000. It was hoped that a 20% breast cancer mortality reduction could be 
demonstrated statistically with a group of this size. The study group was to 
receive an initial examination, followed by 3 annual ones. All women were then 
to be followed up (for more than 20 years so f a r ) . Women in the control 
group were to be followed only through medical records. The results of the 
HIP study were extensively p u b l i s h e d . 1 5 1 6 l 7 1 8 l 9 About two-thirds of the 
women actually responded. Nearly 60% of those received all 4 examinations. A 
total of 606 cancers were diagnosed among the 62,000 women during the f i r s t 
5 years of the study; 306 in the study group and 300 in the control group. 
Of the 132 screen-detected cases, 33% were detected by mammography only 
and not by physical examination; 44% were detected by physical examination 
only. More than 70% of the se ree η-detected cancer cases had negative axi l lary 
nodes at the time of s u r g e r y ; only 45% of the control patients was f r e e of 
axil lary lymph node involvement. A f t e r 5, 7 , 9 , and 11 years of follow-up, 
the survival rate of the study group t u r n e d out to be higher than t h a t of the 
control group. It has been estimated that mortality from breast cancer was 
reduced by about 20-30% in all age groups in the study group. This 
decrease was observed from 7 to 14 years after the start of HIP (more recent 
data have not been published y e t ) . 1 9 At f i r s t the reduction of breast cancer 
mortality was not v e r y obvious in the study group aged 40-49 at e n t r y , but 
after 14 years a reduction of 25% was observed in this group too. 
Utrecht 
The favourable results of the HIP study, such as they were f i r s t pub­
lished in 1971, inspired a medical team to set up population screening in 
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Utrecht, the Netherlands. This programme became operational in December 
1974 . ï 0 It was decided to screen only women of age 50-64 at ent ry . This was 
the age-group for which the HIP study had shown statistically significant 
results. The screening programme included a study of the etiology of breast 
cancer, in particular of the relation between nutrit ion and hormonal status. 
The screening examination consisted of inspection, palpation, and xero-
mammography. The attendance rate of the f i rs t screening round was 71.5% 
(14,697 women). From 1977 onwards they were joined by another 8,814 women 
from suburbs of Utrecht. The second screening round was performed after 1 
year , after which the time interval was widened to 2 years for screening 
rounds 3 -4 , and to 3 years for rounds 4 - 5 . The f i f th screening round took 
place in 1983-84. Up to 1977 most cancers (58%) were detected by means of 
mammography only. Just 1 case of cancer would have been missed if palpa-
tion had been left o u t . 2 1 Th i r ty -n ine per cent of the cancers were "minimal" 
cancers, which means either intraductal or invasive and <1 cm. Two-thi rds 
of the patients had a negative axil lary status at surgery; no information 
about the axi l lary status of 10% of the patient group was available. Compre-
hensive data have recently been publ ished. 2 0 Mortality and case fatality rates 
are current ly analysed. 
Nijmegen 
In the pre-screening period in February 1970 modern mammography equip-
ment with a molybdenum-anode was installed in the Department of Radiology in 
the University Hospital in Nijmegen, the Netherlands. The technique involved 
proved capable of detecting non-palpable breast cancer. Almost all of these 
cancers were in stage I . 2 2 This early detection of breast cancer, the favoura-
- 12 -
ble results of the HIP study, the improvement in the quality of mammography 
since that time, and the still relatively poor prognosis of breast cancer: these 
have been reasons to examine the possibility of using mammography as the 
only detection method in a population screening programme for breast cancer. 
The Nijmegen screening programme was launched in January 1 9 7 5 . 2 Э Unlike 
the screening programme in Utrecht, that in Nijmegen did not include physical 
examination, but offered mammography only. Also, the age range of the t a r ­
get population in Nijmegen was wider: women of age 35-49 and 65 and over 
were invited too. The screening interval was 2 y e a r s . The attendance rate 
turned out to be ca. 75% ( 2 0 , 0 0 0 ) ; in the age-group 70 and over this rate 
was less than 25% ( 3 , 0 0 0 females). Among women initially examined the detec­
tion rate was almost 5 per 1000. This rate decreased to 2-3 per 1000 women at 
the second and following examinations. The number of biopsies performed was 
2-3 times as high as the ultimate number of screen-detected cancer cases. Six 
years after the start of the screening programme about 200 screening cancer 
cases had been detected. The same number of cases were diagnosed among 
the nonparticipants. In this period 64 so-called interval cancers were also 
recorded. These are carcinomas that surfaced clinically after a negative 
screening t e s t , but before the next. 
Screening Projects in Sweden 
The projects in Sweden offered single modality mammography in preference 
to physical examination. Since 1974, when it was b e g u n , population screening 
by single-view mammography has been performed in an increasing number of 
regions in Sweden. The f i r s t population-based screening programme was car­
ried out in Gävleborg County and in the urban parish of Sandviken, a small 
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industrial town in Gävleborg County, in the middle of Sweden . 2 ' 2 5 The lat-
ter study population, originally 6,845 women of age 40 and over, was 
screened by means of single oblique-view mammography in 1974, 1977, and 
1980. The attendance rate was over 90%. Of the 111 breast cancers diagnosed 
in the 6-year study period, 78% were detected at screening examinations, 15% 
as interval cancers, and 7% among nonresponders. Sixty- three per cent of the 
cases had tumours in clinical stage I , and 59% had tumours <10 mm. The 
predictive value for patients referred from screening examination to hospital 
was 50%. 
The impact of screening by single-oblique view on breast cancer mortality 
is now being studied in several randomised trials in Sweden. On the initiative 
of the Swedish National Board of Health and Welfare the f i rst started in the 
city of Ma I mo, (randomised on an individual basis) , and (randomised on com-
munity level) in Kopparberg (1977) and Ostergötland (1978) 2 of Sweden's 24 
count ies . 2 ' 2 7 These projects were followed by the Stockholm screening pro-
gramme in 1 9 8 1 . 2 * 
Breast Cancer Detection and Demonstration Projects (USA) 
After the favourable results of the HIP study had been published, the 
Breast Cancer Detection and Demonstration Project (BCDDP) was implemented 
to disseminate the techniques of early detection of breast cancer to both the 
public and the medical profession. The project, which was financed by the 
American Cancer Society and the National Cancer Institute, became operational 
in 1973. By 1975, 29 BCDDP centres had been established at 27 locations 
throughout the United States, and more than 280,000 women had enrolled in 
the programme.2 9 The purpose of each screening project was to have 10,000 
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women participating in the screening programme within 2 years, to screen 
each woman once every year for 5 years, and to follow them up for an addi-
tional 5-year period. Participants were annually screened for breast cancer 
by means of an examination combining medical history, physical examination, 
mammography, and thermography. The screenees were also taught breast self 
examination ( B S E ) , and they were encouraged to practise BSE monthly. Since 
the BCDDP was not originally designed as a research or investigational 
project, no provision was made for the systematic collection of data from the 
centres. It became apparent, however, that data collected in the BCDDP pop-
ulation would provide valuable information about breast disease, and a few 
months after the programme had begun, a Data Management Center (DMC) was 
added. A uniform set of data collection forms was developed, and the DMC 
attempted to acquire and add to the files all data from the operational cen-
t res . 
Screening was completed in March 1981 and a Data Management Advisory 
Group was appointed by the NCI to begin a descriptive analysis of the 
BCDDP data base. The results of the f i rs t 2 rounds were published in 
1979. 2 9 The descriptive analysis became available in 1982.3<l A majority of the 
participants came to all 5 annual screening examinations (51.7 % ) . Approxi -
mately one th i rd of the 3,557 cancers detected at the centers were small: 
either noninfiltrating cancers or infi l trating cancers (<1 cm) . Eighty per cent 
of all cancers detected did not show any evidence of nodal involvement. A 
high proportion of cancers detected within the BCDDP proved localized. 
According to tumour registry data, these patients should have an excellent 
prognosis. The relative contribution of mammography only (no positive physi-
cal f indings) to detection was 41.6 per cent of all cancer cases, compared 
with 8.7 percent for physical examination (no positive mammographical f ind-
ings) . The relative contribution of mammography was impressively high in 
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the detection of smaller cancers: 59 per cent of noninfiltrating cancers and 
52.6 per cent of inf i l trat ing cancers <1 cm. The relative contribution of mam-
mography and physical examination was 33 per cent and 36.4 per cent respec-
t ive ly . 
A summary of 6 of the above-mentioned screening projects is presented in 
table 2 . 2 . I t is quoted from VAN PUTTEN et a l . 3 * and has been updated to 
1983 with new screening data. 
Canada 
The results of the early years of the BCDDPs showed that substantial 
numbers of breast cancers were detected in women over age 50, as well as in 
women under age 50, and a large proportion of these were detected by mam-
mography only. These findings have prompted a trial in Canada with rando-
misation on an individual basis set up for the evaluation of the efficacy of 
mammography and physical examination in women aged 40-49 and of the inde-
pendent effect of mammography in women aged 50-59. Screening began in 
Toronto in January 1980 and will be extended to 8 Canadian cities. So far , 
response to invitations to attend screening has been low. 3 1 Further results 
have not been published yet . 
United Kingdom 
A large population-based tr ial has been initiated in the United Kingdom. 
Eight health districts (each 25,000 women) are part icipating. This study com-
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pares annual screening by mammography and/or physical examination in 2 are-
as. In 2 other areas breast self-examination is propagated. Another 4 areas 
are used as controls.32 This is essentially a non-randomised trial. Initial 
results are available.31 
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Table 2.2 Sunimary of 6 screening programmes 
PROJECT 
Study design 
Start of project 
Number of 
screening rounds 
Interval between 
screening rounds 
Screening test 
HIP 
USA 
randomised con-
trolled trial on 
individual level 
December 1963 
BCDDP 
USA 
repeated follow-up 
for attendere on 
community level 
1973 
MALMO 
Sweden 
randomised 
trial on indi 
vidual basis 
January 1977 
1 year 1 year 
physical examina- combination of medi- cranio-caudal 
tion and mammo- cal history, physi- and mediolate-
graphy cal exam and mammo- ral oblique 
graphy: xero-mammo- view 
graphy or film-screen 
Age-groups 
invited 
Follow-up period 
(published) 
Number of women 
invited 1st time 
Attendance rate 
Detection rate 
1st screening 
(X) 
45-64 years 
at entry 
14 years after 
start19 
31,000 
65% 
2.7 per 1000 
35-74 at entry 
screening completed 
in 198129 
276,593 females 
entered 
5.6 per 1000 
45-69 years 
197926 
21,242 
74% 
7.5 per 1000 
Interval cancer 0.9 per 1000 
rate within 1 year 
after 1st screening 
0.8 per 1000 0.7 per 1000 
Detection rate 
2nd screening 
Mortality 
1.5 per 1000 2.7 per 1000 
30% reduction in not available 
study group 
after 10 years 
not yet availa-
ble 
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PROJECT KOPPARBERG NIJMEGEN UTRECHT 
Sweden Netherlands Netherlands 
Study design 
Start of project 
Number of 
screening rounds 
Interval between 
screening rounds 
Screening test 
Age-groups 
invited 
Follow-up period 
(published) 
Number of women 
invited 1st time 
Attendance rate % 
Detection rate 
1st screening 
Interval cancer 
rate within 1 
year after 1st 
screening 
Detection rate 
2nd screening 
Mortality 
controlled trial, 
randomised on 
community level 
October 1977 
2 
2 1/2 years 
single mediolate-
ral oblique view 
40+ years 
1st screening 
round2' 
47,000 
84% 
7 per 1000 
0.4 per 1000 
2.7 per 1000 in 
age-group 40-54 
(Tabâr 1982) 
not yet available 
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repeated follow-up 
study on a dynamic 
population 
January 1975 
5 
2 years 
single mediolateral 
oblique view (since 
1981 
35-64 in 1975 
Since 1977 all 
women born <1940 
6 years23 
32,519 
75% 
5.2 per 1000 
0.6 per 1000 
2.8 per 000 
not yet available 
prospective 
cohort, repeat-
ed follow-up 
December 1974 
Suburbs: 1977 
5 
1, 1.5, 2, 3 
years 
xeromammogram, 
mediolateral 
plus physical 
examination 
50-64 in 1st 
round 
6 years20 
Utrecht Suburbs 
20.555 13.000 
72% 68% 
Utrecht Suburbs 
7.2 per 6.5 per 
1000 1000 
0.1 per 1000 
based on 3 
cases 
1.3 per 3.4 per 
1000 1000 
not yet availa-| 
ble | 
I 
Comments on breast cancer screening 
The mortality from breast cancer in western countries is estimated to be 
30-40 per 100,000 females per year. In the therapeutical area a spectacular 
break-through is not in sight and there are not any preventive measures to 
avoid the occurrence of breast cancer.9 Early detection and treatment on the 
other hand are expected to decrease the mortality. In this respect mammogra-
phy has made significant contributions to the diagnosis of breast disease in 
symptomatic women of age 50 and over. Since the reports from the BCDDPs 
were favourable, the following statement was approved by the Board of Direc-
tors of the American Cancer Society on June 4th, 1983: 
"Because of the detection of some palpable and small breast cancers and 
because of the reduced radiation exposures now possible with optimum mammo-
graphie technique and carefully monitored equipment, a favorable beni f i t / r isk 
ratio can be expected in women beginning at age 40 and older."3 5 The ACS 
recommends asymptomatic women of age 40-49 to have a physical examination 
of the breast annually, and to have mammography performed at intervals of 
one to two years. Perhaps this recommendation on the part of the ACS is 
somewhat hasty. There are many questions left to be answered and criticism 
on screening is stil l put forward.3 6 37 l e 
False-positive cases 
Maybe both mammography and physical examination are necessary to give 
the screening test an acceptable sensitivity. In order to achieve high sensi-
t i v i ty concessions have to be made with respect to specificity. A lower specif-
icity corresponds with a higher false-positive percentage, which means that a 
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larger number of women without breast cancer have to undergo fur ther diag-
nostic examinations and will prove false-positive cases later on . 
Screening also detects lesions or proliferations that raise the question 
whether they have to be regarded as cancers or as tumours which may never 
develop into inf i l trat ive carcinomas during a woman's l i fet ime.2 5 ^ " The 
following example shows that the identity of a tumour may sometimes be d i f f i -
cult to assess.^" In June 1976, 1810 carcinomas had been detected in the 
BCDDPs, 592 of which were in situ carcinomas or invasive lesions of <1 cm 
tumour size. When the biopsies of 506 of these small tumours (taken from 
women already treated as cancer patients) were later on reviewed by other 
pathologists, 66 of them turned out to be benign, while 22 others were re in-
terpreted as "borderl ine"; 66/506 and 88/506 equal 13% and 17% respectively. 
A second review of the 66 questionable cases by a panel of pathologists 
showed that 48 of them were doubt fu l . * 1 
Radiation-induced breast cancer 
It is also possible that screening causes adverse effects due to the 
carcinoma-inducing property of the procedures used in mammography.17 
Information about the carcinogenic effects of ionizing radiation on the breast 
has been obtained from Japanese atomic bomb survivors, from women undergo-
ing fluoroscopy of the chest to monitor artificial pneumothorax, and from 
women with mastitis treated by radiation. The doses of radiation in these 
studies were greater than those used for diagnosis, but on the assumption 
that the risk is linear down to the lowest levels and that there is no thresh-
old level, the National Academy of Science has estimated that for a breast 
dose of 1 rad 6 new cases of breast cancer will occur per million women per 
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year after a delay of 10 y e a r s . * 2 There has been considerable improvement in 
mammography-tech niques in recent years. In the Netherlands for the purpose 
of mammography nearly always film-screen combinations are used that expose 
the glandular tissue to 0.1 rad or less, and this makes the risk of tumour 
induction almost negl igible. 2 9 
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Chapter 3 
THE THEORETICAL EFFECT OF 
SCREENING ON TODAY'S BREAST 
CANCER MORTALITY 
This chapter discusses the theoretical impact of today's screening on 
breast cancer mortality. In theory the benefits of screening (in the sense of 
a higher cure rate) are considered greater if breast cancer is detected in a 
disease stage earlier than that in which it is diagnosed because of signs and 
symptoms. But is this theory applicable to breast cancer? 1 
ZELEN (1976) gives a lucid exposition of the theory of screening. 2 Sup­
pose, he argues, that the tumour starts to develop at a point in time 0 . See 
f igure 3 . 1 . 
ι ι 
| Curable t Incurable | 
| disease phase I disease phase | 
I • | 
I 0 5 10 15 | 
| Time with breast cancer (years) | 
ι ι 
Figure 3.1 Natural h i s t o r y of b r e a s t 
cancer 
If the tumour is removed surgically or destroyed with radiotherapy when it 
is still localized, treatment will result in c u r e . If the tumour is diagnosed 
after a certain time-period " t " , however, it will have metastasized and no 
longer be considered curable. Not all cases of breast cancer have the same 
progress. The point in time " t " that stands for the transition from curable to 
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incurable varies with each tumour. If at point "O" a total number of N cases 
of breast cancer start to develop, then, at point t i the first tumour will 
already have reached the incurable stage. See figure 3.2. 
Number of 
tumours 
Incurable 
t l 
Time with d isease (years) 
Figure 3.2 Natural h i s tory of a number of N breast 
cancer 
There may be an initial period during which all breast cancers are cura­
ble: if diagnosed and treated then, they will be cured. As time goes on 
without the cancers being diagnosed, some women will enter the incurable dis­
ease stage, and the breast cancer population will consist of a mixture of 
curable and incurable women. If breast cancers remain undiagnosed, all of 
them will become incurable after Τ years. The value of early diagnosis 
depends on the time gained by early diagnosis through screening and on the 
number of breast cancer cases that are still curable at that point. This num­
ber is related to the prevalence of the different kinds of breast cancer with 
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respect to growth r a t e . The dividing-line drawn in f i g u r e 3 . 2 indicating c u r a ­
ble and incurable disease stages may actually be quite d i f f e r e n t . In f i g u r e 3 . 3 
4 different, theoretically possible, lines are drawn, line С being the one from 
f igure 3 . 2 . 
Number of 
tumours 
Incurable 
Time with disease (years) 
Figure 3.3 Four d i f ferent d i s t r i b u t i o n s of n a t u r a l 
h i s t o r y with respect to c u r a b i l i t y for N breas t 
cancer cases 
Line A indicates t h a t a relatively large number of these developing tumours 
have made the transition from the curable stage to the incurable stage in an 
early phase. Line D draws the opposite situation. Line В suggests the exis­
tence of 2 kinds of tumours: one variety that rapidly enters the infaust stage 
and another that grows slowly and is characterised by a rather benign natu­
ral history. 
It is difficult to predict whether a somewhat earlier detection will result in 
a substantial therapeutical improvement, or, conversely, whether a considera-
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Ы у earlier detection will have any impact at al l. This depends on the point in 
the natural history when the diagnosis is made nowadays and on the actual 
dividing-l ine. T h a t population screening can have a favourable effect on 
breast cancer mortality was shown in the HIP t r i a l . ' Within 10 years after the 
s t a r t of the HIP population screening programme, a mortality reduction of 30% 
was achieved.* Since that time the detection capability of mammography has 
improved strongly. Consequently more tumours of all preclinical disease stages 
should be detected now and more women should benefit from t h e r a p y . Fur­
thermore, because of the improved sensitivity of mammography, more tumours 
in a f a i r l y advanced stage of development will now be detected before they 
become incurable. T h u s , modern mammography could not only produce a 
stronger effect of screening on breast cancer mortality, but the effect would 
also be observable sooner ( t h e f i r s t HIP results were observed 5 years after 
the start of the t r i a l ) . However, this expectation is weakened b y the fact 
that in Nijmegen mammography was used as the only screening modality, 
whereas the HIP study included palpation. Moreover, the screening interval in 
Nijmegen is 2 y e a r s , and not 1 year, as in the HIP study. All in all a rela­
t ively great number of carcinomas in a curable disease stage could be missed 
in Nijmegen, so that the impact on breast cancer mortality would not be as 
strong and prompt as has just been suggested. An additional question is 
whether biennial screening with modern mammography would produce an obvi­
ous mortality reduction among women younger than 50. This has been a con­
troversial question ever since the HIP study was published. Another issue is 
whether the HIP results can be applied to the Nijmegen situation. T h e r e could 
be differences in the nature and the incidence of the carcinomas, and the 
prognosis of today's breast cancer patients may have improved so much that 
early detection by population screening could have less impact than was 
expected. 
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ROBBINS et a l . observe that in the 1940s and 1950s cancers were general-
ly diagnosed earlier than be fore . ' In the Netherlands a similar shift was 
observable. In the 1950s cancers had an average size of 5 cm. 6 In the late 
1960s and early 1970s the average clinical tumour size had shrunken to 3 .5 -5 
cm, while today's average radiological tumour size observed among patients 
diagnosed because of signs and symptoms is estimated to be less than 3 cm. 7 
' Although there are no exact data available in the Netherlands, it is very 
probable that a higher percentage of all breast cancer patients today have 
tumours of a size less than 2 cm. There are no indications that the nature 
and the growth rate of tumours have changed. Other possible explanations for 
this shift to the left of the tumour size may be: 
1 . a greater inclination on the part of patients with small lesions or minor 
signs to go to the general practit ioner; 
2. a greater inclination on the part of the general practitioner to refer 
patients to the specialist; 
3. an increasing willingness, especially in the younger age-groups, to per-
form regular breast self examination, as is propagated by the mass media; 
4. better diagnostics; 
5. mass screening in some places.9 
It is difficult to check whether this decrease in tumour size has also improved 
the prognosis. Recent survival curves are not available in medical l i terature, 
and foreign curves are not directly applicable to the situation in the Nether-
lands because of dif ferent classification systems and differences in the pro-
portional distribution of the patients over the disease stages. The SEER 
project results of a 5-year follow-up study of 46,959 American breast cancer 
patients in the period 1973-1979 show a 5-year survival rate of 63%, and of 
72% after adjustment for normal life expectancy. 1 0 The stage distribution has 
not been published ye t , however. 
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I t is also difficult to estimate the lethality of breast cancer in the Nether­
lands on the basis of incidence and mortality rates, because there are not any 
reliable incidence rates of a long period available. In addition , valid calcula­
tions would be difficult to do, because of the upward t r e n d in the incidence 
mentioned in international l i terature. It is unknown therefore, whether the 
prognosis in the Netherlands is still 50% or whether it has already improved 
independently of population screening. The latter possibility is d o u b t f u l . ' 
On the basis of past evidence it is agreed t h a t the larger the tumour is, 
the more likely it is that the axillary nodes are positive and that tumour 
recurrence and mortality rates are h i g h e r . 1 1 I t was nevertheless speculated in 
the pre-screening period that if all tumours >2.0 cm ( i . e . 70% of the material 
of the National Breast Project regarding Surgical and Adjuvant T h e r a p y ) had 
been removed when they were 1.0-1.9 cm in size, the overall survival would 
have increased b y only 1 1 - 2 0 % . 1 2 This is explained by the fact that tumour 
size is not strongly related to tumour spread. In a long-term American Col­
lege of Surgeons' study of the therapy results for minimal breast cancer 
( i n f i l t r a t e d carcinoma <1 cm, N= 1423, 20% of whom had positive lymph nodes) 
the 5-year survival rate was 6 5 % . 1 Э As a result of screening breast cancer is 
diagnosed earl ier: it was estimated that b y means of modern mammography up 
to 3 years could be g a i n e d . ' " In spite of this, 20 per cent of the screen-
detected cases in Nijmegen proved to have axil lary lymph node involvement.' 
Nearly 20% of all cancer patients within the BCDDPs had positive nodes at 
s u r g e r y t o o . 1 5 On the one hand, t h e n , the average tumour size of today's 
patients is more favourable than 10-20 years ago, and consequently the p r o g ­
nosis could be improved, while on the other hand a substantial p a r t of the 
screen-detected cases t u r n s out to be already affected with regional tumour 
spread. I t is possible that the improvement in prognosis b y early diagnosis, 
as It was observed in the HIP study, will be less strong in Nijmegen. For 
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this reason the proper assessment of the effect of screening on mortality 
deserves great attention. A proper assessment is the more diff icult because 
the Nijmegen project has a nonexperimental study design. When a randomised 
controlled tr ial is done well , a comparison of the mortality rates in the ran -
domised groups to be screened and not to be screened provides a valid est i -
mate of the benefi ts, but the Nijmegen project requires a nonexperimental 
evaluation. A comparison has to be made between the breast cancer mortality 
in the screened and the nonscreened group or a control group. Such a com-
parison has serious limitations. The screened women are self-selected. Selec-
tion factors with respect to screening attendance can be related to the risk of 
developing a particular cancer. In this way, the underlying incidence rate of 
breast cancer may be lower in the screened group than in the nonscreened 
group. This would make the mortality rates of both groups incomparable. 
Selection factors can also be related to health consciousness and willingness to 
comply with the therapeutic regimen, which can be related to the ultimate 
outcome of the disease. This holds for other prognostic factors as well. 
It is very diff icult to control for the effects of these selection factors in a 
trial that is not randomised controlled, and a low breast cancer mortality rate 
among voluntary screenees cannot be validly attr ibuted to screening, unless 
the effect is prompt and substantial. 
In conclusion it can be argued that , considering the favourable results of 
the HIP study, the steady improvement in mammographical techniques, and 
the relatively bad prognosis of a breast cancer patient (case fatality rate 
50%), it must be possible to reduce the breast cancer mortality in Nijmegen by 
means of a population screening programme. The assessment of the efficacy 
and effectiveness of screening, however, is hindered to some extent by the 
nonexperimental study design involving possibly severe selection bias. 
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Chapter 4 
POPULATION SCREENING FOR BREAST 
CANCER BY MEANS OF MAMMOGRAPHY 
IN NIJMEGEN 1975-1982 
Introduction 
This chapter gives a description of the f i rst 4 screening rounds of the 
Nijmegen breast cancer programme. It is a continuation of Hendriks' descrip-
tive study of screening rounds 1 - 3 . l At the same time it constitutes the frame 
work within which the analyses of the next chapters should be considered. A 
summary is given of the organisation of the screening programme, and of 
attendance, re fer ra l , and detection rates. The screening test is br ief ly dis-
cussed in terms of sensit ivity, specificity, and predictive value. Finally, the 
stage distribution of cancers detected among screening participants is com-
pared with that of cancers diagnosed among nonparticipants. An evaluation of 
the impact of screening on breast cancer mortality is presented in chapters 5, 
7 , and 8. 
Organisation of the screening programme 
With the help of the local authorities population screening for breast can-
cer started officially in January 1975. The screening centre is housed in the 
Municipal Health Care building (GG and G D ) . The female inhabitants of Nijme-
gen are invited by the town council of Nijmegen. The names and addresses 
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are taken from the statistical tape of the population department. The tape is 
continuously updated for removal and death mutations. Appointment cards and 
computer cards are made up according to district of residence and sorted in 
such a way that women are invited door by door and street by street (this 
procedure was believed to create a kind of mutual check among invi tees) . In 
the f i rst screening round all women born in the period 1910-1939 were invit -
ed . From the second screening round onwards all women born before 1940 
received an invitation: 30.574 at that time. 
Since early diagnosis of a malignant lesion is an essential point of screen-
ing, an optimal mammographie technique is required to show a lesion in the 
earliest possible stage that necessitates therapy. The quality of mammography 
is dependent on: 
1 . X - r a y equipment, e . g . film-screen combinations and developer techniques; 
2. the required dose of ionizing radiation; 
3 . the positioning technique of the mammographer; 
4 . the film reading by the radiologist. 
In particular a bad positioning technique ( e . g . insufficient compression of the 
breast) can cause mammographical e r r o r s . 2 In Nijmegen, as in many other 
centres, the lateral-view is made in the latero-medial projection and not in the 
medio-lateral projection, because in that way more breast tissue is more accu-
rately represented on the mammogram. Because of radiation hazards, only 1 
view of every breast is made in the latero-medial projection. Since August 
1981 medio-latero-oblique view mammography has been applied. Many tumours 
are localised in the lateral upper quadrant . In oblique-view mammography 
these tumours lie nearer to the fi lm, and are now better represented and rec-
ognized. 1 z The films are processed immediately and studied by the radiogra-
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pher . If no lesions are discovered on this film the examination is f inished. An 
extra view in a craniocaudal direction of both breasts is made, if the quality 
of one of the lateral projections is not good enough for evaluation ( e . g . due 
to overprojection), or if there is a suspect lesion. The frequency of this sec-
ond projection varied with each radiographer and with the occurrence of dys-
plasia, but the second view rate was never more than 5%. The day after the 
screening examination all mammograms are read by the radiologist. I t is stan-
dard procedure not to inform women without mammographical f indings. When a 
mammogram shows evidence of malignancy, the general practitioner is informed 
and advised to refer the patient to hospital for a diagnostic test. The next 
day the patient will receive a letter from the screening centre requesting her 
to visit the general practitioner. In order to reduce the number of unneces-
sary biopsies, a weekly meeting of the so-called Diagnostic Mamma Team takes 
place involving all specialists concerned ( in )d i rect ly with the screening pro-
gramme: radiologists, surgeons, and pathologists. 
At f i rs t , the examinees were required to contribute Df l . 2.50 towards the 
costs of the invitation procedure. After screening round 3 the contribution 
was raised to D f l . 1 0 . - . The actual costs of one examination are (1 .1 .1984) 
D f l . 4 0 . - (= US $ 12.65 or Eng £ 8 .70 ) : D f l . 2 8 . - for personal costs and D f l . 
12 . - for material costs. 
Invitation and attendance 
In the period from January 1975 to December 1982, a screening examination 
for breast cancer took place every 2 years . In screening round 1 
(1975-1976) all women born between 31.12.1909 and 1.1.1940 were invited 
(age-group 3 5 - 6 5 ) . In the following screening rounds women born before 
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1910 were invited too. Thus, in round 1 23,224 women, and in round 2 
30,574 women were invited (see table 4 .1) . 
Table 4 .1 Attendance r a t e s per screening round according t o b i r t h cohort 
Birth 
period 
1935-39 
1930-34 
1925-29 
1920-24 
1915-19 
1910-14 
1905-09 
1900-04 
1885-99 
Total 
Birth 
1st round 1975-
Number 
76 
of women 
invited attended 
4006 
4020 
3939 
4165 
3486 
3608 
23224 
3rd round 1979 
3504 
3506 
3386 
3546 
2900 
2859 
19701 
-80 
Number of women 
period invited attended X 
1935-39 
1930-34 
1925-29 
1920-24 
1915-19 
1910-14 
1905-09 
1900-04 
1885-99 
Total 
3820 2854 
3864 2765 
3774 2609 
4002 2640 
3342 2049 
3386 1843 
2852 1030 
2052 537 
1741 190 
28833 16517 
74.7 
71.6 
69.1 
66.0 
61.3 
54.4 
36.1 
26.2 
10.9 
57.3 
% 
87.5 
87.2 
86.0 
85.1 
83.2 
79.2 
84.8 
2nd round 1977-78 
Number 
invited 
3918 
3935 
3850 
4105 
3432 
3536 
3046 
2339 
2341 
30574 
4th round 1981-
Number 
invited 
3684 
3754 
3636 
3854 
3201 
3192 
2674 
1895 
1487 
27377 
of women 
attended % 
82 
of women 
3083 
3039 
2915 
2995 
2424 
2253 
1632 
932 
479 
19752 
attended % 
2635 
2500 
2365 
2395 
1769 
1521 
763 
360 
74 
14382 
71 
66 
65 
62 
55 
47 
28 
19 
5 
52 
5 
78 
77 
75 
73 
70 
63 
53 
39 
20 
64 
(b) 
5.2% 
6 - 6.7% 
0 
1 
3 
7 
5 
0 
0 
5 
• 7.0% 
• 7.6% 
• 9.3% 
•10.4% 
•12.6% 
-10.4% 
• 7.8% 
•10.4% 
7 
2 
7 
0 
6 
7 
6 
8 
5 
6 
1 
(b/Pl) I 
- . - I 
- 5 
- 7 
- 8 
- 8 
-11 
-13 
-23 
-26 
-38 
-12 
9% 
7% 
1% 
9% 
2% 
1% 
5% 
1% 
0% 
3% 
(b)= slope (per round) of the l i nea r regress ion l i n e for at tendance r a t e s . 
Pl= at tendance r a t e in 1st screening round; (b/Pl)= slope r e l a t i v e to PI ; 
e .g . for b i r t h cohort 1935-39 : (b /P l )= -5 .2 : 87.5 * 100%= -5.9%. 
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In rounds 3 and 4 the number of invited women declined because the c r i -
terion for invitation remained the year of b ir th 1940. The total attendance 
rate in round 1 was 85% and fell to 53% in round 4 . This decline is strongly 
age-dependent. To show th is , all women have been stratified according to 
bir th cohort, as in table 4 . 1 . The youngest bir th cohort 1925-1939 shows a 
high attendance rate ranging from 87% in round 1 to 68% in round 4. The 
attendance rate in bir th cohort 1910-1924 is fa i r ly h igh , ranging from 81% in 
round 1 to 55% in round 4 . Attendance in the oldest cohort (<1910) is low: 
39% in round 2 and 20% in the last round. The bir th cohort specific atten-
dance rates of 4 screening rounds (3 rounds for bir th cohort <1910) were 
analysed for t rend using linear regression. Column ( b ) in table 4 .1 shows the 
slope of the regression line per round. This slope can be interpreted as a 
kind of average decline in the attendance rate per round. In all birth cohorts 
a decrease in the attendance was observed. In order to relate this bir th 
cohort specific decline to the attendance rate in the f i rst round, the ratio 
b /P I (last column table 4 .1 ) was calculated. The older the birth cohort, the 
stronger the decline in attendance. 
In table 4 .2 all women invited in round 4 are stratified according to the 
number of screening examinations. In bir th cohort 1910-1939 47.7% had the 
maximum number of 4 screening examinations; 12% of this cohort never 
entered the screening programme. In the oldest cohort (<1910) 55.3% were 
never screened and only 12.5% all 3 times. 
Detection and predictive value 
As has just been said, women born 1910-1939 could have a maximum of 4 
screening examinations, while women born before 1910 could only have 3. In 
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Table 4.2 D i s t r i b u t i o n (%) of women i n v i t e d in screening round 4 
according t o the number of examinations and b i r t h cohort 
53.1 
51.7 
48.7 
43.0 
34.9 
17.5 
16.3 
17.0 
18.0 
18.7 
10.0 
11.6 
11.5 
13.0 
14.8 
9 . 2 
9 .9 
11.3 
12.6 
13.7 
10.1 
10.6 
11.5 
13.3 
18.0 
Number of women Percentage of women with χ examinations 
Bir th inv i ted in 
period round 4 4x 3x 2x lx never 
1935-39 3684 (=100%) 54.8 17.8 9.9 9.0 8.6 
1930-34 3754 
1925-29 3636 
1920-24 3854 
1915-19 3201 
1910-14 3192 
1910-39 21321 47.7 17.5 11.8 10.9 12.0 
1905-09 2674 
1900-04 1895 
1885-99 1487 
1885-09 6056 
Total 27377 (=100%) 37.5 
21.4 
13.0 
3.0 
12.5 
16.8 
16.0 
13.7 
7.2 
12.3 
12.0 
22.1 
20.6 
16.9 
19.9 
13.0 
40.4 
52.7 
72.9 
55.3 
20.0 
the course of the project it turned out that a number of women did not attend 
one screening round but reattended the next. To calculate the referral rates 
and detection rates only 2 groups of women were taken into account: b irth 
cohort 1910-1939, screened for the f i r s t time in 1975-76, and birth cohort 
1885-1909, screened for the f i r s t time in 1977-78. For these calculations data 
of regular attenders were analysed, and in the case of irregular attendere 
only data collected before the f i r s t examination that was missed. 
This selection was made because irregular attenders who have been 
screened for the second time, but who were f i r s t screened, say, 4-6 years 
ago have a higher breast cancer risk because of a longer screening interval. 
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Table 4.3 Screening results of women screened for the 1st time in 
1975-76 (if born between 1910-39), and in 1977-78 (if born before 
1910). Only regular attenders are analysed 
1ST EXAM 
Birth cohort 
1925-39 
1910-24 
1885-09 
Total 
2ND EXAM 
Birth cohort 
1925-39 
1910-24 
1885-09 
Total 
3RD EXAM 
Birth cohort 
1925-39 
1910-24 
1885-09 
Total 
4TH EXAM 
Birth cohort 
1925-39 
1910-24 
1 
Examined 
N 
10398 
9305 
3041 
22744 
Examined 
N 
8468 
7226 
1492 
17186 
Examined 
N 
7084 
5637 
863 
13584 
Examined 
N 
5892 
4366 
Referred 
N (%) 
117 (1.13) 
137 (1.47) 
61 (2.01) 
315 (1.38) 
Referred 
N (%) 
69 (0.81) 
58 (0.80) 
15 (1.01) 
142 (0.83) 
Referred 
N (%) 
42 (0.59) 
44 (0.78) 
11 (1.27) 
97 (0.71) 
Referred 
N (%) 
36 (0.61) 
32 (0.73) 
Screen-
detected 
24 
52 
30 
106 
Screen-
detected 
13 
29 
6 
48 
Screen-
detected 
11 
19 
4 
34 
Screen-
detected 
5 
15 
1 
Interval 
cancer 
18 
13 
5 
36 
Interval 
cancer 
14 
16 
1 
31 
Interval 
cancer 
16 
9 
-
-
Interval 
cancer 
-
. 
If A is the number of women examined, В the number of women refer­
red, С the number of screen-detected cases, and D the number of 
interval cancer cases, then the sensitivity rate is defined as 
C/(C+D) and the specificity rate as (A-B-D)/(A-C-D). 
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I 
1ST EXAM 
Birth cohort 
1925-39 
1910-24 
1885-09 
Total 
2ND EXAM 
Birth cohort 
1925-39 
1910-24 
1885-09 
Total 
3RD EXAM 
Birth cohort 
1925-39 
1910-24 
1885-09 
Total 
4TH EXAM 
Birth cohort 
1925-39 
1910-24 
1 
I 
Detection 
rate (:103) 
2.31 
5.59 
9.87 
4.66 
Detection 
rate (:103) 
1.54 
4.01 
4.02 
2.79 
Detection 
rate (:103) 
1.55 
3.37 
4.63 
2.50 
Detection 
rate (tlO1) 
0.85 
3.43 
Predictive 
value + 
21% 
38% 
49% 
34% 
Predictive 
value + 
19% 
50% 
40% 
34% 
Predictive 
value + 
26% 
43% 
36% 
35% 
Predictive 
value + 
14% 
47% 
Breast cancer 
Screening + | 
1-
test - | 
1 
+ 
С 
D 
C+D 
-
ι I 
B-C В 
A-B-D A-B 
I 
A-C-D A 
Sensi­
tivity 
57% 
80% 
86% 
75% 
Sensi­
tivity 
48% 
64% 
86% 
61% 
Sensi­
tivity 
41% 
68% 
-
-
Sensi­
tivity 
. 
1 
Speci­
ficity 
99.10% 
99.08% 
98.97% 
99.08% 
Speci­
ficity 
99.34% 
99.60% 
99.39% 
99.45% 
Speci­
ficity 
99.56% 
99.55% 
--
--
Speci­
ficity 
_. 
ι 
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Including these irregular attendere in the group of regular attenders would 
artif icially raise the detection rate. The results are summarized in table 4 . 3 . 
At the f i rs t screening examination the total referral percentage was 1.38, 
ranging from 1.13 in the youngest birth cohort 1925-39 to 2.01 in the oldest 
cohort 1885-1909. This corresponds with the incidence rate commonly found in 
medical l i terature. At the second screening examination the total referral per-
centage was lower: 0 .83 . At the subsequent examinations the referral per-
centages seem to have remained stable at just over 0 .70. This t rend can be 
observed in all birth cohorts. 
The detection rate is the ratio of the number of diagnosed cases of breast 
cancer and the number of examined women. Unlike the referral rate, the 
detection rate is expressed per 1000 examined women in table 4 . 3 . At the 
f i rst screening examination 4.66 cases per 1000 women were detected. This 
rate decreases to 2.5 per 1000 at the third screening examination. The birth 
cohort specific detection rates show a trend similar to the referral rates. 
The predictive value of the mammographie breast cancer tests (predictive 
value positive) is in this study expressed in terms of the number of screen-
detected breast cancer cases per 100 referrals. The predictive value at each 
screening examination was ca. 35%, in other words, 3 or 4 out of 10 women 
referred for diagnostic evaluation were found to have breast cancer. Strat i f i -
cation according to birth cohort shows a predictive value of 14-26% in the 
youngest cohort, 38-50% in the middle cohort, and 36-49% in the oldest 
cohort. 
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Sensitivity and specificity in mammography 
A screening test is expected to mark persons with early disease "positive" 
(sensitivity of the test) and those without "negative" (specificity of the 
t e s t ) . 1 The sensitivity of a screening test is diff icult to estimate because 
there is not a hard and fast criterion by which to judge early disease. An 
acceptable way of estimating the sensitivity would be to follow up the negative 
screenees and see how many of them develop cancers within a certain limited 
time interval . If these interval cases are assumed to have been false neg-
atives, the sensitivity can be assessed by relating these interval cancers to 
the number of cancers detected by the screening test. Obviously, the dura-
tion of the follow-up influences the estimate of sensitivity: the longer the time 
lapse between a last screening examination and a cancer's clinical surfacing, 
the more likely it is that this cancer is not false-negative, but simply was not 
yet detectable at the last screening examination. In table 4 . 3 , the duration 
of follow-up was set at less than 2 years because that is the interval between 
the screening rounds in Nijmegen. In this way the sensitivity was estimated 
to be lower among the younger patients than among the older ones: roughly 
50% vs . 86%. When calculated independently of age, the sensitivity of the 
f i rst examination turns out higher than that of the subsequent examinations: 
75% vs . 61%. A tr ivial explanation is that at the f i rs t examination a high pro-
portion of cases m the so-called detectable preclinical phase will be close to 
producing symptoms and so they are fair ly easily detectable. In subsequent 
examinations a smaller proportion of cases will be close to producing symptoms 
and the same screening test will have lower sensitivity estimates. 
Because population screening on a large scale is involved, the specificity 
of the screening test deserves special attention. The specificity of the test is 
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its capability to identify as such women without breast cancer. A specificity 
of 99% amounts to almost 1% of the total target population being qualified as 
false-positive. They have to sustain adverse effects of screening like unnec-
essary diagnostic evaluation and concomitant anxiety. In a breast cancer 
screening programme the specificity is very easy to calculate. The denomina-
tor of specificity ( I . e . healthy women with respect to breast cancer) can be 
made up of all subjects tested, because the prevalence of women with cancer 
in the detectable preclinical phase is low. The nominator of specificity, the 
number of t rue negatives, can be determined after the results of the subseq-
uent diagnostic evaluation of all referred women have become available. The 
estimated specificity rates are presented in the last column of table 4 . 3 . The 
specificity of the 3 birth cohorts at all screening examinations did not vary 
much, but remained stable at about 99% or more. In the course of the project 
the specificity increased somewhat, most probably as a consequence of an 
improvement in techniques and an accretion of mammographical knowledge. In 
addition, the prevalence of the suspect lesions plays a role, as well as the 
fact that for participants who have been screened more than once material of 
comparison from the last screening examination is available. 
Disease stage 
The disease stage of the screen-detected cases is often studied in order 
that something may be said about the impact of screening on mortality in an 
early phase of the evaluation. The classification system of table 4 .4 is based 
on the largest measurable size on mammogram of a tumour and on the histolo-
gical examination of the axil lary lymph nodes. If the tumour size is <2 cm and 
the lymph nodes are not involved, the tumour is qualified as stage I , and, if 
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not, as stage I I * . If no shadow can be observed on the mammogram (but e.g. 
only microcalcifications), the pathological results are used to classify the dis­
ease stage. This happened in 14% of the cases studied here. In the early 
years of the screening programme it was neither a national nor a local prac­
tice to remove the axillary lymph nodes during the operation and examine 
them histologically. These diagnoses from the period 1975-82 that were made 
after a first invitation to the programme were included in this study; seven 
screening attendere with lobular carcinoma in situ were not included. There 
were 485 cases, who were stratified into nonparticipant, se ree η-detected, 
interval, and so-called pseudo-interval cases. Pseudo-interval cases are 
patients who were screened once and then skipped at least one examination 
before they had breast cancer diagnosed. The results are summarized in table 
4.4. 
T a b l e 4 . 4 D i s t r i b u t i o n of 485 b r e a s t c a n c e r c a s e s d i a g n o s e d a f t e r t h e i r 1 s t 
i n v i t a t i o n and b e f o r e 1983 a c c o r d i n g t o d i s e a s e s t a g e ( I o r 11+) and age a t 
d i a g n o s i s 
Age a t S c r e e n - d e t e c t e d I n t e r v a l c a n c e r Pseudo i n t . c a . N o n p a r t i c i p a n t 
d i a g ­
n o s i s M I 11+ % M I 11+ % M I 11+ % M I 11+ % 
35-49 8 17 15 38% 2 11 18 58% 1 5 9 60% 0 2 4 67% 
50-64 19 76 28 23% 6 20 35 57% 1 3 12 75% 3 5 22 73% 
65+ 24 42 21 24% 1 7 7 47% 0 6 10 63% 2 3 40 89% 
T o t a l 51 135 64 26% 9 38 60 57% 2 14 31 66% 5 10 66 81%* 
The p e r c e n t a g e s d e n o t e t h e r a t i o of t h e number of s t a g e 11+ c a s e s and t h e 
t o t a l number of c a s e s i n t h e d e t e c t i o n c a t e g o r y . 
See e . g . * 81%= 6 6 / ( 5 + 1 0 + 6 6 ) . M= m i s s i n g d a t a w i t h r e s p e c t t o d i s e a s e s t a g e . 
Seven c a s e s of l o b u l a r c a r c i n o m a i n s i t u were e x c l u d e d . 
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I n t e r p r e t i n g this table is diff icult because there are data missing. T w e n t y -
six per cent of the se ree η-detected cases were estimated to have disease 
stage l l + , as opposed to 81% of the nonparticipating breast cancer patients. 
The interval and pseudo-interval cancers constitute an intermediate group. In 
the age-group <50 at diagnosis there is a shift from 67% stage l l + nonpartici-
pant cases to 38% stage II+ screen-detected cases. 33 (7%) out of 485 cases 
were histologically diagnosed for intraductal carcinoma: among screen-detected 
cases the percentage of intraductal carcinoma was 8.4% ( N = 2 1 ) , among interval 
and pseudo-interval cancers 7.8% ( N = 1 2 ) , whereas no case of intraductal car­
cinoma was observed among 81 nonparticipant cases. 
So f a r , a description has been given of the Nijmegen screening results of 
the f i r s t 4 screening rounds. The next chapters will go f u r t h e r into the 
question of the impact of screening on breast cancer mortality in Nijmegen 
covering the period up to the end of 1982. 
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Chapter 5 
BREAST CANCER MORTALITY IN 
NIJMEGEN 1969-1982 
This chapter evaluates trends in mortality from breast cancer in Nijmegen 
in the period 1969-1982. I t is argued by some that a fall in the breast cancer 
mortality could be attr ibuted to the screening programme that started in 1975, 
and that this fall could be regarded as an estimate of the effectiveness of the 
programme. 
Material and methods 
To evaluate trends in mortality, data about the numbers of breast cancer 
deaths were used that were taken from publications of the Central Bureau of 
Statistics ( C B S ) , or directly made available by the C B S . 1 The CBS is the 
institute in the Netherlands that compiles the causes of death according to the 
International Classification of Diseases of the World Health Organisation. The 
data used here are based on death certificates which register breast cancer 
as the primary cause of death. Each death was assigned to the municipality 
where the deceased resided, even if she had died elsewhere. The period 
1969-1982 was studied, because age-specific death numbers from this period 
were available. Population data were also obtained from the CBS. The mortali-
t y rates were estimated with age-specific mid-year population numbers (age 25 
and o v e r ) . The breast cancer mortality in Nijmegen will be compared with that 
in the Netherlands, Arnhem, and some other large municipalities. 
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Temporal and geographical comparisons were based on crude and age-
adjusted mortality rates, and on mortality ratios. Tests of significance and 
homogeneity were performed and 95% confidence limits calculated.2 ' * 5 The 
computer package Statistical Analytical System was used to plot mortality f i g -
ures. Most of the graphs were smoothed by means of spline funct ions. 6 
Results 
On the average 28 women from age-group 25+ died from breast cancer each 
year in Nijmegen in the period 1969-1982. The exact numbers are summarized 
in appendix 5 . 1 . The mean number of female inhabitants (aged 25+ ) in 
1969-1982 was 44,194. Because the numbers of breast cancer deaths were 
small and f luctuat ing, 5-year moving averages were calculated to estimate the 
annual mortality rates. In this way the mortality rates from 1969-1973 were 
averaged to calculate the 1971-rate; the rates from 1970-1974 were averaged 
to calculate the 1972-rate, etc. Figure 5.1 displays these annual breast cancer 
mortality rates. 
There is a clear dip in the annual breast cancer mortality in Nijmegen in 
the mid-1970s, the lowest rate being 52 per 100,000 woman-years. This rate is 
25% below the rates of 1970 and 1980. Since 1975 the mortality has increased. 
To determine whether this trend is located in a particular age-group, the 
age-calendar-specific mortality rates have f i rs t been presented as frequency 
blocks in f igure 5 . 2 . 
Dips in breast cancer mortality occur again in the period 1973-1977, spe-
cifically in the age-groups 50-69. They cannot be attr ibuted to screening. 
Figure 5.3 presents the annual rates from the period 1969-1982 classified 
into 5 age-categories: 35-49, 50-59, 60-69, 70-79, and 80+. The rates are 
connected by means of spline functions. 
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Figure 5.1 Nijmegen 1969-1982: annual breast cancer morta-
lity per 100,000 woman-years, age 25+ 
Calendar-period 
25 30 35 40 45 50 55 60 65 70 75 80+ Age 
Figure 5.2 Breast cancer mortality per 100,000 woman-years in Nijmegen 
1969-1982 according to age-group and calendar-period 
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B r e a s t c a n c e r m o r t a l i t y 
p e r 10 woman-years 
A 80 
360 
240 
120 
age 80+ 
35-49 
τ 1 Γ-
1970 72 74 76 78 80 82 y e a r s 
F i g u r e 5 . 3 B r e a s t c a n c e r m o r t a l i t y p e r 100,000 woman-years i n 
Nijmegen 1969-82 i n 5 a g e - g r o u p s 
As could be concluded from figure 5 . 3 , the level of the age-specific rates 
is fair ly constant, except in the period 1973-76 in the age-group 50-69. 
To adjust for age in the period 1969-1982, indirectly age-standardised mor­
tality ratios (SMR) were calculated. These are displayed in f igure 5 . 4 . Direct 
standardisation would cause too large a fluctuation in the expected numbers of 
breast cancer deaths in the standard population. The mortality rates of the 
Nijmegen sumpopulation 1969-1982 were used as standard. To compute the 
expected number of breast cancer deaths in each of the 5 age-groups, the 
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age-specific rates of the standard population are multiplied by the annual 
numbers of woman-years in Nijmegen. Σ Oi 
SMR = 
The formula for the SMR is: j ;
 E i 
where Oi is the number of breast cancer deaths in the i-th age-group and Ei 
is the expected number of deaths.2 3 * The 95% confidence intervals of the 
SMRs were calculated on the assumption that the observed numbers are 
Poisson-distributed and that the variance of the expected numbers is negligi­
ble because the rates in the standard population are stable. The 95% confi­
dence limits of an observed number are calculated by adding and subtracting 
1.96 times its square root. 5 The calculated SMRs plus the corresponding 95% 
confidence limits are graphed in f igure 5.4, and summarized in appendix 5 . 1 . 
Figure 5.4 Standardized m o r t a l i t y r a t i o s and 95% confidence i n t e r v a l s 
for b r e a s t cancer in Nijmegen 1969-1982; Nijmegen sumpopulation is 
s tandard 
Here the same dip as in f igure 5.2 can be observed. Linear regression 
analysis was applied to the SMRs. The slope of the regression line was almost 
zero: -0.00265 per year; P= 0.85. This suggests a rather stable breast cancer 
mortality pa t tern , but at the same time the 95% confidence limits of the annual 
SMRs indicate what difficulties can be expected when a decline in the 
observed mortality has to be interpreted. 
A geographical comparison 
In this section a simultaneous comparison will be made between the period 
of 1969-1982 in Nijmegen and in the Netherlands. Arnhem, a neighbouring city 
without a screening programme, will be used for comparison too. A list of the 
age-adjusted breast cancer mortality rates 1979-1982 in the 17 largest munici-
palities in the Netherlands will give some idea of the variation of breast can-
cer mortality in comparable cities. 
The 5-year age-specific mortality rates of Nijmegen, Arnhem, and the 
Netherlands are displayed in f igure 5 .5 . The curves of Nijmegen and Arnhem 
oscillate within a narrow margin of the stable curve of the Netherlands. 
For a numerical comparison the 13 age-groups were again reduced to 5 
groups: 35-49, 50-59, 60-69, 70-79, and 80+. As standard population in each 
year the mortality rates of the Netherlands were used. The results are sum-
marized in appendix 5 . 2 . There were no differences in mortality in the period 
1969-1982 between Nijmegen and the Netherlands, and Arnhem and the Neth-
erlands. 
The indirectly age-standarised mortality rates and the SMRs of the 17 
largest municipalities, with the Netherlands as standard, are summarized in 
table 5 . 1 . 
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Breast cancer mortality 
per 100.000 woman-years 
(logarithmic scale) 
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Figure 5.5 Age-specific b reas t cancer m o r t a l i t y r a t e s of Nijmegen, 
Arnhem, and t h e Netherlands 1978-1982 
T h e r e is a str iking variation in mortality rates ranging from 56.5 per 
100,000 woman-years in Groningen to 72.8 in U t r e c h t ( ! ) and 76.6 in Ensc­
hede. A large variation such as in the annual rates of Nijmegen in t h e 
period 1969-82 can also be observed in the simultaneous comparison of 17 
municipalities in the period 1979-82. Again it will be clear that it would be 
diff icult to explain a potential downward mortality t r e n d in Nijmegen as well 
as simultaneously d i f f e r e n t mortality rates in Nijmegen and comparable munici­
palities. 
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Table 5.1 Indirectly age-standardised breast cancer mortality, age-group 
25+, in 17 municipalities of more than 105 inhabitants in 1979-82. Standard 
population: the Netherlands 1979-1982. Rank order within brackets 
ι 
Mean number Breast cancer 95% confidence 
Municipality of female mortality per SMR interval 
inhabitants 105 woman-years 
Amsterdam 
Apeldoorn 
Arnhem 
Breda 
Dordrecht 
Eindhoven 
Enschede 
's-Gravenhage 
Groningen 
Haarlem 
Leiden 
Maastricht 
Nijmegen 
Rotterdam 
Tilburg 
Utrecht 
Zaanstad 
The Netherlands 
365,647 
71,227 
66,680 
60,367 
54,772 
97,605 
71,879 
239,846 
83,668 
81,832 
52,803 
56,649 
75,700 
295,049 
76,719 
121,150 
64,552 
7,149,913 
66.6 
60.3 
65.3 
63.4 
65.3 
71.0 
76.6 
64.1 
56.5 
71.6 
66.6 
57.8 
68.5 
65.9 
57.1 
72.8 
63.4 
62.8 
( 6) 
(14) 
( 9) 
(12) 
( 9) 
( ¿0 
( 1) 
(11) 
(17) 
( 3) 
( 6) 
(15) 
( 5) 
( 7) 
(16) 
( 2) 
(12) 
1.06 
0.96 
1.04 
1.01 
1.04 
1.13 
1.22 
1.02 
0.90 
1.14 
1.06 
0.92 
1.09 
1.05 
0.91 
1.16 
1.01 
Γ -
0.98 , 
0.78 , 
0.85 
0.82 
0.83 
0.96 
1.03 
0.93 
0.75 
0.97 
0.85 
0.73 
0.90 
0.97 
0.73 
1.01 
0.80 
--
1.13 
1.14 
1.22 
1.21 
1.25 
1.30 
1.42 
1.10 
1.06 
1.30 
1.28 
1.12 
1.28 
1.13 
1.08 
1.30 
, 1.21 
--
L 
Discussion 
The breast cancer mortality rates in Nijmegen, other cities, and the Neth­
erlands were analysed to get some insight into the c u r r e n t rates, which could 
perhaps be used to estimate the impact of the screening programme. If the 
30% mortality reduction in the HIP t r i a l , observed 7 years after it started, 
can be applied to the Nijmegen situation, the beginning of a decrease in 
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breast cancer mortality might have been expected in the year 1982, but no 
decrease was observed then. On the other hand, the trend and simultaneous 
analysis showed great statistical fluctuations in the annual numbers of breast 
cancer deaths, with wide 95% confidence intervals. If the annual number of 
deaths in Nijmegen is assumed to be a realisation of a Poisson variable with a 
mean value of 28 deaths, the 95% confidence interval is (18.4; 39.6). A large 
variation in the annual number of deaths was not unusual in the previous 
period 1950-1968 either (see table 5.2). A decrease in mortality has to be evi-
dent for several years at least, before it acquires statistical significance. 
Table 5.2 Total number of breas t cancer deaths in Nijmegen 1950-68 
Calendar 
year 
1950 
1951 
1952 
1953 
1954 
1955 
1956 
1957 
1958 
1959 
Total 
breast 
number of 
cancer 
14 
14 
13 
20 
15 
16 
18 
14 
14 
18 
deaths 
Calendar 
year 
1960 
1961 
1962 
1963 
1964 
1965 
1966 
1967 
1968 
Total 
breast 
1 
number of 
cancer deaths 
23 
23 
18 
22 
21 
17 
29 
23 
18 
1 
Another major limitation of trend study, finally, is the potential for sub-
stantial bias in the effect estimation.7 At the time of the introduction of the 
screening programme, or even before that, other factors may have changed 
that could be expected to influence breast cancer mortality, e.g. changes in 
the breast cancer incidence within a population, changes in the effect of 
- 58 -
therapy on mortality, changes in the degree of malignancy, etc. This could 
be illustrated by the fact that uterus carcinoma mortality (used as a proxy-
variable for cervix carcinoma mortality) turned out to have already declined 
before screening for cervix carcinoma could become effective.* The effect of 
screening on mortality should therefore be prompt and substantial to make 
trend studies relevant. A simultaneous geographical comparison, too, can 
produce bias in the effect estimation. Screened and unscreened areas may dif-
fer in the prevalence of determinants of breast cancer mortality. The inevita-
ble conclusion seems to be that a decrease in mortality figures alone can nev-
er be used as an argument for the effectiveness of screening.9 
The following chapters will further discuss the impact of screening on 
breast cancer mortality by linking individual screening histories to breast 
cancer death. 
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APPENDIX 5.1 
Breast cancer mortality in Nijmegen 1969-1982: data and stat­
istics. Five age-groups (35-49, 50-49, 60-69, 70-79 and 80+) 
were used. Mortality of the sumpopulation 1969-82 was standard 
ι 1 
I Calendar Number of Number of homogeneity | 
| year deaths women SMR 95% CI χ2-score | 
I (all ages) (age 35+) | 
1969 
1970 
1971 
1972 
1973 
1974 
1975 
1976 
1977 
1978 
1979 
1980 
1981 
1982 
34 
24 
25 
32 
20 
21 
17 
24 
29 
32 
24 
31 
36 
37 
30875 
31221 
31418 
31540 
31678 
31844 
32097 
32321 
32478 
32666 
32920 
33257 
33714 
34264 
1.39 
0.96 
0.98 
1.23 
0.76 
0.78 
0.62 
0.86 
1.02 
1.11 
0.82 
1.04 
1.18 
1.20 
0.92 
0.57 
0.59 
0.80 
0.42 
0.44 
0.32 
0.51 
0.65 
0.71 
0.49 
0.67 
0.79 
0.81 
1.85 
1.34 
1.36 
1.66 
1.09 
1.11 
0.91 
1.20 
1.40 
1.50 
1.15 
1.40 
1.57 
1.58 
5.670 
0.656 
2.634 
4.648 
10.171 
3.370 
2.981 
2.541 
4.734 
10.666 
0.885 
2.639 
5.585 
1.264 
To evaluate whether the calculated annual SMR holds in each of 
the five age-groups the test of homogeneity was done. 
5 (Oi-SMR-Ei)2 
The formula is χ 2 = £ 
i=l Ei 
where i stands for age-group i. x2(4 ; 0.95) = 9.488. 
This test shows only significant results in the year 1973 and 
1978 (because X2>9.488) and this means that the SMRs of these 
2 years do not hold for every age-group. 
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APPENDIX 5.2 
Comparison of breast cancer mortality in Nijmegen, Arnhem, and in the 
Netherlands in the period 1969-82 for each year separately; 5 age-groups; 
X2(4 ; 0.95)= 9.488 
Nijmegen 
| (Netherlands 
stand, pop.) 
Arnhem 
(Netherlands 
stand, pop.) 
1 
Year 
69 
70 
71 
72 
73 
74 
75 
76 
77 
78 
79 
80 
81 
82 
69 
70 
71 
72 
73 
74 
75 
76 
77 
78 
79 
80 
81 
82 
SMR 
1.44 
1.02 
0.99 
1.26 
0.78 
0.82 
0.63 
0.91 
1.09 
1.20 
0.84 
1.10 
1.21 
1.22 
1.14 
0.94 
1.09 
1.12 
0.96 
1.19 
0.95 
0.81 
0.96 
1.21 
1.13 
0.97 
1.12 
0.89 
X2-score 
homogeneity 
6.548 
1.829 
0.469 
6.487 
11.307 
4.981 
,4.573 
5.587 
9.974 
7.902 
0.330 
2.742 
9.610 
1.361 
7.049 
7.563 
5.172 
1.108 
4.445 
3.803 
1.484 
1.318 
2.500 
3.221 
5.199 
6.241 
5.684 
12.753 
95% con 
interval 
0.96 
0.62 
0.60 
0.83 
0.44 
0.47 
0.33 
0.54 
0.69 
0.78 
0.50 
0.71 
0.81 
0.83 
0.73 
0.56 
0.69 
0.72 
0.59 
0.78 
0.58 
0.65 
0.58 
0.79 
0.74 
0.60 
0.74 
0.55 
1 
fidence 
for SMR 
1.92 
1.42 
1.38 
1.69 
1.12 
1.16 
0.94 
1.27 
1.49 
1.61 
1.18 
1.49 
1.61 
1.62 
1.55 
1.32 
1.49 
1.52 
1.33 
1.60 
1.32 
0.97 
1.34 
1.63 
1.52 
1.34 
1.52 
1.23 
] : 
1 
For the years 1973, 1977, and 1981 the Nijmegen - The Netherlands compa-
rison yields a x2>9.488. This means that the SMRs of these years do not 
hold for all 5 age-groups and that therefore the SMR is not a valid sum-
mary measure. The 95% confidence interval of the other years shows that 
the breast cancer mortality rates in Nijmegen and The Netherlands do not 
differ. 
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Chapter 6 
METHODS OF ANALYSIS 
Introduction 
Following the descriptive study of the last 2 chapters, this chapter pres-
ents a study of the analytical techniques which will be applied In the next 
chapter. For this purpose the publications of Breslow and Day 1 , Kleinbaum et 
a l . 2 , Schlesselman1, Sturmans*, and Vandenbroucke5 were used. 
The following types of epidemiologic research techniques will be discussed: 
the randomised controlled t r i a l , the cohort study, and the case-control study. 
In a case-control study the odds ratio is a good estimate of the risk ratio of 
screening and breast cancer mortality. Among other factors age has a con-
founding influence on this effect estimate. It can be controlled for by match-
ing on age and calculating the odds ratio with the Mantel-Haenszel formula or 
the maximum likelihood method. A separate section will go fur ther into this 
latter method. The (multiple) logistic regression is a th i rd method of estimat-
ing the odds ratio. By means of this model the effect of screening, controlled 
for age and other confounding factors, can be estimated as well as the joint 
effect of e . g . screening and age on breast cancer mortality. For these estima-
tions the maximum likelihood method is applied too. 
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Randomised controlled tr ial 
Since the 1960s mammography has steadily gamed recognition as a reliable 
method for the purpose of diagnostic examination of patients with signs or 
symptoms involving their breasts. Combined with physical examination mam-
mography would also be suitable for screening asymptomatic women. In this 
way breast cancer would be detected in an early stage so that the death risk 
might be reduced. It remains difficult, however, to assess the actual protec-
tive power of screening against breast cancer mortality because early detec-
tion may not be early enough at al l . What is required here is a t r i a l , i .e . a 
comparison of the breast cancer mortality in 2 groups of women to one of 
which screening is offered. It is essential to the tr ial that both groups are 
alike m all respects except screening status. The only sure way of setting up 
2 such comparable groups is randomisation. This study design was used m 
the breast cancer screening study of the Health Insurance Plan of Greater 
New York , which started m 1963. 62,000 women aged 40-64 and initially free 
of breast cancer were randomly distributed into 2 groups of 31,000 women 
each. Both groups were followed for 7 years after the date of en t ry . To esti-
mate the risk of breast cancer death the proportion of women has to be calcu-
lated that died from breast cancer during the observation period. The 
results are summarized m table 6 1 . 
In the study group the proportion of women that died from breast cancer 
during the 7-year follow-up period is: 165/31,000= 5 .3 per 1000, and in the 
control group: 212/31,000= 6 .8 per 1000. The breast cancer mortality risk 
ratio (RR) is: 
165 212 
RR = / = 0 78 
31 ,000 31 ,000 
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Table 6.1 Cumulative numbers of deaths due to 
breast cancer after 7 years of follow-up from date 
of entry in the Health Insurance Plan trial 
ι 1 
| Breast cancer death | 
| Number of women Yes No | 
| Study group 31,000 165 30835 ] 
| Control group 31,000 212 30788 j 
I I 
As the study design is randomised, the effectiveness of the screening pro­
gramme can be estimated directly b y a comparison of the mortality risks in 
the 2 groups. The screening programme brought about a 22% breast cancer 
mortality reduction. In the HIP study the participants and nonparticipants of 
the study group differ not only with respect to age, but also with respect to 
morbidity and mortality. As far as breast cancer mortality is concerned, the 
participant and nonparticipant groups cannot be compared directly as opposed 
to the study and control groups, which are comparable because of the rando­
misation procedure. 
Cohort study with case-control analysis 
An epidemiologic study is not always randomised controlled. Sometimes a 
nonexperimental design is opted for. In a nonexperimental study the subjects 
are not allocated to the screening and control group by a randomisation pro-
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cedure. In order to determine the effect of screening on mortality in such a 
study, a so-called cohort study design can be used which involves the com­
parison of all screened and unscreened women. To describe this analytic 
method it is assumed here t h a t the screened and unscreened group in the 
cohort study are comparable in all respects except screening status. Both 
groups are followed up and the accumulated numbers of breast cancer deaths 
t h a t occur are counted. See table 6.2 for the basic data lay-out of a cohort 
study. 
Table 6.2 Basic analys i s of a cohort 
study with a follow-up period of Τ years 
ι 1 
Breast cancer death | 
Yes No Total | 
Screened women А В A+B | 
Unscreened women С D C+D | 
I I 
It is expected that if screening is effective, the breast cancer death risk 
will be smaller in the screened group, consisting of A + B women, than in the 
unscreened g r o u p , consisting of C + D women. If both groups are followed up 
for the same period of time the risk ratio ( R R ) of breast cancer death in the 
screened and unscreened group will be 
А С 
RR = / (1) 
A+B C+D 
The results of the HIP study in table 6.1 show t h a t the accumulated num­
bers of breast cancer deaths in the screened and unscreened groups are small 
in comparison with the original size of the groups. This will still be the case 
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if the women are followed up for more than 7 years. Since A and С are small, 
the following approximation of RR (see formula ( 1 ) ) can be obtained: 
A C A C 
RR = / = / ( 2 ) 
A+B C+D В D 
A C A B 
RR = _ / _ _ = _ / _
 ( 3 ) 
В D С D 
The ratio A/C in formula ( 3 ) and table 6.2 is defined as the odds of being 
screened among breast cancer deaths which occurred during the follow-up 
period. Strictly speaking, the odds is the quotient of the proportions of 
(A+C) breast cancer death cases that were screened, A / ( A + C ) , and 
unscreened, С / ( А + С ) . The odds of being screened equals 
( A / ( A + C ) ) / ( C / ( A + C ) ) = A / C . In the same way the quotient B/D in formula ( 3 ) 
and table 6.2 is the odds of being screened among women who did not die 
from breast cancer dur ing the follow-up period ( b u t are still alive or died 
from other causes). I t is the quotient of the probability among the ( B + D ) 
controls of their being screened and not screened: ( B / ( B + D ) ) / ( D / ( B + D ) ) = 
B/D. The quotient of the odds A/C and the odds B/D is called the odds 
ratio ( A / C ) / ( B / D ) . The odds ratio (OR) is a good approximation of the risk 
ratio: see formulas ( 1 ) , ( 2 ) , and ( 3 ) . 
The risk ratio ( R R ) is estimated with a cohort approach, but instead, the 
odds ratio (OR) could be estimated with a case-control approach. Then the 
case group consists of all breast cancer deaths in women with breast cancer 
diagnosed after the start of the study and the control group consists of all 
the other women involved in the study (B+D in table 2, and not C + D ! ) . 
Finally, the odds of being screened among controls, B/D, can be estimated 
much more efficiently in a sample from all controls. If P% (say, 5%) of all con­
trols are randomly sampled, the odds of being screened in this sample can be 
regarded as a reliable estimate of the odds in the whole control group. In a 
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case-control study the breast cancer mortality risk ratio in the screened and 
unscreened groups is very efficiently approximated by an odds ratio. 
Odds ratio according to Mantel and Haenszel 
To estimate the breast cancer mortality risk ratio for screened and 
unscreened women the odds ratio can be determined among breast cancer 
deaths and a sample from all other women invited to the screening programme. 
See table 6.3 for the basic calculus. 
Table 6.3 Distribution of breast cancer 
deaths and controls according to screening 
status 
Screened 
Yes 
No 
Total 
Breast cancer 
deaths 
a 
с 
a+c 
1 
Controls 
b 
d 
b+d Τ 
1 
68 
In this table a, b, c, and d denote the number of women in each cell, and 
T= a + c + b * d the total number of women in the case-control study. The odds 
ratio is calculated as follows 
a b a*d 
OR = — / = ( 4 ) 
с d b*c 
If screening does not have any effect on breast cancer mortality, OR= 1 . 
Then the odds of being screened among the breast cancer deaths is similar to 
that among the controls. If screening has a b e n e f i c i a l ' e f f e c t , then OR < 1 , 
e . g . OR= 0 . 7 0 , which can be interpreted as a 30% death risk reduction. 
The OR estimate may be biased, however, for instance b y age. Age is 
positively correlated with the risk of breast cancer death and negatively with 
attendance in the screening programme. The attendance rate among younger 
women is higher, so the unscreened women tend to be older than the 
screened ones, and will have a higher risk of breast cancer death. The odds 
ratio estimate will be biased unless the confounding influence of age is adjust­
ed for. This means that cases and controls should be of the same age. In the 
Nijmegen case-control study all subjects can be stratif ied into 3 birth cohorts: 
1) 1925-1939, 2) 1910-1924, 3) <1910. Table 6.4 replaces table 6 . 3 . 
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Table 6.4 D i s t r i b u t i o n of b reas t cancer deaths and 
c o n t r o l s according t o screening s t a t u s and b i r t h cohort 
Birth cohort 
1) 1925-1939 
Screened 
2) 1910-1924 
Screened 
3) <1910 
Screened 
1 
Breast cancer 
Yes 
No 
Total 
Yes 
No 
Total 
Yes 
No 
Total 
deaths 
al 
cl 
al+cl 
a2 
c2 
a2+c2 
a3 
c3 
a3+c3 
Controls 
Ы 
dl 
bl+dl 
Ь2 
d2 
b2+d2 
ЬЗ 
d3 
b3+d3 
1 
Tl 
T2 
T3 | 
The ORs can be calculated for the 3 birth cohorts separately. These birth 
cohort-specific odds ratios are: 
a l * d l 
OR(1925-39) = 
Ы * с 1 
a2*d2 
OR(1910-24) = 
Ь2*с2 
a 3 * d 3 
OR(<1910) 
ЬЗ*сЗ 
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If the ORs are relatively constant across the birth cohorts, e . g . if t h e y 
are consistently < 1 , they can be combined to form a summary OR estimate. 
"Summary" implies t h a t the effect of b i r t h cohort has been adjusted f o r . 
MANTEL and HAENSZEL (MH) (1959) proposed a method of estimating such a 
summary OR. 
(a ld l/Tl + a2d2/T2 + a3d3/T3) 
OR-MH = (5) 
(b lc l/Tl + Ь2с2/Т2 + ЬЗсЗ/ТЗ) 
The OR-MH is a weighted average of the ORs from the different birth 
cohorts, where the birth cohorts with more information c a r r y more weight: 
the weighting factors are particularly dependent on T 1 , T 2 , and T 3 . 
Example. Suppose the effect of screening is analysed b y a case-control 
approach to 46 breast cancer death cases and a fivefold number of controls. 
It is checked whether or not these 276 subjects were screened. The results 
are summarized in table 6 . 5 . 
Table 6.5 A d i s t r i b u t i o n of 46 b r e a s t ' c a n c e r 
deaths and 230 c o n t r o l s according t o 
screening s t a t u s 
ι 1 
| B r e a s t c a n c e r C o n t r o l s | 
| d e a t h s | 
| Yes 26 162 | 
| S c r e e n e d | 
i No 20 68 | 
| T o t a l 46 230 | 
ι l 
26*68 
The odds ratio is calculated to be OR = = 0.55 
162*20 
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This can be interpreted as a breast cancer mortality risk reduction of about 
45%. Because the factor "year of b i r t h " may have a confounding influence, all 
subjects have been stratif ied into 2 birth cohorts here: <1920 and 1920-1939 
(women born >1940 were not invited to the screening programme). This could 
give the following results, presented in table 6 . 6 . 
Table 6.6 D i s t r i b u t i o n of the 276 subjects of t a b l e 6.5 according t o 
screening s t a t u s and b i r t h cohort <1920 and 1920-1939 
1 
Birth 
cohort 
<1920 
Screened 
ι 
Yes 
No 
Tota 
Breast 
cancer 
deaths 
12 
15 
1 27 
Controls 
80 
55 
135 
Birth 
cohort 
1920-39 
Screened 
Yes 
No 
Tota 
Breast 
cancer 
deaths 
14 
5 
1 19 
I 
Controls | 
82 | 
13 | 
95 | 
1 
The OR according to Mantel and Haenszel can now be calculated according 
to formula ( 5 ) . 
12*55 14*13 
+ 
135 95 
80*15 82* 5 
+ 
6.805 
— - . — Π г *? 
13.205 
OR-ΜΗ 
135 95 
Adjusted for birth cohort, the OR of screening and breast cancer death is 
now 0 . 5 2 , d i f f e r i n g slightly from the crude OR= 0.55 just found. 
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Matching 
To adjust for the confounding effect of year of birth, cases and controls 
can be stratified into periods of birth year, and a summary OR can be calcu­
lated. Instead, for each case one control can be selected from exactly the 
same year of birth. This is called pair-matching on year of birth. Y(es) and 
N(o) denoting "screened" and "unscreened" respectively, the 4 possible out­
comes for such case-control pairs are ( Υ , Υ ) , ( Υ , Ν ) , ( N , Y ) , and ( N , N ) . 
These 4 possible pairs can be displayed as in table 6.7. 
Table 6.7 C a s e - c o n t r o l s tudy of 4 p o s s i b l e matched p a i r s 
Case Control 
Yes 
Screened 
No 
Case Control 
1 | 0 
0 I 1 
T o t a l 1 
Screened 
Case Control Case Control 
Yes 
No 
T o t a l 
0 
1 
1 
1 
0 
1 
г 
L 
2 
0 
1 
1 
1 
0 
1 
I 
1 
If the whole study population consists of these 4 case-control pairs, the 
OR according to Mantel and Haenszel, adjusted for birth cohort, will be (see 
formula (5) and table 6 . 7 ) : 
1*0/2 + 1*1/2 + 0*0/2 + 0*1/2 1*1/2 
OR-MH = = = 1 
1*0/2 + 0*0/2 + 1*1/2 + 0*1/2 1*1/2 
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This calculation of OR-MH uses only the discordant pairs, viz. pairs in 
which either the case or the control is screened. The product terms a*d/T 
and b*c/T of the concordant pairs always equal zero (1*0/2= 0 ) . Further­
more, if there were Q discordant pairs in which only the case is screened, 
and R discordant pairs in which only the control is screened, the OR-MH 
would be: 
OR-MH 
Q*((l*l)/2) 
R*((l*l )/2) 
The total number of concordant pairs is irrelevant to the OR-MH estimate. 
The results of a case-control study with N case-control pairs matched on year 
of birth can be summarized in the following lay-out, which is different from 
the lay-out used so far. See table 6.8. 
Table 6.8 Screening status of N matched pairs 
1 
Screened 
Case 
Unscreened 
Total 
ι 
Control 
Screened Unscreened 
Ρ Q 1 
R S | 
I I 
P+R Q+S 
1 
Total | 
P+Q | 
R+S | 
N | 
1 
Table 6.8 shows that there are Ρ pairs in which both case and control are 
screened, R pairs in which the case is not screened, whereas the control is, 
etc. The OR-MH is now simply calculated as Q/R. 
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For each case 2 randomly sampled controls from the same year of birth can 
be chosen, instead of 1. The 6 possible outcomes are represented in table 
6.9. 
Table 6.9 Case-control study of 6 poss ib le outcomes for matched t r i p l e t s 
of 1 case and 2 c o n t r o l s 
Case Control Case Control Case Control 
Yes 
Screened 
No 
Total 1 
ι 1 1 
Ι ι Ι ι I 
I I 1 
I о | ι | 
I I . I 
2 3 
1 I 2 
— - I — -
o I о 
Case Control Case Control Case Control 
Screened 
Yes | 
1 
No | 
L 
0 
1 
0 
2 
1 
0 
1 
ι | 
i ¡ 
Total 
The OR according to Mantel-Haenszel is (see formula (5 ) ) : 
1*2/3 + 1*1/3 + 1*0/3 + 0*2/3 + 0*1 /3 + 0*0 /3 1*2/3 + 1*1/3 
0R-MH 
0*0 /3 + 1*0/3 + 2*0/3 + 0*1/3 + 1*1/3 + 2*1 /3 1*1/3 + 2*1 /3 
Again this OR-MH does not use the concordant combinations of 1 case and 
2 controls, in which case and controls are all screened or unscreened. Sup-
pose there are: 
N(1,0) combinations in which the case is screened but the 2 controls are not; 
N(1,1) combinations in which the case and 1 of the 2 controls are screened; 
N(0,1) combinations in which the case is not screened but 1 control is; 
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N(0,2) combinations in which the case is not screened but both controls are. 
The OR-MH will then be, irrespective of the number of concordant combina­
tions: 
N ( l l 0 ) * l * 2 / 3 + N ( l > l ) ' , a * l / 3 
OR-MH =• 
N ( 0 , l ) * l * l / 3 + N ( 0 , 2 ) * 2 * l / 3 
Because the nominator and the denominator of OR-MH include a factor 3, 
the odds ratio is equal to: 
2 * N ( 1 , 0 ) + 1*N(1,1) 
OR-MH = 
1*Ν(0,1) + 2 * N ( 0 ) 2 ) 
When all N combinations of 1 case and 2 controls are grouped as in table 
6.10, the OR-MH can easily be computed. 
Table 6.10 Screening s t a t u s of matched t r i p l e t s of 
1 case and 2 contro l s 
Case 
Screened 
Unscreened 
Numi 
С 
I N(1 
1 N(0 
OR-MH 
>er < 
)
0) 
0) 
2 
3 f 
1 
1 
1  
1 
I 
* 
c o n t r o l s 
1 
N(1,1) 
N(0,1) 
N(1,0) + 
screened 
2 
1 N(1,2) | 
1 1 
ι 1 
N ( 0 , 2 ) 
1 * N ( 1 , 1 ) 
1 * N(0,1) + 2 * N(0,2) 
To this OR-MH the N(0,0) and N(1,2) concordant pairs 
contribute no information 
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The next step is the sampling of 3 controls for each case, all from the 
same year of birth. The 8 possible outcomes are presented in table 6.11. 
Table 6.11 Case-control study using 8 poss ib le outcomes for matched combina­
t ions of 1 case and 3 contro l s 
Case Control Case Control Case Control Case Control 
Yes 
Screened 
No 
2 I 
— - I 
ι I 
Total 1 3 4 1 3 4 1 3 4 1 3 4 
Case Control Case Control Case Control Case Control 
Π 
Yes 
Screened 
No 
ι I 1 
ι I 
Total 
These data can also be grouped as follows: 
Number of controls screened 
Screened 
Case 
Unscreened 
0 1 2 3 
I I I 
ι Ι ι Ι ι Ι ι 
— I 1 1 — 
ι Ι ι Ι ι Ι ι 
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The upper p a r t of tab le 6.11 y ie lds the fo l l ow ing odds rat io accord ing to 
Mantel and Haenszel: 
OR-MH = 
1*3 1*2 1*1 
4 4 4 
1*1 2*1 3*1 
+ + + 
4 4 4 
3*1 + 2*1 + 1*1 
1*1 + 2*1 + 3*1 
Th i s calculus can also be de r i ved f rom the lower p a r t of table 6 . 1 1 . Sup-
pose the re are N ( i , j ) combinat ions w i th j con t ro ls (ou t of 3) screened, where 
i= 0 i f the case is unscreened , and where i= 1 i f the case is screened. See 
tab le 6 .12 . 
T a b l e 6 .12 S c r e e n i n g s t a t u s of matched c o m b i n a t i o n s 
of 1 c a s e and 3 c o n t r o l s 
Sc reened 
Case 
Unscreened 
Number of c o n t r o l s s c r e e n e d 
0 
N ( 1 , 0 ) 
1 N(0,0) 
1 
N ( 1 , 1 ) 
N ( 0 , 1 ) 
2 
N ( 1 , 2 ) 
N ( 0 , 2 ) 
3 
N ( 1 , 3 ) 
N ( 0 , 3 ) | 
1 
The OR-MH computed w i t h the data of tab le 6.12 is 
OR-MH = 
3*N(1,0) + 2*N(1 ) 1) + 1*N(1,2) 
1*N(0,1) + 2*N(0 ,2 ) + 3*N(0,3) 
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The cell entries N(0,0) and N(1,3) are irrelevant to the calculation of 
OR-MH. 
The complete results of a matched study on year of birth with К controls 
for each case can be summarized as in table 6.13. 
Table 6.13 Screening s t a t u s of matched combinations of 1 case 
and К c o n t r o l s 
1 
Screened 
Case 
Unscreened 
ι 
Number of К controls 
0 1 2 
| N(1,0) | N(1,1) 1 N(1,2) 
ι ι 
| N(0,0) | N(0,1) | N(0,2) 
1 1 1 
1 
screened 
К 
... I N(1,K) 
ι 
... | N(0,K) | 
1 I 
The Mantel-Haenszel odds ratio can be written according to formula (6) as 
Σ (K-k+l)*N(l ) k-l) 
k=l 
OR-MH = (6) 
Σ k*N(0,k) 
k=l 
In formula (6) "k" is the number of controls screened; "k" ranges from k= 
0 to k=K. Suppose a case-control study was done involving 62 cases who 
died from breast cancer, and 5*62= 310 women as matched controls. For all 
372 subjects it was checked whether they were screened. The results are 
summarized in table 6.14 according to the basic lay-out of table 6.13. 
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Table 6.14 Distribution of 62 case-control sets according to 
screening status 
Screened 
Case 
Number of controls screened 
ι 1 1 1 
I 2 1 1 I 2 1 A 
U n s c r e e n e d | 0 ¡ 6 | 4 | 5 
I I I I 
T o t a l 
1 1 
13 I 15 | 37 
ι I 
5 I 5 I 25 
I I 
The OR-MH calculated according to formula ( 6 ) is 
5*2 + 4*1 + 3*2 + 2*4 + 1*13 41 
OR-MH = —• = — = 0.55 
1*6 + 2*4 + 3*5 + 4*5 + 5* 5 74 
Maximum likelihood estimation 
(This section can be skipped without loss of continuity) 
In the last section the odds ratio was calculated according to the formula of 
Mantel and Haenszel. Another way of reliably estimating the OR is the so-
called maximum likelihood method. With that it is attempted to f ind the OR 
which best predicts the observed numbers of screened and unscreened cases 
and controls. It is assumed that the actual OR in the t a r g e t population best 
represents the observed numbers. Suppose 62 cases and 310 controls were 
screened as is presented in table 6.15. 
The conditional maximum likelihood method aims to establish the OR 
offering the greatest chance that cell entries 3 7 , 218, 25, and 92 are 
observed, given the f ixed marginals 62, 310, 117, and 255. These marginals 
constitute the condition of 62 cases and 310 controls, of whom 255 are 
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Table 6 15 D i s t r i b u t i o n of 62 cases and 
310 c o n t r o l s according t o screening s t a t u s 
1 
Screened 
I 
Yes 
No 
Total 
Cases 
37 
25 
62 
Controls 
218 
92 
310 
I 
Total 
255 
117 
372 
ι 
screened and 117 are not. If the marginals are given and the left upper cell 
has to contain 37 subjects, the other cell entries are f ixed and no longer 
variable. The probabil ity theory and its applications help to determine the 
probability that the left upper cell contains 37 screened cases, given the mar­
ginals and a y e t unknown OR. 
P r o b a b i l i t y (37 screened cases given the marginals 62, 310, 117, 255 and 0R)= 
i62\ / 310 \ 
\37J 1255-37/ OR3 
62 
Σ 
u=l 
/62] / 310 \ u 
\ u j 1255-и/ OR 
(7) 
The numbers in brackets are binomial coefficients, OR is the unknown 
odds ratio, and " u " ranges from 0 to 62. Numerical computer programmes can 
calculate the odds ratio which maximizes the probability t h a t 37 screened cas­
es are observed. The solution of this is asymptoticly approximated by formula 
( 4 ) : 37*92/218*25= 0 . 6 2 . 
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Actually, the 310 controls of table 6.15 were selected after being matched 
on year of b i r t h . For this reason a matched data analysis should have been 
conducted. In table 6 . 1 5 , which is based on the data of table 6 . 1 4 , the 
matched design was ignored, and an OR= 0.62 was calculated. The OR-MH 
estimation for the same data with the matched design taken into account, gave 
a different value: OR-MH= 0.55 (see table 6 . 1 4 ) . Generally speaking, an 
unmatched analysis of data collected in a matched design leads to an OR 
biased towards OR= 1 . 
On the basis of the data in table 6.14 the OR will now be calculated b y 
means of the maximum likelihood method. To do this the data of table 6.15 
concerning 62 cases and 310 controls are again represented in the basic lay­
out of the matched study design. See table 6 . 1 6 . 
Table 6.16 shows that there are 6 combinations (marked * ) in which the 
case Is unscreened and 1 of the 5 controls is screened. There are also 2 
combinations in which the case is screened and none of the 5 controls a r e : 
see cell e n t r y N ( 1 , 0 ) . This means a total Τ of 2 + 6= 8 combinations in which 
exactly 1 subject is screened: T1= 8. The diagonal lines in table 6.16 indicate 
the pairing of combinations with exactly к subjects screened (k ranges 1 - 5 ) . 
So T4= 9 means 9 combinations in which 4 persons out of 1 case and 5 con­
trols are screened. 
Again the question can be put forward what OR is most likely to give the 
observed cell entries, or, in other words, what is the OR estimated by the 
maximum likelihood method (OR-MLE)? On the analogy of formula ( 7 ) the 
conditional probability that the entire data set of table 6.16 is observed can 
again be written as an equation formula, and the question is which OR maxim­
izes this equation. Mathematical derivation (not presented here) shows t h a t 
maximizing the equation is the same as solving the equation ( 8 ) : 
- 82 -
Table 6.16 Screening status of matched combinations of 1 case and 5 
controls 
Screened 
Case 
Unscreened 
Number of 5 controls screened 
1 2 3 4 
1 
6* 
13 
5 
15 
5 
18 
Number of 5 c o n t r o l s s c r e e n e d 
0 1 2 3 4 5 
ι 1 1 1 1 1 
S c r e e n e d | N ( 1 , 0 ) | N ( 1 , 1 ) | N ( 1 , 2 ) | N ( 1 , 3 ) | N ( 1 , 4 ) | N ( 1 , 5 ) 
Case | 4 c " Η ς - \ - - \ - H r 
U n s c r e e n e d | N ( 0 , 0 ) | N ( 0 , 1 ) | N ( 0 , 2 ) | N ( 0 , 3 ) | N ( 0 , 4 ) | N ( 0 , 5 ) 
I ι ι ι ι ι 
T l T2 T3 T 4 T5 
5 К Tk*k*0R 
Σ N ( l , k - 1 ) = Ζ 
k = l k = l k*0R+K-k+l 
( 8 ) 
Substituting the data of table 6.16 into equation ( 8 ) leads to 
8*1*0R 5*2*OR 
2+1+2+4+13 = 22 
7*3*OR 
(1-0R+5-1+1) (2--'-0R+5-2+l) (3-OR+5-3+1) 
9*4*0R 18í-'5'-OR 
+ + 
(4*0R+5-4+l) (5*0R+5-5+l) 
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What OR solves this equation? The equation can be seen as a function of 
OR and be represented concisely as 22= f ( O R ) . In other words, for what va l -
ue of OR is f (OR)= 22 or f (OR)-22= 0? Solving this equation is complex, but 
a solution can be approximated by a so-called iterative procedure. 
I terative calculations 
(This section can be skipped without loss of continuity) 
Solving equation f (OR)-22= 0 corresponds to determining the cross-section of 
the function f ( O R ) - 2 2 and the x-axis . See f igure 6 . 1 . I t is assumed that the 
OR-MLE to be calculated lies somewhere in the interval OR= 0.274 to OR= 
1.098, and that f ( O R ) - 2 2 is a monotone increasing function. These 2 ORs are 
arbi t rar i ly set at about half and twice the OR= 0.55 (see table 6 . 1 4 ) . Substi-
tution of these 2 ORs in f ( O R ) - 2 2 gives the values -5 .43 and 6 .08 . They are 
displayed in f igure 6 . 1 . 
In view of the negative value -5.43 and the positive value +6.08 the solu-
tion of f ( O R ) - 2 2 must lie somewhere between OR= 0.274 and OR= 1.098. In 
the middle of this interval lies OR= (0.274+1.098)72= 0.686. Substituting 
0.686 in equation (8) gives f (0 .686)-22= 2.26: a positive value. Therefore the 
solution of f ( O R ) - 2 2 , which is the unknown OR-MLE, lies between OR= 0.274 
and OR= 0.686 and not between OR= 0.686 and OR= 1.098. Right between OR= 
0.274 and OR= 0.686 lies (0.274+0.686)/2= 0.480; f (0 .480) -22= -0 .750 . Consid-
ering the course of the signs of the function scores it can now be concluded 
that OR-MLE lies between OR= 0.480 and OR= 0.686. These iterative numerical 
calculations can be conducted ad libitum with a computer. They are continued 
until the function f ( O R ) - 2 2 intersects the x-axis at a point between 2 ORs 
with a distance between them that has been decided on in advance. A dis-
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f(OR)-22 
6 . 
5 
¿ι 
3 -
2 . 
1 . 
( 2 . 2 6 ) 
• 
( 6 . 0 8 ) 
" ^ — Ί ^ ^ Τ — ^ ^ ™
1
» — l i l i 
0 . 2 . 0 .4 _ 0.6 . 0 . 8 1.0 
- 1 
- 2 
- 3 · 
- 4 
- 5 
Ι Ч ' t 
0 . 2 7 4 0 .480 0 .686 
( - 0 . 7 5 ) 
é 
( -5 .43) 
1.098 
OR 
F i g u r e 6 . 1 Some v a l u e s of t h e f u n c t i o n f (OR)-22 
tance of 0.001 OR had been chosen for table 6 .17 , and to achieve it 15 i tera-
tions were necessary. 
The OR-MLE has now come to lie between OR= 0.525140 and OR= 0.52519. 
Rounded off at 3 decimals, it equals 0.525. This odds ratio hardly differs 
from the OR-MH= 0.55 of table 6.14. 
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Table 6.17 Odds r a t i o s and values of the function f(OR)-22 
Iteration 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
OR 
left 
274648 
274648 
480634 
480634 
480634 
506382 
519256 
519256 
522475 
524084 
524889 
524889 
525090 
525090 
525140 
1 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
OR 
right 
09859 
68662 
68662 
58363 
53213 
53213 
53213 
52569 
52569 
52569 
52569 
52529 
52529 
52519 
52519 
OR 
middle 
0.686620 
0.480634 
0.583627 
0.532130 
0.506382 
0.519256 
0.525693 
0.522475 
0.524084 
0.524889 
0.525291 
0.525090 
0.525190 
0.525140 
0.525140 
Value 
left 
-5.4351 
-5.4351 
-0.7502 
-0.7502 
-0.7502 
-0.3082 
-0.0957 
-0.0957 
-0.0434 
-0.0174 
-0.0044 
-0.0044 
-0.0012 
-0.0012 
-0.0003 
f(OR)-22 
Value 
right 
6.08034 
2.25510 
2.25510 
0.89157 
0.11151 
0.11151 
0.11151 
0.00857 
0.00857 
0.00857 
0.00857 
0.00209 
0.00209 
0.00047 
0.00047 
Value 
middle 
2.25510 
-0.75015 
0.89157 
0.11151 
-0.30819 
-0.09568 
0.00857 
-0.04339 
-0.01737 
-0.00439 
0.00209 
-0.00115 
0.00047 
-0.00034 
-0.00034 
The logistic model 
In the preceding sections the OR, adjusted for the confounding influence 
of year of birth by matching, was estimated in 2 different ways: OR-MH and 
OR-MLE. There is still another method of determining the effect of screening 
on breast cancer mortality with control of extraneous factors, by means of 
mathematical-modelling procedures, v iz . the logistic model. By way of i l lustra-
t ion, the logistic model will f i rst be applied to the breast cancer death risk in 
a certain age-group. 
The vital statistics published annually in the Netherlands by the Central 
Bureau of Statistics, give age-specific breast cancer mortality rates as sum-
marized in table 6 .18 . 
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Table 6.18 Age-specific breas t cancer mor t a l i t y r a t e s 
(per 10s woman-years) in the Netherlands 1978-1982 
1 
Age-
group 
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
85+ 
No. of breast 
cancer deaths 
38 
137 
314 
559 
851 
1232 
1560 
1520 
1601 
1689 
1522 
1301 
1301 
Number of 
woman-years 
2815400 
2832700 
2220900 
1957700 
1896300 
1863400 
1831000 
1590500 
1485100 
1281600 
971500 
606400 
388400 
Morta 
(per 
lity 
10' 
1 
5 
14 
29 
45 
66 
85 
96 
108 
132 
157 
215 
335 
rate 
WY) 
The mortality rates in the last column of table 6.18 can be regarded as the 
breast cancer death risk in a certain age-group. The rates are also displayed 
in figure 6.2. 
The dots in figure 6.2 seem to follow a curve which can be represented by 
certain mathematical functions known as logistic functions. They have the fol-
lowing general notation: 
1 
f(x) = 
-(a+bx) (9) 
1+e 
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Breast cancer 
mortality per 10 
woman-years 
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Figure 6.2 Age-specific breas t cancer m o r t a l i t y r a t e s (per 10 s 
woman-years) in t h e Netherlands 1978-1982 
The graph of a logistic function where b>0 is shown in f igure 6 . 3 . 
Whatever the value of x , f ( x ) ranges between 0 and 1 . Such a function seems 
suitable for an approximation of the breast cancer death risk or probability in 
a certain age-group because this probability lies between 0 and 1 . The dots 
of f igure 6.2 follow a curve similar to the graphed function in f igure 6 . 3 . It 
will now be attempted to f i n d a logistic function f ( x ) which as closely as pos­
sible corresponds with the observed rates of table 6.18 and f igure 6 . 2 . The 
function f ( x ) is f i x e d , if the parameters a and b in formula ( 9 ) can be esti­
mated. The maximum likelihood estimation is applied to estimate the parameters 
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I 
L 
Figure 6.3 Graph of a l o g i s t i c function 
f(x) = l/( l+exp(-(a+bx)) , when b >0 
in a likelihood function that maximize the value of t h a t function. For the data 
of table 6.18 a= -4.6038 and b= 0.3160 were estimated. With these values, for 
every age-group χ (to be substituted in formula ( 9 ) ) f ( x ) can be calculated 
that represents the breast cancer death probabil ity in that age-group. With 
this model the line - - · · - - in f igure 6.4 was found that closely follows the 
line --4 * - - connecting the observed rates. 
I t has been shown t h a t the breast cancer death risk at age χ can be mod­
elled by means of a logistic function Now an attempt can be made to deter­
mine the probabil ity t h a t women screened or unscreened, of certain age, 
marital status, and socioeconomic status, die from breast cancer. It is obvious 
that sufficient numbers of subjects have to be collected in each category sep­
arately to make precise risk estimates for them. Sufficient information in all 
categories may not always be available, but information from neighbouring 
categories can be used to estimate these risks. This is precisely the point of 
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Figure 6.4 Observed and predicted age-speci f ic b r e a s t cancer morta­
l i t y r a t e s (per 10' woman-years) in the Netherlands 1978-1982 
a model: it gives a simplified, quantitative description of the relation. The' 
example of age and breast cancer death risk showed that the risk in any age-
group could be estimated by logistic modelling, even though only 13 points 
were given. The following logistic model specifies breast cancer death risk in 
terms of 4 dichotomous variables. See table 6.19. 
Depending on these 4 variables χ the probability that a woman dies from 
breast cancer can be presented by means of a logistic function as 
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1 
Pr-x = (10) 
-(а+ЫхІ + Ь2х2 + ЬЗхЭ + Ь4х4) 
1+е 
Table 6.19 Four var iab les t o be used in a 
l o g i s t i c regress ion model 
1 
1 
xl= 
x2= 
x3= 
x4= 
screening: 
age: 
marital status: 
social economic 
status: 
xl= 
xl= 
x2= 
x2= 
x3= 
x3= 
x4= 
x4= 
1, 
0, 
1, 
o, 
1, 
0, 
1, 
0, 
1 
if screened 
if unscreened 
if <50 
if « 0 
if married 
if unmarried 
if low SES 
if high SES 
I 
Variable xl (screening status) is the one we are particularly interested in: 
x1= 1 denotes "screened" and x1= 0 denotes "unscreened". The others, x2, 
x3, and x4, are confounding variables which have to be adjusted for in order 
to get a proper assessment of the effect of screening on breast cancer mortal­
ity. 
It can be derived mathematically that the odds ratio estimate of the effect 
of screening on individuals who are otherwise identical with respect to con­
founding variables is given by е х р ( - Ы ) , where Ы is the estimated coefficient 
of the screening variable xl in the logistic function. In this way, on the 
basis of the data in table 6.16 (with only age adjusted for) Ы was estimated 
to be 0.6280. Then the OR is exp(-0.6280)= 0.533. This value corresponds 
with the OR= 0.55 of table 6.14 and OR-MLE= 0.525 of table 6.17. 
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Breast cancer death cases and controls differ not only in age, but also in 
other characteristics that influence their participation in the screening pro­
gramme. The above-mentioned OR= 0.53 may not be val id. For instance, mari­
tal status and district of residence could influence the OR estimate. T h a t is 
why the logistic function (10) also specifies coefficients for marital status 
(ЬЗ) and socioeconomic status ( b 4 ) . If the categories of table 6.19 are used, 
the Ы for the screening variable is now - 0 . 6 8 1 1 . The OR becomes OR= 
e x p ( - 0 . 6 8 1 1 ) = 0 . 5 1 , which is hardly d i f f e r e n t from the OR adjusted for age 
only. 
An analysis with the logistic model is preferable to the classic multivariate 
analysis, because the former also analyses dichotomous variables, while the 
latter only analyses continuous variables which in addition have to be multi­
variate normally distr ibuted. I t is theoretically possible to find a breast can­
cer death probability > 1 . This is biologically odd, and impossible in terms of 
logistic functions, which are always 0 < f ( x ) < 1 . Furthermore, there is not a 
simple relation between the estimated parameters from, for instance, the linear 
regression model, and the OR; the opposite is the case for the logistic 
regression model. 
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Chapter 7 
MAMMOGRAPHICAL SCREENING AND 
BREAST CANCER MORTALITY 
REDUCTION 
Evaluation by means of a case-control study 
Introduction 
In Nijmegen a case-control study was conducted to assess the efficacy of 
mammographical screening on breast cancer mortality. With the help of the 
population base, for each case of breast cancer death, diagnosed after a f i rst 
invitation to screening, a number of controls from the same age-group were 
randomly selected. It was checked whether these subjects participated in the 
screening programme. The difference in attendance between the breast cancer 
deaths and the controls is the basis of the estimate of the efficacy. 
During the period 1975-1981, 46 breast cancer deaths were registered 
which were eligible for the case-control study. On the basis of these 46 
deaths and a fivefold number of controls the case-control study was carried 
out. The results were published in THE LANCET of June 2 , 1984. l This 
chapter contains the paper as it was published. 
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REDUCTION OF BREAST CANCER MORTALITY 
THROUGH MASS SCREENING WITH MODERN 
MAMMOGRAPHY 
First Results of the Nijmegen Project, 1975-1981 
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Depjrrments of Social Medicine, Radiology, and Pathology, 
University o/ Nijmegen, The Netherlands; Department of Pathology, 
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Summary Since 1975 four rounds of screening with 
modern mammography for breast cancer 
have been carried out among 30 000 Nijmegen women born 
before 1940. The results up to the end of 1981 show that the 
odds ratio of screened vs unscreened sub]ects among women 
who died from breast cancer compared with women who did 
not, was 0· 48 (95% confidence interval 0 · 23-1 · 00) in all age 
croups. 
INTRODL'C ΠΟΝ­
Α RANDOMIS1D, controlled trial of about 62 000 women 
aged 40-64, who were insured with the Health Insurance 
Plan of Greater New York, (HIP study) was started 21 years 
ago to find out whether screening could reduce breast cancer 
mortality. The study group was offered four annual 
screenings, including physical examination and 
mammography, and the control group had their usual 
medical care. Over 5 years periodic screening led to a 30% 
reduction in mortality from breast cancer.' Even after longer 
follow-up2 the reduction in mortality was still evident. The 
discussion about the effect of screening on women under 50 
years old has not yet been closed, although a recent analysis of 
the HIP data suggests that screening does have a statistically 
significant effect in this age group.' 
Since the HIP study the technique of mammography has 
improved greatly and mass screening for breast cancer has 
been started in several places. Unfortunately, in many of 
these screening programmes, like ours in Nijmegen, a non-
experimental design has been used, which makes it difficult to 
evaluate the effect of screening on mortality. 
- 95 -
SI BJICTSANDMl 1 HODS 
Subjects 
In Niimegen (150 000 inhabitants) a population based breast 
cancer screening proçrammc started on Jan 1, 1975 Single-view 
mammography (Ы-Гок August, 1981, lateromedial projection since 
then, mediolatcro-oblique proiection) was Ljrned out as the only 
screening examination every 2 years For the first screening round 
all women living in Nijmegen, born between 1910 and 1939, were 
invited to take part (aged 35-65, η = 23 000) For the next three 
rounds all women living in Nijmegen, born before 1940, were 
invited (n = 30 000)4 
Methods 
In the period 1976-81 in Nijmegen the crude mortality rate for 
breast cancer in women of 35 and over remained stable at 0-9 per 
1000 woman years Λ case-control design has been used to assess the 
efficacy of screening on morbidity and, in accord with recent 
recommendations,5 ' on mortality 
Cases —The case series consists of female residents of Nijmegen, 
who, according to their death certificates, died from breast cancer in 
1975-81 and who were diagnosed as having primary breast cancer 
after their first screening invitation, there were 46 such deaths 
Controls —All women invited who had not died from breast 
cancer at the time when the case died were eligible for the control 
group To control the confounding influence of age, the controls 
were matched for age For each case, 5 controls of the same year of 
birth were selected at random from the statistical tape Then we 
checked whether the case and the 5 controls had had a screening 
examination before the date of diagnosis of the case 
Non experimental studies are liable to self-selection bias The 
existence and influence of s ich bias can be studied by estimating the 
underlying incidence of breast-cancer in the screened and 
unscreened groups In a randomised, controlled trial the incidence 
rate in the control group can be used to estimate the rate in the 
screened group if there had been no screening In this study women 
of the city of Arnhem, where mass screening has never taken place, 
were used as the control group Arnhem (150 000 inhabitants) is 
about 15 miles from Nijmegen Since 1975, data on Arnhem 
patients diagnosed as having primary breast cancer have been 
carefully recorded by the Carcinoma Werkgroep. The data about 
patients diagnosed before 1975 were gathered with the help of the 
pathology department of the Arnhem hospitals In 1970-74, 
Arnhem and Nijmegen had the same age-adjusted breast cancer 
incidence and mortality rates 4 We have assumed that since the start 
of the screening programme in Nijmegen the age-year specific rates 
if there had been no screening would have been similar to those in 
Arnhem The Arnhem age-year specific rates were applied to the 
Nijmegen unscreened group to determine whether the underlying 
breast cancer incidence rates in the screened and unscreened groups 
diflered 
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Data analysis.—The odds ratio of screened vs unscreened subjects 
among women who died from breast cancer compared with women 
who did not was estimated by means of a matched data analysis,8 
according to the formula of Mantel and Haenszel. 
RESULTS 
Four screening rounds for breast cancer were carried out in 
Nijmegen between 1975 and 1982. The attendance rates 
according to age at time of invitation are shown in table I. 
Attendance rates fell in all age groups from the first round to 
the fourth. 
46 women diagnosed as having breast cancer after their first 
invitation died from the disease. Of these women, 13 were 
younger than 50 at the time of their first invitation, 20 aged 
50-64, and 13 aged 65 and over. 26 of the 46 women who died 
from breast cancer had been screened; 12 were diagnosed at 
their first screening, 3 before their next screening, and 11 at 
or after the time of their second screening. 
The results of the matched data analysis are summarised in 
table H. The odds ratio estimate of screened vs unscreened 
among women who died from breast cancer compared with 
those who did not, was 0-48 (95% confidence interval, 
0-23-1-00). 
The 5-year age-specific incidence rates of Arnhem (table III) 
were applied to the Ni] megen unscreened women. 84 • 6 cases 
would have been expected in this group, whereas 84 occurred 
(table i\). Thus, the underlying incidence rate for the 
-eened group is similar to that in the unscreened group. 
ГАВ1 1- l-A(,l· .SPFCIHO ATTENDANCE RATES IN Ю І Ж SCREENING ROUNDS 
•\g<."(H) 
<w 
40-49 
50-59 
60-69 
¿70 
/ H Í J / 
Round 1. 
No im ned 
M 70 
8007 
7756 
4.'7J 
2 i 205 
1975-76 
AttcndjiKi; 
rJlL' (%) 
87 6 
87 I) 
84 2 
7Ч-Ч 
Ш 8 
Round 2 
No mviti'd 
1831 
7743 
7748 
6950 
6180 
3Ü5Ü2 
1977-78 
Attendance 
rate(%) 
79-3 
77-2 
73-3 
64-3 
34-5 
6 4 8 
Round 3 
No invited 
234 
7700 
7813 
6707 
6379 
28 833 
1979-80 
Attendance 
rate (%) 
71-8 
73-0 
67-3 
57-1 
25-7 
57-3 
Round 4, 
No invited 
6666 
7527 
6613 
6571 
27 377 
1981-82 
Attendance 
rate (%) 
69-5 
64-3 
53-5 
21-0 
52-5 
'Age at lime úl im il anón 
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TAHl.E 11-DISTRIBUTION OF 46 CASE CONTROL COMBINATIONS, 
SCREENED VS UNSCREENED 
C a « 
Screened 
Not scrtened 
Number of controls screened 
0 
0 
2 
1 
0 
2 
2 
4 
4 
3 
5 
2 
4 
8 
4 
5 
9 
6 
Total 
26 
20 
(5x0) + (4x0) + (3*4) + (2x5) + (|x8) 30 
Odds ratio- — - Ό - 4 8 
(Ix2)+(2x4) + (}x2) + (4x4)+(5x6) 62 
TABLE HI-INCIDENCE OF BREAST CANCER IN ARNHEM* 
Age group 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
>85 
Cases of 
breast cancer 
11 
22 
39 
58 
51 
45 
Я 
50 
39 
32 
23 
VComan-years 
27 892 
36 856 
28 558 
31 063 
30 861 
28 421 
20 178 
16 702 
12 039 
7227 
4654 
Incidence per 
1000 uoman-years 
0-394 
0-819 
1-366 
1-867 
1-653 
1-583 
2 676 
2-994 
3-239 
4 428 
4-952 
T o r age- groups 35-64, in 1975-82, for age group ¿65, in 1977-82 
- OBSERVED AND EXPECT ЕП NUMBERS OF BREAST CANCER 
CASES IN UNSCREENED NIJMEGEN WOMEN* 
Birth cohort 
1935-39 
1930-34 
1925-29 
1920-24 
1915-19 
1910-14 
1905-09 
1900-04 
1895-99 
1885-94 
Total 
Woman-months 
at risk* 
30 927 
34 234 
36 627 
42 478 
40 196 
53 152 
70 759 
68 749 
49 027 
31 157 
457 306 
Number of breast cancer cases 
Observed 
1 
3 
9 
10 
13 
8 
11 
11 
18 
84 
Expected 
1 0 
2-3 
4-2 
6-6 
5-5 
7-0 
15-8 
17-2 
13 2 
11-8 
84-6 
* \diusicd forbrcastcancers.deaths, removals, and participauon after (he next 
imitai ion 
bor birth cohort 1910-39, m 1975-82, and for birth cohort 1885-1909, in 
1977-82 Birth cohons correspond to age groups in table III 
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DISCUSSION 
The odds ratio of 0-48 shows that the breast cancer 
monalitv rate in women of 35 and over can be reduced by 
roughly 50% by regular mammographie screening of all 
eligible women. Possible reasons why there has been no fall in 
breast cancer mortality rate in Nijmegen up to the end of 1981 
are that the attendance rate for screening in the older age 
groups was low and that many women are still dying from 
breast cancer diagnosed before their first invitation—in 1981 
almost 65% of those who died were diagnosed before the 
study. A time trend in breast cancer mortality could also be an 
explanation Since the upper 95% confidence limit of the 
odds ratio is Ι Ό , more data are required to ensure that the 
odds ratio really does differ from unity. 
The confounding influence of age on the odds ratio is 
controlled by the matched design and analysis. The self-
selection bias is probably small, because the underlying 
breast cancer incidence rate in the unscreened group is the 
same as that in the screened group on the basis of the Arnhem 
data. Because there is no national cancer registry in the 
Netherlands, a special study will be done to determine the 
time trend of the breast cancer incidence in Arnhem. It is 
possible that publicity about the Nijmegen screening 
programme has led to an increased rate of physical and 
mammographie examinations in Arnhem Consequently, an 
excess number of breast cancer cases may have been 
diagnosed in Arnhem An increase in the incidence in 
Arnhem compared with other unscreened areas, would lead 
to too large a number of expected cases in the non-
participating group in Nijmegen and would invalidate 
comparison of the underlying incidence rates. Variables like 
age at diagnosis, stage at diagnosis, and treatment are not 
necessarily independent of screening and should therefore 
not be taken into account in the analysis.9 
It is possible that the screening history of a Ni] megen breast 
cancer patient might increase the likelihood of her death 
being attributed to breast cancer. However, it is assumed that 
any such misclassification on death certificates is small. 
Further analysis, which will focus on the clinical history of 
the breast cancer patients in Nijmegen, is necessary to 
determine the sensitivity and specificity of the death 
certificates. 
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Early treatment of breast cancer may not influence the 
chance of recovery, but may merely postpone death due to 
breast cancer. Longer follow-up of the Nijmegen breast 
cancer patients is necessary to see whether the odds ratio 
remains constant or returns to unity Longer follow-up is also 
necessary to determine the effect of screening on the slow-
growing type of breast cancer. 
In this study the odds rano for women of 55 and older is 
0-49. Because of the small number of cases and the higher 
attendance rate in the younger age-groups, we cannot yet 
study the effect of screening on women under age 55. 
The negative effects of the introduction of the screening 
programme should be mentioned The positive predictive 
value of mammography is 35%,4 thus, for each screen-
detected case 2 women had a referral and 1 of them had a 
biopsy that they would not have had if there had been no 
screening. Strong efforts should be made to reduce the 
number of false-positive results by further improving the 
specificity of mammography. Another important side-effect 
of screening may be the diagnosis and treatment of clinically 
irrelevant non-invasive cancers. The annual diagnostic rate of 
primary breast cancer in Nijmegen is still somewhat higher 
than the rate before the screening programme We are 
investigating whether this rate corresponds to the current rate 
in unscreened areas. Ahother difficulty associated with 
screening is the false-negative rate, the sensitivity of 
mammography in Nijmegen was estimated to be 80% 4 
About a third of the false-negative cancers on scrpemng 
mammograms are caused by technical faults, a third are 
radiologically occult, and a third are fast-growing tumours 
not yet detectable at screening.10 By following a number of 
strict rules, we are attempting to reduce the number of false-
negative cases to the theoretical minimum. ' ' 
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(l)Lpartment of Social Medicine), and К Janmnk (Department of Radiology) 
lor data analysis, processing, and gathering, F de Groot for his comments, and 
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cancer incidence in Arnhem, the Central Bureau for Statistics, and the local 
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- 100 -
REFERENCES 
1 Shapiro S, Strax Γ, Vencí L Penodic breast cancer screening in reducing mortality 
from breast cancer JAMA 1971,215: 1777-85 
2 Shapiro S, Venti W, Strax PH, Venet L, Roeier R Ten io-four teen-year effect of 
screening on breast cancer mortality У Nati Cancer ¡пи 1982, И: 149-55 
3 Habbcnu JDF, Putten DJ van, Lubbe JThN, Maas PJ van der, Oortmarssen GJ van 
Geen verichillen in resultaten tussen vrouwen onder en boven de 50 jaar bij 
bevolkingsonderzoek op borstkanker Τ Soc Gaondhaäiz 1983, βΐ: 694-97 
4 Hendriks JHCL Population screening for breast cancer by means of mammography in 
Nijmegen 1975-1980 Ph D Thesis University of Niimcgcn, the Netherlands, 
1982 
5 Clarke EA, Anderson TW Docs screening by MPap smears help prevent cervical 
cancer? Lancet 1979, n 1-4 
6 Morrison AS Casedefinitionmcase-controlsiudiesoftheefncacyofKreening AmJ 
EpiJtmtol 1982, IIS: 6-8 
7 \λ CJSS S'S Control deiinuion in case control studies of the efTicacy of screening and 
diagnostic testing Am J Epidemiol 1983, 118. 457-60 
6 Breslovt NE, Day NE Classical methods of analysis of matched data In Davis W, ed 
Statistical methods in cancer research lARC Scientific publication no 32 Lyon 
1ARC, 1980 170-72 
9 Prorok PC, Hankey HI-, Bundy BN Concepts and problems in the evaluation of 
screening programs J Otmn Dis 1981, 34: 159-71 
10 Holland R, Mravunai. M, HcndnksJHCL, Всккег BV So called intervalcancersofthe 
breast, pathologic and radiologic analysis of 64 cases Сажег 1982, 49: 2527-33 
11 Holland R, HcndnksJHCL, M ra vu пас M Mammographicallv occult breast cancer, a 
pathologic and radiologic study dneer 1983,52: 1810-19 
- 101 -
A second case-control study 
To study age effects a new case-control study has recently been conducted 
including 16 additional cases, who died from breast cancer in 1982, and a new 
randomly selected control group. The results of this second study will be 
presented now. Special attention will be paid to the age-specific efficacy of 
screening on mortality in the age-group under 50 at entry (bir th-cohort 
1925-1939). The study population and study design are the same as described 
in the above paper covering the period 1975-1981. 
To estimate the rate ratio of breast cancer death for participants in com-
parison with nonparticipants the odds ratio was calculated with the Mantel-
Haenszel formula for matched data and with maximum likelihood methods. The 
95% confidence limits were calculated as proposed by Miett inen. 2 3 In addition, 
risk ratios were estimated by means of a logistic regression analysis. The 
logistic equations were f i t ted by the method of maximum likelihood and includ-
ed terms for participation, number of examinations, age, marital status, and 
district of residence. 
Results 
From 1975 through 1982, 62 women were diagnosed for breast cancer after 
their f i rs t invitation, and died from the disease. The results of the matched 
data analysis are summarized in table 7.1 
The odds ratio estimate according to Mantel and Haenszel (OR-MH) of 
screened vs . unscreened, among women who died from breast cancer compared 
with those who did not, was 0.55 (95% confidence interval 0 .29; 1 .07) ; the 
maximum likelihood estimate (OR-MLE) was hardly dif ferent: 0.53 (95% confi-
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Table 7.1 Distribution of 62 case-control sets according to 
screening status 
Number of controls screened 
Case 
Screened 
Unscreened 
0 
2 
о 
1 
1 
6 
2 
2 
4 
3 
4 
5 
4 
13 
5 
5 
15 
5 
Total 
37 
25 
(5*2)+(4*l)+(3*2)+(2*4)+(l*13) 41 
OR-MH = = = 0.55 
(l*6)+(2*4)+(3*5)+(4*5)+ 5*5) 74 
OR-MH = 0 . 5 5 ; 95% c o n f i d e n c e i n t e r v a l ( 0 . 2 9 ; 1.07) 
OR-MLE = 0 . 5 3 ; 95% c o n f i d e n c e i n t e r v a l ( 0 . 2 6 ; 1.08) 
dence interval 0.26; 1.08). This is to say that the relative risks of dying 
from breast cancer among women ever screened compared with women never 
screened were 0.55 and 0.53 respectively. In general the results are the same 
as in the previous analysis covering the period 1975-1981. ' 
For the purpose of studying the age-specific effects of screening, the cas­
es were stratified into 4 birth cohort groups of comparable numbers: those 
born before 1910, in 1910-1919, 1920-1924, and 1925-1939 (see table 7.2). 
The Mantel-Haenszel and maximum likelihood odds ratio estimates with 95% con­
fidence limits for these birth cohorts are summarized in table 7.3. 
A strong OR= 0.36 and a very strong OR= 0.16 were observed in the birth 
cohort groups 1920-24 and 1910-19 respectively. A weak OR= 0.83 was found 
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Table 7.2 Distribution of 62 cases 
of breast cancer death according to 
birth cohort 
Birth cohort Number of cases 
<1910 
1910-1919 
1920-1924 
1925-1939 
16 
11 
16 
19 
Table 7 . 3 Mantel-Haenszel e s t i m a t e s of odds r a t i o (OR-MH) 
w i t h 95% c o n f i d e n c e i n t e r v a l (95% CI) and corresponding 
maximum l i k e l i h o o d e s t i m a t e s (MLE) a c c o r d i n g t o b i r t h 
cohort 
1 
Birth cohort 
<1910 
1910-1919 
1920-1924 
1925-1939 
OR-MH (95% CI) 
0.85 (0.25; 2.87) 
0.11 (0.02; 0.70) 
0.36 (0.11; 1.13) 
1.18 (0.30; 4.68) 
1 
OR-MLE (95% CI) 
0.83 (0.20; 3.13) 
0.16 (0.02; 1.06) 
0.36 (0.10; 1.32) 
1.17 (0.26; 5.91) 
ι 
for the oldest birth cohort of women born before 1910, and no effect of 
screening could be observed in the youngest birth cohort 1925-1939. The 
test of homogeneity was performed to assess the statistical significance of the 
differences in the ORs in the 4 birth cohort groups.2 The P-value for birth 
cohort was 0.20<P<0.30 (see appendix 7.1). In the youngest birth cohort the 
95% confidence interval of OR= 1.17 appears to be so wide that, statistically 
speaking, an OR smaller than 1 seems possible in this group. On the other 
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hand the test of homogeneity may show statistically significant results if larg-
er numbers are used. In that case the conclusion would be that there is no 
effect in the youngest group. 
Finally, a conditional logistic regression for matched data sets was applied 
to study the interaction between age and the effect of screening. The 
results were exactly the same as those in table 7 .3 . 
Confounders 
After the confounding influence of age had been controlled for by matching 
on year of b i r t h , the analysis was foe us sed on 2 potential confounders: resi -
dential district and marital status up to the time of diagnosis. Residential dis-
t r ic t may be regarded as a crude indicator of socioeconomic status. It was 
dichotomized according to educational level based on the percentage of stu-
dents in the district attending high school. In terms of this dichotomy, a 
quarter of the invitees lived in districts of a low educational level. There , 
the attendance rate, varying with each screening round, was 10-20% lower 
than in other districts. The factor of marital status was dichotomized into the 
categories never married and (ever ) married. The regression coefficients and 
standard errors for 3 birth cohorts are presented in table 7 .4 . 
The odds ratio adjusted for residential distr ict and marital status is 
exp(-0 .6801)= 0 . 5 1 , with exp( -0 .6801i1 .96*0 .3399)= (0 .26 ; 0.99) as 95% confi-
dence limits. The adjusted odds ratio in bir th cohort <1910 was 0.81 (95% CI 
0 .23 ; 2 . 7 5 ) ; in bir th cohort 1910-1924 OR= 0.26 (95% CI 0 .10; 0 . 6 7 ) ; and in 
bir th cohort 1925-1939 OR= 1.23 (95% CI 0 . 3 1 ; 4 . 8 1 ) . The adjusted odds rat -
ios in the 3 birth cohorts are comparable with the crude ones in table 7 .3 . 
District of residence and marital status proved to be weak confounders. 
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Table 7.4 Regression coe f f i c i en t s (standard e r -
ro r s ) of screening e f f ec t , r e s i d e n t i a l d i s t r i c t , 
and mar i ta l s t a t u s , according to b i r t h cohort 
1 
Birth-
cohort 
All 
Born<1910 
1910-1924 
1925-1939 
1 
Screened 
-0.6801 
(0.3399) 
-0.2203 
(0.6285) 
-1.3624 
(0.4943) 
0.2031 
(0.6974) 
Residential 
district 
0.1856 
(0.1578) 
0.4028 
(0.3113) 
0.0890 
(0.2289) 
0.2861 
(0.3332) 
Marital 
status 
0.4218 
(0.3896) 
0.0797 
(0.7268) 
0.4285 
(0.6361) 
-1.2289 
(0.7371) 
1 
Number of screening examinations 
An analysis was made of the influence that the number of screening exami-
nations may have on the odds ratio. First , the 62 combinations were st rat i -
fied according to the number of screening examinations, while the matched 
design on year of bir th was ignored. Next , a dose-effect relationship was 
determined with the help of the logistic model. The results are summarized in 
table 7 .5 . 
The upper part of table 7.5 shows a statistically significant t rend towards 
lower odds ratios (P<0 .10) , and so does the lower part (P<0.05) . After s t ra t i -
fication similar trends could be observed in the respective birth cohorts, 
except in the youngest ones (not presented h e r e ) . 
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Table 7.5 The influence of the number of screening examinations 
on the odds ratio 
Number of screenings Number of 
(matching broken) cases 
0 25 
1 24 
2 10 
3 3 
Number of screenings 
(logistic model) 
0 
1 
2 
3 
25 
24 
10 
3 
Odds r a t i o (95% CI) 
1 (base l ine category) 
0.67 (0 .33 ; 1.38) 
0.59 (0 .23 ; 1.52) 
0.44 (0.09; 2.15) 
1 (base l ine category) 
0.63 ( 0 . 3 1 ; 1.27) 
0.42 (0 .16; 1.14) 
0.25 (0 .25; 6.57) 
Discussion 
The odds ratio estimate of 0.53 (95% confidence limits 0.26 and 1.08) sug-
gests that the breast cancer mortality rate in women of age 35 and over can 
be reduced by almost 50%, if all eligible women are regularly screened with 
mammography. This result is based on evidence including data from 1982 and 
corresponds with the OR= 0.48 (95% confidence limits 0.23 and 1.00) which 
was found in the previous case-control study covering 1975-1981. Although 
the second study includes 16 new cases, the upper 95% confidence limit has 
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not dropped to a point where results could be regarded as statistically signif-
icant. The variance of the log(OR) has become smaller indeed, but the odds 
ratio has increased from 0.48 to 0.53 and as a consequence of this the upper 
limit is now >1.00 . The small increase in the odds ratio can be explained by 
a less strong protective effect among the new cases and controls of 1982. 
This was due to the fact that 8 out of 16 cases from 1982 were so-called early 
killers with a diagnosis-to-death interval of less than 2 years. 
The point estimate of the odds ratio does not change when it is estimated 
by the method of maximum likelihood. On the other hand, this method widens 
the 95% confidence interval somewhat. Since most of the odds ratios indicate a 
protective effect and since a dose-effect relation has been observed, it is 
plausible to suppose that the absence of statistical significance, at least at 
the 5% level, is due to the small number of cases, rather than the absence of 
any effect. 
Age is an obvious confounder, since breast cancer mortality increases with 
advancing age, while attendance of screening decreases. The present study 
has adjusted for age by matching controls to cases on year of b i r t h . It is 
possible, however, that acceptors and refusors of screening differ in yet oth-
er confounding factors, as a result of which even outside the screening pro-
gramme screened and unscreened women may have different probabilities of 
dying from breast cancer. By a simultaneous/geographical comparison with the 
city of Arnhem it was ascertained that the incidence rates of breast cancer in 
the screened and unscreened groups were the same.1 Because the death cer-
tificates of Arnhem, where no screening programme is carried out, are not 
yet available, it cannot be determined whether the underlying mortality rates 
are similar too. 
In addition to year of b i r t h , potential confounders like marital status and 
district of residence were analysed. The latter confounder can be regarded as 
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an indicator of socioeconomic status, which according to medical l i terature is 
associated with breast cancer mortality." 5 Adjustment for residential distr ict, 
however, hardly affected the OR estimate. In Nijmegen it was decided as y e t 
not to gather f u r t h e r information on socioeconomic status. Furthermore, mari­
tal status did not have any confounding influence either. 
Cigarette smoking and oral contraceptive use are generally considered indi­
cators of health behaviour. Although it is likely that these 2 factors are asso­
ciated with attendance of the screening programme, l iterature on this subject 
does not suggest a correlation with breast cancer mortality. A recent study 
has shown there is not any relation between breast cancer incidence and ciga­
rette smoking.6 Oral contraceptives do not have any influence on the inci­
dence of breast cancer (see chapter 10 for the Nijmegen study r e s u l t s ) . 7 β 
One American study seems to suggest the opposite. 9 In addition, it has not 
been proven that taking oral contraceptive steroids has any harmful effect on 
tumour growth and tumour s p r e a d . 1 0 l l Oral contraceptive steroids may have 
had some biologically benificial effect, but this could be attr ibuted to diagnos­
tic bias. It is therefore presumed that the factors of cigarette smoking and 
oral contraceptive use do not have any confounding influence on the effect 
measures m this study. 
The screening history of a breast cancer patient may increase the l ikeli­
hood of her death being attributed to breast cancer, but misclassification of 
death certificates is probably rare. Further analysis focussing on the clinical 
history of breast cancer patients m Nijmegen is necessary to determine the 
validity of death certif icates. 
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The Nijmegen results can be part ly compared with those of the Utrecht 
breast cancer screening project. In the latter project, which started in 
December 1974, only the b i r th cohort 1911-25 (women 50-64 years old at 
entry) was invited to be screened.12 In the Utrecht project in the period 
1975-1981 46 matched sets (of 1 case and 3 controls) yielded an OR-MH= 0.30. 
In Nijmegen in the period 1975-1982 the odds ratio of the corresponding bir th 
cohort 1910-24 (27 matched sets) was OR-MH= 0.26. Stratification of these 
sets according to bir th cohort resulted in the following ORs. See table 7.6. 
Table 7.6 Odds r a t i o s of the Utrecht and Nijmegen screening 
p ro jec t s according to b i r t h cohort 
Utrecht 1975-19811* Nijmegen 1975-1982 
Bir th cohort Cases (N) OR Birth cohort Cases (N) OR 
1921-1925 12 0.82 1920-1924 16 0.36 
1916-1920 14 0.31 1910-1919 11 0.11 
1911-1915 20 0.05 
In Utrecht a strong trend in the effect of screening was observed within 
the 15-year range of the bir th cohort 1911-1925: the odds ratio drops from 
OR-MH= 0.05 in the oldest bir th cohort 1911-1915 to an OR-MH= 0.82 in the 
youngest b i r th cohort 1921-25. In Nijmegen the same trend was observed. It 
is remarkable that in Nijmegen the OR in the stil l younger bir th cohort 
1925-39 was 1.17. At the start of the Nijmegen programme in 1975 this group 
was 35-49 years old. It is comparable with the age-group 40-49 at entry in 
the tr ial of the Health Insurance Plan. Five years after the HIP screening 
programme had begun, the number of breast cancer deaths in the study 
group was 19 and in the control group 20, which means a risk ratio of 
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0 .95 . 1 3 Ten years after the start the risk ratio was 42*54= 0 .78 , and, f inal ly, 
14 years after the start 46*61= 0.75. ' * This last result is statistically signifi-
cant.1 1 1 15 The HIP investigators hesitated to accept this f inding as evidence 
of the effectivenes of screening under age 50. Their reservation was based 
on the observation that the decrease in mortality in the study group aged 
45-49 at ent ry was concentrated entirely in cases diagnosed after they had 
reached the age of 50. This suggests that screening under the conditions of 
the HIP study has little or no impact on the fast killing tumours. In Nijmegen 
no benefit at all was observed in the birth cohort 1925-1939, roughly corre-
sponding with the age-group 35-50 at ent ry . On the other hand, the 95% con-
fidence interval of the OR in this group is fair ly wide, making an actual OR 
<1 possible. Moreover, since the test of homogeneity was not significant, an 
OR= 0.53 in the youngest group is, statistically speaking, possible. (See 
appendix 7.2 for more information). However, the observed point estimate was 
not <1.00 and most of the death cases appeared to have been screened. (The 
fact that the estimated OR= 1.17 is greater than 1 is caused by sampling 
variabi l i ty. The attendance rate in the youngest group of the control sample 
turned out to be somewhat smaller than the corresponding rate in the total 
population). The use of sophisticated techniques like the logistic regression 
analysis does not change the odds ratios already estimated. 
It is probable that the effect of screening on cases detected at the f i rst 
screening examination is weaker than that on cases detected at subsequent 
examinations. The screen-detected cancers in the former group are more 
advanced than those in the latter group (assuming the screening interval is 
not too wide) . Table 7.5 supports the fact that the impact increases with the 
number of screening examinations. However, stratification according to birth 
cohort (not presented here) did not show this to be the case for the young-
est cohort 1925-1939. Other reasons should be considered to explain why 
biennial mammography in 
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Nijmegen showed no effect on mortality in this group. Maybe carcinomas diag-
nosed in women under age 50 are more malignant than those diagnosed in 
women over age 50. Table 7.7 summarizes some characteristics with respect to 
the degree of malignancy of the 62 breast cancer deaths dichotomized accord-
ing to age at diagnosis <50 and 550. 
Table 7.7 C h a r a c t e r i s t i c s concerning degree of malig-
nancy (%) of 14 b reas t cancer death cases aged < 50 at 
d iagnos i s , and 48 cases aged > 50 a t diagnosis 
C h a r a c t e r i s t i c 
Family h i s t o r y pos i t i ve 
Histology: ducta l ca 
lobular ca 
No a x i l l a r y lymph node 
involvement ( h i s t o l o g i c a l l y 
examined) 
No mastectomy performed 
Ratio of No. i n t e rva l cancer 
cases and No. i n t e rva l cancer 
plus sc reen-de tec ted cases 
Age at diagnosis 
<50 (N=14) >50 (N=48) 
7% 
71% 
21% 
7% 
29% 
58% 
6% 
83% 
4% 
17% 
27% 
46% 
A slightly higher percentage of the younger group had axillary lymph node 
involvement, but not all axil lary lymph nodes had been histologically examined. 
Also, the diagnosis "lobular carcinoma" was made more often in the younger 
group. Many of these carcinomas are occult . 1 6 The ratio of the number of 
interval cancer cases and the total number of cancer cases diagnosed among 
attenders ( i . e . the number of screen-detected cases plus the number of inter-
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val cancer cases) is higher in the younger group than in the older group. 
This suggests a greater number of false-negative mammograms, in other 
words, a lower sensitivity of mammography. It may also suggest a higher 
tumour growth rate and, by implication, a shorter lead-time. This would 
necessitate screening more than once every 2 years, although that would not 
guarantee a positive effect. Considering the stage distribution of the cases in 
the age-group 35-49 at diagnosis (see table 4 .4 ) a subsequent mortality 
reduction can be expected in the youngest age-group. 
Finally, attention should be paid to the effect of screening on breast can-
cer mortality in the oldest age group. It is assumed that breast cancer grows 
rather slowly in this g r o u p . 1 7 1' As a consequence, the lead-time should be 
very long, and a rather strong effect could be expected, but the odds ratio 
for the birth cohort born before 1910 is just 0 .83. Maybe this odds ratio is 
rather weak because of different underlying mortality risks (independent of 
any screening effect) in the participating and non-participating groups. 
Maybe differences in patient's delay explain that the effect was less favoura-
ble than expected. And maybe selective misclassif¡cation of the death cer t i f i -
cates is another explanation. Further studies will focus on these potential 
biases. 
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APPENDIX 7.1 
Test of homogeneity for OR-MLE =0.53 in 4 birth cohorts 
Birth-
cohort 
< 1910 
Number of controls screened OR-MLE OR-MH к ECnl.k-l) Var 
(nl.k-l) 
Case + 
Screened 
0 1 2 3 4 5 Tot 
--\--
L 1 0 
•\--4-Vl-
8 3 3 1 0 
5 
11 
0.83 0.85 
2 
3 
4 
0.767 
0 .628 
1.039 
0 . 5 1 4 
0.000 
4 
2.948 
0 . 6 9 3 
0 .497 
0 .679 
0 . 2 5 0 
0 .000 
4 
2.119 
Birth-
cohort 
1910-19 
Number of controls screened OR-MLE OR-MH к ECnl.k-l) Var 
(nl,k-l) 
Case + 
Screened 
0 1 2 3 4 5 Tot 
" \ ~ \ - \ - \ - \ -
1 2 
0 . 1 6 0 . 1 1 
0.000 
0.209 
0 .346 
1.029 
2 .178 
4 
3.762 
0.000 
0 . 1 6 6 
0 . 2 2 6 
0 .500 
0.597 
4 
1.480 
Birth-
cohort 
1920-24 
Number of controls screened OR-MLE OR-MH к E(nl,k-1) Var 
(nl.k-l) 
Case + 
Screened 
0 1 4 5 Tot 
:\-:\--\--\--\-
1 0 4 8 
10 
6 
0 . 3 6 0 .36 
0.000 
0.209 
0 .000 
2.058 
5.808 
0.000 
0.166 
0 . 0 0 0 
0 .999 
1.591 
8.075 2.756 
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Birth- Number of controls screened OR-MLE OR-MH к E(nl,k-1) Var 
cohort — 
1925-39 0 1 2 3 4 5 Tot 
Case + 
Screened 
-ч-ч-^ -ч-ч-
2 7 
16 
3 
1.17 1.18 
0.000 
0.000 
1.039 
1.029 
5.082 
ц 
7.150 
( n l , k - l ) 
0.000 
0.000 
0.679 
0.500 
1.392 
4 
2.571 
X 2 ( 3 ) = 
(4-2.948) 2 (2-3.762) г (7-8.075) 2 (9-7.150) 2 
2.119 1.489 
= 4.360; 0.20 < Ρ < 0.30 
2.756 2.571 
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APPENDIX 7 .2 
X 2 (OR) 
АО. 00 
30.00. 
20.00. 
10.00 
1 subjects 
Born <1910-
Born 1925-
! 
:tS 
*10-| 
-39 | 
Odds r a t i o 
Figure I Chi-square as a function of OR according to three case 
groups. The cases were individually matched on year of birth with 
5 controls 
A one-degree of freedom x2-statistic was estimated to check the possibility 
that hypothetical odds ratios correspond with the observed odds ratio in the 
study population, and in the birth cohort <1910 as well as in the birth cohort 
1925-1939. This method is presented in more detail in appendix 10.2. 
It can be deduced from figure I that a wide range of ORs smaller than 1 could 
yield the observed data as presented in table 7.3. However, the curves are 
rather flat on account of the small numbers. 
- 118 -
Chapter 8 
PROBLEMS WITH SURVIVAL ANALYSIS 
Introduction 
It is common practice in clinical trials to estimate the patient's survival 
rate to evaluate a cancer treatment of clinically diagnosed disease. The 
patients who are eligible according to the tr ial protocol are entered in the 
study and randomised to one of the treatment groups. By the randomisation 
procedure it is attempted to make sure the treatment groups are comparable 
with respect to all factors that affect prognosis including stage of disease. 
These prognostic factors must be equally distr ibuted over the groups in both 
the presence and absence of the treatment under study. However, if a popu­
lation is randomised to be screened or not, the randomisation takes place some 
time before, and not shortly after, the diagnosis is made. The time interval 
between randomisation and diagnosis is different for se ree η-detected patients 
and patients not subjected to the screening programme. Because of the d i f fer­
ence in time lag, the patient-groups will not be comparable, although they 
were at the time of randomisation ( e . g . with respect to age). For this reason 
alone, a comparison of survival rates (to evaluate the impact of screening on 
mortality) will be invalid. 
In a nonexperimental study a few other biases will occur in addition to 
time lag. There are 3 kinds of biases which complicate or, str ict ly speaking, 
preclude a valid comparison between the survival of breast cancer cases 
detected inside and outside the screening programme.1 2 э First of all there 
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will be length time bias. Assuming breast cancers have different growth 
rates, a screening programme will detect more slow growing tumours than fast 
growing ones. Slow growing tumours are assumed to have a better prognosis 
than fast growing ones. The second kind of bias is selection bias. This means 
that women who participate in a screening programme would be more inclined 
than nonparticipants to seek medical help in the case of signs and symptoms 
if there were no screening. As a consequence the former group would have 
above-average survival rates, independently of any screening effect. The 
th i rd bias concerns the possibility that screening also detects small tumours 
with a fair ly benign behaviour. Outside a screening programme these tumours 
would not be detected, nor would they necessarily become clinically manifest. 
When these tumours are nevertheless included in the survival analysis, the 
prognosis will be highly f lat tered. 
A randomised controlled tr ial is in principle not affected by length time 
bias and selection bias. In a nonexperimental study, like the one in Nijmegen, 
however, all 4 biases are present, and their magnitude and direction are dif-
ficult or even impossible to measure and to adjust for . To illustrate th is , the 
case fatality rates of participating and nonparticipating breast cancer cases 
will be shown. The influence of each of the 4 biases will be considered sepa-
rately. 
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Material and method 
Survival analysis comprises a follow-up study, which, in this case, com-
pares several groups with respect to participation in the screening pro-
gramme. In this analysis all patients are included who were born before 1940, 
who had primary breast cancer diagnosed in the period 1.1.1975-31.12.1982, 
and who were living in Nijmegen at the time of diagnosis. The data were col-
lected with the assistance of the Pathology Departments of the St. Radboud 
University Hospital and the Canisius-Wilhelmina Hospital, to which all Nijmegen 
patients are re ferred. All subjects were followed for vital status through 
December 1982 with the help of records from the above-mentioned hospitals 
and of death certificates from the Central Bureau of Statistics. As the sub-
jects were not all followed for the same durat ion, the survival analysis was 
conducted with the product-limit method of estimating the probability that a 
case dies from breast cancer within a certain period after diagnosis.'* Death 
from other causes is considered censoring. Survival curves were constructed 
and plotted with the Statistical Analysis System computer programme. 
Results 
During the study period 485 breast cancer cases were diagnosed: 81 non-
participants and 404 participants. In the nonparticipant case group 32 cases 
died: 25 of them from breast cancer. In the participant case group 51 
patients died: 37 of them from breast cancer. The survival curves are pre-
sented in f igure 8 . 1 . 
The group of participant cases has a greater cumulative survival than the 
group of nonparticipant cases. For the entire study period there is a signifi-
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Figure 8.1 Survival curves of 404 p a r t i c i p a n t s and 85 nonpar t ic ipant 
b reas t cancer cases . Nijmegen 1975-1982 
cant difference between the 2 curves (logrank test P O . 0 0 5 ) . 5 The number of 
nonparticipant cases at risk during the study period decreases sharply, and 
the last 2 squares in the nonparticipant curve , indicating more than 3 , and 
more than 5 years of fol low-up, are based on 12 and 2 cases respectively. 
The 2-year survival rate for nonparticipant cases is 68%, but still rather 
unstable: the 95% confidence limits are 56% and 80%. 
Age may have a confounding influence on the surv iva l . In order to study 
this influence, the relation between participation and breast cancer death was 
- 122 -
calculated for all patients b y means of an odds ratio. The odds ratio was 0.23 
(95% CI 0 . 1 3 ; 0 . 9 3 ) . All patients were stratif ied into 3 groups in 3 ways: 
year of birth (<1910, 1910-24, 1925-39), age at f i r s t invitation, and age at 
diagnosis (<50, 50-64, 6 5 + ) . The odds ratios were homogeneous for all catego­
ries. The summary odds ratio according to Mantel-Haenszel was OR= 0.21 with 
0.12 and 0.39 as 95% confidence l imits.' 7 Age did not prove to be a con-
founder. 
Lead-time 
One of the problems in the comparison of the case fatal ity in participant 
and nonparticipant cases is lead-time bias. Lead-time is the time interval b y 
which the diagnosis of cancer is moved back in time as a result of early 
detection. This means that if a lethal disease is detected, say, 2 years e a r l i ­
er (without any effect on the cure r a t e ) , it might be (erroneously) supposed 
that this patient diagnosed in the screening programme will live 2 years long­
e r . With early material HENDRIKS calculated a mean lead-time of 3 years for 
the Nijmegen screening programme." The average tumour size was 1.3 cm in 
se ree η-detected cases and 2.8 cm in symptomatic patients. A growth from 1.3 
cm to 2 . 8 cm equals an increase in diameter by a multiplication factor of 2 . 2 , 
and this equals 3.5 tumour volume doublings. On the basis of data of 35 can­
cers, a mean tumour volume doubling time of 312 days was calculated, 
yielding an estimated lead-time of 3.5*312 days = 3 years. 
There are several other ways to estimate the mean lead-time. WALTER and 
DAY have recently presented a lead-time estimation based on the observed 
prevalences of breast cancer at screening examinations and on the incidence 
of breast cancer dur ing intervals between examinations.9 >° In this model it 
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is assumed that before screening began the incidence rate of breast cancer in 
the population remained constant at value " I " and would have remained con­
stant if there had been no screening. A t the f i r s t examination a certain num­
ber of cancers are detected which have not surfaced clinically. The incidence 
of clinical cancer (diagnosed because of signs and symptoms) in the group 
newly screened for the f i r s t time will comprise individuals who had false-
negative screening results. If β denotes the false negative rate, the incidence 
just after examination 1 equals ß*l . As time elapses after the f i rst examina-
t ion, new cancers will develop, become incident, or , in the case of a second 
examination, be perhaps detected when screened. These frequency measures 
depend on I and the duration of the preclinical disease stage (PCP= preclini-
cal phase) . 
The incident cases among women examined twice comprise women who have 
had 2 false-negative screening results; or whose disease developed between 
examinations 1 and 2 , the second test result being false-negative; or whose 
disease developed after the second examination and soon surfaced clinically. 
This process will repeat itself if fur ther screening examinations are done. If 
the screening examinations are stopped, the incidence will gradually return to 
I. The incidence of breast cancer at time t , l ( t ) , and the prevalence at 
examination n, P ( n ) , can be seen as a function of the underlying incidence 
rate I , the false-negative rate β, and the preclinical phase (PCP) of the dis­
ease: 
I ( t ) = f ( I , β, PCP, t ) 
P ( n ) = g U , β, PCP, η) 
For these functions f and g , mathematical expressions have been derived 
which are used to estimate Ι , β, and PCP, based on observed l ( t ) s and P ( n ) 
rates. T h e PCP is variable, and the prevalence of the various durations of 
PCP consists of a certain mixture of short and long PCP values and may be 
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distributed in a specific way. If the variable PCP is assumed to be exponen-
tially distributed, the mean PCP is similar to the mean lead-time.9 This sta-
tistical model was applied to the observed prevalence and incidence rates in 
Nijmegen. The data were fitted with the iterative weighted non-linear least 
square estimation. The results are summarized in table 8 .1 . 
Table 8.1 Estimated incidence, s e n s i t i v i t y and lead-t ime in 
3 b i r t h cohorts 
Numbers of regular 
a t t enders 
No. of prevalent cases 
No. of incident cases 
Estimated incidence 
(per 1000 woman-years) 
Estimated s e n s i t i v i t y 
Estimated mean 
lead-t ime (in years) 
Goodness of f i t : 
X 2 - s t a t i s t i c 
P-value 
<1910 
2835 
5 .6 
0.627 
(df=2) 
0.72 
Bir th cohort 
1910-1924 1925-1939 
8142 
2.2 
1.684 
(df=4) 
0.79 
9203 
40 
6 
2.3 
80% 
114 
38 
2.8 
99% 
54 
48 
1.7 
51% 
2 . 6 
2.767 
(df=4) 
0.58 
A mean lead-time of 2.5 years was estimated for birth cohort 1910-39, and 
one of more than 5 years for the older group born before 1910. It must be 
noted, however, that a wide range of lead-time estimates can be regarded as 
consistent with the observed data. In this light one should consider the esti-
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mated sensitivity of nearly 100% in the bir th cohort 1910-24, which seems 
implausible. The estimated underlying incidence rate in the bir th cohort 
1910-24 seems too high as well . Therefore it seems unwise to use these est i -
mates to adjust the survival curves in f igure 8.1 for lead-time. 
Length time bias 
As a result of length time biased sampling slow growing lesions are over-
represented among screen-detected cases, whereas fast growing tumours are 
relatively more often diagnosed clinically between 2 screening examinations. If 
slow growing tumours can also be expected to grow slow in their fur ther 
course, screening will select cases with a longer than average survival in 
comparison with the incident cases. Figure 8.2 shows schematically the 
occurrence of breast cancer cases with various preclinical durations. It is 
clear that cases with higher PCP values are more likely to be detected at a 
screening examination. 
Consider the following hypothetical incidence series, consisting of 25% fast 
growing tumours with a PCP of, say, 5 years and 75% slow growing tumours 
with a PCP of, say, 10 years . In this case the proportion of slow growing 
tumours in the prevalence series will not be 75%, but a little over 85%, 
because relatively more fast growing tumours will have surfaced clinically and 
been diagnosed by the time of the screening examinat ion. 1 1 
HENDRIKS was able to show different growth rates for screen-detected 
cancers and interval cancers." He observed, in a retrospective study, a tum-
our shadow on the mammograms initially qualified "negative" of 18 screening 
cases and 17 interval cancer cases. The volume-doubling time of these 35 can-
cers could be calculated on the basis of two measurements: one of tumour 
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-Time 
Screening Examination 
Figure 8.2 Representation of length biased sampling. A horizon-
tal line represents the duration of the preclinical disease 
phase; those cases with longer duration are more likely to be 
prevalent at the screening examination 
diameters on the mammogram, and the other of the interval between the 2 
X-ray examinations. The results are summarized in table 8.2. 
Table 8.2 Tumour volume doubling time' 
18 screening cancers 
17 interval cancers 
35 cancers 
Mean 
426 days 
190 days 
312 days 
Range 
98-960 days 
60-434 days 
60-960 days 
Median 
372 days 
152 days 
299 days 
Table 8.2 shows that screening is selective because the slow growing tum-
ours are more likely to be detected at a screening examination (length time 
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biased sampling). The question is now whether length biased sampling could 
also cause differences in survival . The effect of length time bias is claimed to 
be stronger for cases detected at the f i rst examination, and weaker at later 
examinations.2 
Figure 8.3 displays the survival curves of 3 groups consisting of cases 1) 
detected at their f i rst examination (N= 125); 2) after their f i rst but before 
their second examination (N= 69 ) ; and 3) at or after their second examination 
(N=210). In the study period 15 subjects of the f i rst group died from breast 
cancer, 9 of the second, and 13 of the th i rd group. Group 2 consists of 
interval cancers and is assumed to include relatively more fast growing tum-
ours, because the slow growing ones are supposed to be more often detected 
at the f i rst examination (although a certain percentage of interval cases may 
have been false-negatives) . 
Figure 8.3 suggests the presence of length time bias because the survival 
of the f i rs t group is better than the survival of the other 2 groups. But it is 
difficult to derive from this f igure a reliable estimate of length time bias, for 
it is unknown whether group 3 is free of length-time bias or in any degree 
subject to i t . 
Selection bias 
It was studied whether participant cases differ from nonparticipant cases 
with respect to prognostic factors other than disease stage. In the same way 
as has been done for the detection of possible confounding influence of age, 
the relation between the cases' participation in the screening programme and 
breast cancer death was calculated by means of an odds ratio. The following 
factors were separately studied for a confounding influence on the odds ratio: 
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0.90 • 
1st exam 
0 12 24 36 48 60 72 84 
Month of follow-up 
Figure 8.3 Survival curves of 125 cases detected a t i n i t i a l examina-
t i o n , 69 cases diagnosed af te r i n i t i a l but before the second examina-
t ion and of 210 cases diagnosed at or a f t e r the second examination 
breast tissue pattern (Wolfe's classification), residential d istr ict , marital sta-
tus , family history of breast cancer, menopausal status, and estrogen recep-
tor status (thanks are due to Dr L Beex, endocrinologist, St. Radboud Uni-
versity Hospital, for data on this last factor ) . See table 8 . 3 . 
The crude odds ratio is 0.23 and hardly changed after adjustment for the 
above-mentioned factors. 
Another analysis was done to detect other prognostic differences between 
nonparticipant and participant cases. Figure 8.4 compares the survival curves 
of the 81 nonparticipant cases and of 87 breast cancer cases diagnosed after 
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Table 8.3 Results of s t r a t i f i e d analyses of the a s s o c i a t i o n of p a r t i ­
c i p a t i o n in the screening programme and b r e a s t cancer death; 25 out of 
81 nonpar t ic ipant cases and 37 out of 404 p a r t i c i p a n t cases died from 
b r e a s t cancer 
Control variable 
None 
Wolfe pattern 
District of residence 
Marital status 
Family breast cancer 
Menopausal status 
Estrogen receptor 
Numb 
of str 
-
2 
4 
2 
2 
2 
4 
er 
ata 
X2-score 
28.205 
9.687 
27.097 
29.223 
4.040 
17.796 
,27.194 
OR-ΜΗ 
0.23 
0.31 
0.24 
0.22 
0.20 
0.24 
0.22 
95% CI 
0.13; 0.39 
0.15; 0.65 
0.14; 0.41 
0.13; 0.38 
0.04; 0.96 
0.12; 0.46 
0.12; 0.39 
ι 
1.1.1975 (when the screening programme was s t a r t e d ) , but before their f i r s t 
invitation. 
This latter group emerged because it took 2 years for birth cohort 1910-39 
to be screened and y e t another 2 years for the women of birth cohort <1910 
(not invited to screening round 1) to receive their f i r s t invitation. These 87 
cases will be called pseudo-nonparticipants. In this group 25 patients died 
from breast cancer during the study period. The nonparticipant group has a 
significantly worse survival than the pseudo-nonparticipant group (P= 
< 0 . 0 0 7 ) . Because disease stage is a well-known prognostic factor, in both 
case groups a study was made of the distribution of factors like mammograph-
ical tumour size, axil lary lymph node involvement (histologically demonstrat­
e d ) , and mastectomy as primary treatment. Age distribution was also 
checked. T h e results are summarized in table 8 . 4 . 
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0.2
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Figure 8.4 Survival of 81 nonpar t ic ipant cases and 87 pseudo-nonpar-
t i c i p a n t cases 
34% of the nonparticipant cases have a radiologically measured tumour size 
of at least 5 cm, compared with 12% of the pseudo-nonparticipant cases. The 
distribution of the factors axillary lymph node involvement and mastectomy 
also suggests that nonparticipant cases have a more advanced disease stage 
than pseudo-nonparticipant cases. It may be that the Nijmegen nonparticipant 
cases, more than incident breast cancer patients, are women who postpone 
medical examination in spite of signs and symptoms. But it is not clear wheth-
er the nonparticipant cases have an unusually bad prognosis, or whether the 
pseudo-nonparticipant cases have a surprisingly good prognosis. 
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Table 8.4 D i s t r i bu t ion of prognost ic fac tors and age in nonpa r t i c i -
pant and pseudo-nonpart icipant cases 
Variable Nonpart icipants Pseudo-nonpart icipants 
Mammographie signs 
micro cale , or occult 
3- 19 mm 0 
20- 49 mm 0 
50-100 mm 0 
mast i t is carcinomatosa 
Axi l lary involvement 
yes 
no 
not h is to log ica l ly invest . 
Mastectomy 
yes 
no 
Age at diagnosis 
35-49 
50-64 
65+ 
Birth cohort 
<1910 
1910-1924 
1925-1939 
N= 80 
4 
9 
40 
19 
8 
N= 81 
31 
29 
21 
N= 81 
61 
20 
N= 81 
6 
30 
45 
N= 81 
38 
33 
10 
(100%) 
( 5%) 
( m) ( 50%) 
( 24%) 
( 10%) 
(100%) 
( 38%) 
( 36%) 
( 26%) 
(100%) 
( 75%) 
( 25%) 
(100%) 
( 7%) 
( 37%) 
( 56%) 
(100%) 
( 47%) 
( 41%) 
( 12%) 
N= 84 
6 
19 
49 
8 
2 
N= 87 
23 
16 
48 
N= 87 
82 
5 
N= 87 
4 
18 
65 
N= 87 
65 
15 
7 
(100%) 
( 7%) 
( 23%) 
( 58%) 
( 10%) 
( 2%) 
(100%) 
( 26%) 
( 18%) 
( 55%) 
(100%) 
( 94%) 
( 6%) 
(100%) 
( 4%) 
( 21%) 
( 75%) 
(100%) 
( 75%) 
( 17%) 
( 8%) 
In addit ion, a simultaneous comparison was made between the Nijmegen 
nonparticipant cases and the Arnhem breast cancer patients. Only disease 
stage information about cases from 1979-82 is avalaible in Arnhem now. A dis-
ease stage could be determined for 190 of the 265 Arnhem cases, according to 
the classification used in chapter 4. 71% of them had disease stage ll + , which 
corresponds with the 81% of the Nijmegen nonparticipant cases from 1975-82 
(see chapter 4 , table 4 .4 ) suggesting a not too great extent of selection bias. 
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Overdiagnosis bias 
In a screening programme tumours may be detected which would never 
have surfaced clinically. These cases have a 100% relative surv iva l . Unlike 
ductal carcinoma in s i tu , lobular carcinoma in situ is not supposed to be l i fe-
threaten ing . 1 2 That is why in the analysis depicted in f igure 8 . 1 , 7 cases of 
lobular carcinoma in situ were excluded, while all ductal carcinomas in situ 
were included. This may be arb i t rary , however, due to insufficient knowledge 
about the natural history of breast lesions, and it is still unknown to what 
extent the survival curves of participant and nonparticipant cases are incom-
parable because an unknown number of "benign" lesions have been included 
in the former group. 
An analysis was done to get an idea of the possible extent of overdiagno-
sis. In 1970-74, Arnhem and Nijmegen had the same age-adjusted breast can-
cer incidence.8 Assuming a similar underlying incidence rate in Arnhem and 
Nijmegen after the start of the screening programme, an excess number of 
breast cancer cases diagnosed in Nijmegen, in comparison with Arnhem, would 
suggest overdiagnosis. The Arnhem incidence rates of the age-group 45 and 
over in the period 1975-78 (based on 219 cases) and the period 1979-82 
(based on 236 cases) were used to calculate the expected number of cases in 
Nijmegen in the same periods. The results are summarized in table 8 .5 . (The 
age-group 35-44 was not selected for this analysis because too many cases in 
it were born after 1939, that year being the criterion of invi tat ion) . 
The total numbers observed in Nijmegen in 1975-78 are almost 35% higher 
than would be expected on the basis of the Arnhem f igures. This can be 
explained by lead-time. Women aged 45-64 at entry were f i rs t screened in 
1975-76, and women over age 64 in 1977-78. After a few screening rounds a 
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Table 8.5 Observed and expected numbers of breast cancer cases in Nij-
megen 1975-78 and 1979-82 according to age-specific breast cancer densi-
ties in Arnhem 
Age 
1975-1978 
Arnhem Nijmegen 
Incidence 
per 10' WY Obs Exp 0/E 
45-54 1.557 
55-64 1.327 
65-74 3.101 
75+ 4.110 
Total 2.231 294 218.55 1.35 
1979-1982 
Arnhem Nijmegen 
I n c i d e n c e 
p e r 103 WY Obs Exp 0/E 
87 49 .29 1.77 1.741 
85 3 8 . 2 1 2 .22 1.896 
70 73 .89 0 .95 2 .506 
52 5 6 . 2 3 0 .92 3 .945 
62 53 .07 1.17 
85 55 .99 1.52 
66 62 .77 1.05 
45 6 3 . 9 4 0 .70 
2.352 258 238.20 1.08 
WY= woman-year ; 0= o b s e r v e d number; E= e x p e c t e d number 
decline in the observed numbers should be noticeable in comparison with the 
expected number. This appeared only to be the case in the oldest age-group, 
but not in the group under 65. In the former group in the period 1975-82 the 
total number of diagnosed cases (screen-detected, (pseudo-) interval , and 
nonparticipant cases) was 233, whereas 256 were expected. This yields an 
O/E ratio of 0 . 9 1 . The O/E ratio in the age-group under 65 is 319/196= 1.62. 
The O/E ratio in the age-group 45+ in the whole period 1975-82 is 552/452= 
1.22. If the assumption of similar underlying incidence rates in Arnhem and 
Nijmegen is correct , this ratio suggests a large overdiagnosis due to screen-
ing. Chapter 4 showed that less than 10% of the Nijmegen cancers is non-
invasive. It may be concluded that screening can detect cancers, particularly 
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in women younger than age 65, which would never have developed into clini-
cally detectable tumours during the patient's life time. Entering such carcino-
mas in a survival analyis will bias the result. 
Conclusion 
The separate discussions of the 4 biases that influence case-fatality com-
parison have shown that it is almost impossible to determine the impact of 
these biases on the survival curves. There does not seem to be a way of 
compensating for the lack of randomisation. 
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Chapter 9 
CASE-CONTROL STUDY AND TREND 
STUDY IN THE EVALUATION OF THE 
SCREENING PROGRAMME 
Introduction 
At present the case-control study is the most frequently used analytical 
research method in cancer epidemiology. Its basic design is easy to under-
stand, but in practice it may be subject to substantial bias. Ideally a case-
control study is a mirror-image of a randomised controlled t r i a l . A randomised 
tr ia l is designed to guarantee the uniformity of the study group and the ref-
erence group in all respects except screening status. In a case-control study 
cases and controls should also be uniform with respect to all relevant charac-
terist ics, except the one of interest, v iz . the exposure to the screening pro-
cedure or screening status. The case-control design has been widely used in 
etiologic investigations. Since ANDERSON and CLARKE public health interven-
tions have also been evaluated by means of case-control studies. 1 One of the 
problems with this research technique is the potential influence of selection 
bias. A screening programme may attract volunteers who are self-selected for 
screening. Selection factors can be related to breast cancer mortality r isk, 
e . g . risk factors for developing the disease, health consciousness, or wil l ing-
ness to comply with treatment. It is difficult or even impossible to control for 
the effect of selection factors. Therefore a low breast cancer mortality rate 
among voluntary screenees may invalidly be attr ibuted to screening. If there 
is not any selection bias, the efficacy of breast cancer screening can be 
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assessed b y a case-control study in which "nonparticipation in the screening 
programme" is examined as a potential risk factor for breast cancer death. 
Special attention should be paid to defining cases and controls. 2 э 
In the evaluation of health care services a distinction is made between e f f i ­
cacy and effectiveness. Efficacy is the potential effectiveness that is achieved 
when e . g . the screening programme is accepted b y everyone in the t a r g e t 
population. If the attendance is lower than 100% the term effectiveness is used 
to describe the actual mortality reduction in the total t a r g e t population. 
This chapter will discuss the observed efficacy, but f i r s t go into some 
detail about the effectiveness of the screening programme. 
Prevented fraction 
In chapter 7 it was calculated by means of a case-control study t h a t the 
efficacy of screening was ± 50%. This means a potential mortality reduction of 
50%, if all women invited are examined. The term effectiveness is used to 
denote the actual mortality reduction in the total population. I t is clear that 
not everyone will make use of the health care service of "population screen­
ing". The population attributable risk measures the number of women who 
would benefit from the health care service of screening.* The attendance rate 
and the effect measure of screening on mortality ( h e r e : the odds ratio) are 
necessary to calculate the population attributable r isk, rather, the "prevented 
fract ion", i.e. the proportion of potential new breast cancer deaths in the 
population t h a t were actually prevented b y the screening examinations. 5 The 
next formula presents the prevented fraction as a function of the case f r a c ­
tion and odds ratio: 
Pc*a-0R) 
p F = (1) 
Pc*(l-0R)+0R 
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where Pc is the estimated proportion of breast cancer deaths that were 
screened, and OR is the estimated odds ratio. Substituting the estimated fig-
ures of chapter 7 in the formula yields the following crude PF: 
(37/62)( l -0 .53) 
= 0.347 
(37/62)( l -0 .53) + 0.53 
This means that, given the observed attendance rate, the breast cancer mor-
tality in Nijmegen must reduce by about one-third (which is comparable with 
the HIP effect 7 years after entry). 
Chapters 4 and 7 show that the attendance rate and the estimated effect 
vary which age. That is why the age-adjusted PF has been calculated: see 
table 9 . 1 . 
Table 9.1 Estimated prevented f rac t ion of b reas t cancer deaths by the sc ree -
ning programme 
Age a t b reas t cancer death 
<50 50-54 55-64 65+ All ages 
Proport ion screened 
b reas t cancer deaths 6/8=0.75 8/10=0.80 13/20=0.64 10/24=0.42 37/62=0.60 
0R-HLE 
Prevented fraction 
1. u-n 
0 
0.36 
0.59 
0.42 
0.47 
0.59 
0.23 
0.53 
0.35 
Expected* No. of 
deaths in a 5 y period 
without screening 
programme 16 14 35 95 160 
Actual number of deaths 
in a 5 y period with 
screening programme** 16 5.7 18.6 73.2 113.5 
*Based on the Nijmegen number of breast cancer deaths 1978-1982 
**Calculated according to formula (1) 
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The crude analysis showed a PF of 35% ( 0 . 3 4 7 ) : the breast cancer 
mortality would decrease to 104/160= 65%. Age-specific estimations suggest the 
mortality would decrease to 113.5/160= 71%; (113.5= 16+5.7+18.6+73.2). 
Criticism 
In the Lancet of 25 August 1984, a letter to the Editor was published in 
which it was claimed that the case-control design is unsuitable for estimating 
the effect on mortality and that it justifies only one conclusion with respect to 
screening for cancer: "screened patients will be likely to have longer 
diagnosis-to-death intervals, but this does not necessarily mean that death is 
delayed too." 6 The authors finished their letter to the Editor as follows: 
"There really is no alternative to a randomised study if screening is to be 
properly assessed. Case-control analyses, unfortunately, can be very difficult 
to understand. These two studies [the Nijmegen and Utrecht case-control 
studies were the subject of criticism] seem to suggest great benefit from the 
use of mammography on all women over the age of 35 or 40, but close scruti -
ny shows that the results are artifacts of case selection. Case-control studies 
might seem to be impressive alternatives to randomised studies, but they are 
not ." In a combined reply the Nijmegen and Utrecht study teams made it clear 
that neither case selection nor control sampling was faulty in their studies. 7 ' 
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Baum and MacRae state that the results "can only be 
interpreted to mean that patients who have short diagnosis-to-death 
times are unlikely to have had their breast cancer diagnosed by 
screening Screened patients will be likely to have longer diagnosis-
to-death intervals, but this does not necessarily mean that death is 
delayed too—ie, in addition to diagnosis being made earlier" This 
conclusion is incorrect, since the two studies do demonstrate a delay 
in the time of death, with the caveats normal to an observational 
case-control study The flaw in iheir reasoning seems to stem from a 
misconception about how the two case-control studies were 
designed These studies were designe'd to compare the breast cancer 
mortality rates in two groups of women, both free of disease(ie, not 
diagnosed with breast cancer) before entry to the study—one group 
who agreed to attend the screening programme and one group who 
refused 
As in a randomised trial or in a prospective study, all deaths from 
breast cancer in the first seven years after the start of the study were 
recorded These deaths were in women with breast cancer 
diagnosed after the start of the study In a randomised trial, these 
deaths would be related to the total women-years of follow-up in the 
two groups, to obtain the absolute mortality rates from breast cancer 
in the screened and unscreened groups. In our studies, absolute 
mortality rates were not estimated since this would have required 
abstracting the entire population lists of the two cities for each year 
of the study, to identify completely the group of refusers The ratio 
of the two mortality rates, however, can be estimated very much 
more economically by sampling the population lists, from which 
sample the proportions of the relevant female population who 
attend or refuse screening can be determined This sampling 
scheme forms the basis of the case-control approach. In the first 
seven years after screening started, the breast cancer mortality rate 
in the women accepting screening was only 30% (Utrecht) and 50% 
(Nijmegen) of the breast cancer mortality rate in the groups who 
refused screening Since at the start of the study, both groups were 
free of breast cancer, advancing the time of diagnosis of breast 
cancer will not in itself lead to a subsequent reduction in the 
mortality rate unless the date of death is delayed 
The only difference m principle between these two case-control 
studies and a randomised trial such as the New York Health 
Insurance Plan (HIP) study is the process of randomisation. Both 
approaches aim at comparing the reduction in breast cancer 
mortality in a screened and an unscreened group, both of which 
were initially free of disease, questions of lead time as an explanation 
of an observed reduction are irrelevant to both designs 
The problem with the case-control approach is precisely the lack 
of randomisation, and the possible biases present when groups are 
self-selected This question was discussed at some length1,2 and no 
evidence for appreciable bias was apparent Furthermore, the HIP 
results suggest that whatever bias may be present might reduce 
rather than inflate the estimated effect of breast cancer screening, 
since women who refused screening were at lower risk. 
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The curious feature of the results of the two case-control studies 
referred to by Baum and MacRae in their penultimate paragraph-
that the proportion accepting screening in the control group differs 
substantially from the proportion accepting screening overall—is 
easily explained The screening history of the controls was taken 
only up to the time of diagnosis of the matched case. If the full 
screening history is considered, then the control group is similar to 
the total population 
Baum and MacRae are right to urge caution in the interpretation 
of case-control studies, since without randomisation one cannot be 
sure that bias has been eliminated On this occasion, however, their 
criticism is aimed at the wrong target. The studies under discussion 
do address the fundamental question—Does screening delay death? 
Unless severe bias were operating (a separate issue) the results of 
these two studies do indicate that breast cancer screening delays 
death from breast cancer 
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To assess the efficacy of screening, a randomised controlled tr ial is no 
doubt preferable to a case-control study. In a nonexperimental study there is 
no guarantee that screenees and nonscreenees are comparable with respect to 
all kinds of determinants of breast cancer mortality. In Nijmegen the compar-
ability of both groups was determined only for age, marital status, and dis-
t r ic t of residence. A case-control study may not be an alternative to a ran-
domised controlled t r i a l , but it can be opted for in the analysis of a 
nonexperimental screening project. The role of the case-control method in the 
evaluation of the side-effects of screening is a separate issue. 
Side-effects 
Some disadvantages of screening have to be mentioned. First of al l , the 
term mortality reduction indicates that screening does not provide a 100X pro-
tection. Some women will die from breast cancer in spite of screening. For 
them the diagnosis will only be made some years earl ier. 
There are more disadvantages to screening, which were only touched upon 
in the previous chapters. Just one-third of suspect screen-detected lesions 
proves to be malignant ( the predictive value positive is 35%), so for every 
case detected, another 2 women have to undergo fur ther examination and may 
have to have a biopsy which they would not have had otherwise. Nor has the 
topic of overdiagnosis and overtreatment been discussed exhaustively. 
In chapter 8 it was mentioned that the total numbers of diagnosed cancer 
cases in Nijmegen is still too high in comparison with the Arnhem numbers. 
Screening leads to early diagnosis and will detect an excess number of breast 
cancer cases in the lead-time interval i .e. the period between the time when 
the disease is detected by screening and the time that diagnosis would have 
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occurred in the absence of screening. Consequently, the screened population 
will have a higher breast cancer disease rate. The excess number of screen-
detected cases is expected to decrease as time goes on and more screening 
examinations are performed. The total number of registered breast cancer 
cases in the population will then be equal to the numbers expected in the 
absence of screening. This, however, was not found to be the case in the 
age-group 45-64: see table 8.5. The Arnhem incidence rates in the period 
1975-82 may have been relatively low and consequently the expected numbers 
in Nijmegen underestimated. Therefore the incidence in Arnhem has been com­
pared with the incidence of the population-based cancer registry of the SOOZ 
(Samenwerkings Orgaan Oncologie Ziekenhuizen) covering an area of about 1 
million inhabitants that includes Eindhoven.9 The results are summarized in 
table 9.2. 
Table 9.2 Observed and expected numbers of 
b reas t cancer cases in Arnhem in the period 
1977-81 according t o breas t cancer incidence 
d e n s i t i e s in the SOOZ-region (based on 1596 
cases) 
ι 1 
Age 
45-54 
55-64 
65-74 
75+ 
Total 
Observed 
number 
62 
56 
83 
73 
274 
Expected 
number 
67.71 
83.24 
86.59 
61.92 
299.46 
0/E 
0.92 
0.67 
0.96 
1.18 
0.91 
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Table 9 .2 suggests that the Arnhem incidence in the age-group 55-64 is 
too low and thus biases the expected numbers in Nijmegen. Unfortunately no 
fur ther data of a SOOZ - Arnhem comparison are available. Unlike a random-
ised controlled tr ial the case-control method cannot determine the rate of 
overdiagnosis (and overtreatment) . In a case-control approach breast cancer 
diagnosis is the outcome variable. The problem is that the breast cancer cases 
which were detected during their lead-time interval will falsely suggest an 
excess number of overdiagnosed cases. The eligibil ity of the patients for the 
case-control study is a question that cannot be resolved satisfactorily by 
excluding cases at the f i rs t screening examination, since this would create a 
relative deficit of screen-detected cases suggesting rather an absence of 
overdiagnosis. In Nijmegen, therefore, it could not be established if and how 
many lesions were detected by screening that would never have made the 
transition to metastatic disease. To assess the extent of overdiagnosis a ran-
domised controlled tr ial is essential, assuming the controls do not have 
screening examinations on their own initiative. 
Mortality t rend 
In the Lancet of 30 June 1984, some general points of criticism were raised 
with respect to the estimated mortality reduction, e . g . : "Why, if screening 
for early breast cancer is so effective does the mortality assigned to breast 
cancer remain so constant?"1 0 This question referred in particular to the 
situation in the US, where screening for breast cancer has been propagated 
since the 1970s, especially through the BCDDPs. But this question can also 
be applied to the situation in Nijmegen. Given the fact that screening with 
mammography turned out to be so effective (chapter 7 ) , and that by the end 
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of 1982 80% of the Nijmegen female population born before 1940 had been 
screened for breast cancer at least once (chapter 4 ) , why was there no fall 
in breast cancer mortality in the total population of Nijmegen in that period 
(chapter 5)? A simple answer can be given. It took the years 1975 through 
1978 to get all women at least 1 invitation. I t is estimated that in this period, 
in the absence of screening, about 200 breast cancer cases would have sur-
faced clinically, a 100 cases of whom would have been detected by screening. 
Suppose a 5-year survival rate of 65% and a 50% mortality reduction by 
screening, then by the end of 1981, ca. 17-18 breast cancer deaths would 
have been prevented by screening. However, this number is low compared 
with the 5*30= 150 deaths observed in the period 1978-1982. What is more, 
against the background of the annual f luctuations, an effect so small will 
hardly be noticed. 
I t can only be roughly predicted at what point in time the maximum reduc-
tion in the total number of breast cancer deaths in Nijmegen should be 
observed, given an attendance rate of 2/3 and a 50% mortality reduction by 
screening. To calculate th is , the incidence rates and the corresponding sur-
vival rates from the last 3 decades are indispensable, but unfortunately they 
are not available. By way of alternative a kind of simulation can be made, 
based on some fur ther assumptions: since 1974 the annual number of Nijmegen 
breast cancer deaths has been 30; this absolute mortality would have remained 
constant in the absence of screening; and finally it is assumed that if a 
patient is to die from breast cancer, she will do so within 20 years after 
diagnosis. This time interval is based on a prolonged follow-up study in New 
Zealand where 20 years after diagnosis, the prognosis for women with breast 
cancer approached normal l i fe-expectancy. 1 1 On these assumptions, 30 Nijme-
gen women, who were diagnosed in 1974 just before the start of the screening 
programme, were expected to die before 1995, while the other women diag-
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nosed for breast cancer in the same year were expected to survive the dis-
ease. If 2 /3 of the target population receive a screening examination and in 
this way halve their risk for breast cancer, in due time only 20 instead of 30 
deaths will be observed (30*0.5*2/3= 10) . The invitation schedule was such 
that not until the end of 1978 all eligible women (born before 1940) had 
received a f i rst invitation. Therefore the new stable situation of 20 deaths 
per year is expected in the second half of the 1990s. In addition this sug-
gests that an average reduction of 30 to just 25 annual breast cancer deaths 
is not to be expected until the second half of the 1980s. It is obvious that 
this result is qualified by other quantitative assumptions. 
Another question is whether perhaps a favourable effect of screening is 
masked by an upward t rend in breast cancer mortality. The effect of screen-
ing on the total breast cancer mortality will set in gradually because there 
are various breast cancer growth rates and because there is a time lapse 
between detection by screening and breast cancer death. I f , independently of 
screening, there is an upward trend in breast cancer mortality (not a theo-
retical issue: see the l i terature review in chapter 2) mortality could remain 
constant for a certain period, in spite of a screening effect. Figure 9 . 1 , how-
ever , shows it to be unlikely that a screening effect is masked by an overall 
upward t rend . In the Netherlands in 1969-1982 mortality remained constant in 
all age-groups, except the oldest one. 
The results of the Nijmegen and Utrecht studies indicate that breast can-
cer mortality among women of 35 and over can be reduced by roughly 50% by 
regular mammographie screening of all eligible women. In fact , these results 
do not constitute new evidence but they are the f i rst confirmation of the 
results from the HIP s t u d y . 1 2 In spite of these results it is still too early to 
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Figure 9.1 Age-specific b reas t cancer m o r t a l i t y per 100,000 woman-
years in the Netherlands 1969-1982; 5 age-groups 
make statements about the introduction of population screening on a national 
scale. It would also be inappropiate, because aspects other than mortality 
reduction have to be taken into account as wel l , e . g . economical issues, not 
discussed here. It is claimed that screening could pay for itself by saving 
lives as a result of early treatment instead of qualitative treatment. Further­
more, i t should be remarked finally that the evaluation of the screening 
project has only just begun. Longer follow-up of the Nijmegen population is 
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needed to determine to what extent screening can detect breast cancer early 
enough for the patient to be cured, instead of being worried longer because 
death is merely delayed. A study of the determinants of negative aspects 
must be initiated as well as a study of the costs needed to achieve breast 
cancer reduction. Only then will sufficient material be at the disposal of pol-
icy makers for a decision concerning population screening on a national scale. 
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Chapter 10 
THE ISSUE OF HIGH-RISK GROUP 
SCREENING 
Introduction 
In the previous chapters the question was evaluated how great a reduction 
of breast cancer mortality could be produced by screening with mammography. 
Once an effect has been demonstrated, other questions crop up, e . g . wheth-
er women under age 50 should be screened and if so, how frequent ly; and 
whether there should be different screening schemes for high risk and normal 
risk women. This chapter will attempt to define a high risk group in terms of 
risk factors other than age. First a broad summary will be presented of cur -
rent facts on breast cancer risk factors and special attention will be paid to 
those factors that may be relevant to selective screening. Falling within the 
scope of risk factors, the relation between mammographie breast pattern and 
oral contraceptive use respectively and breast cancer risk will be discussed 
on the basis of Nijmegen material. 
Risk factors: a short review 
In this section a short review of the risk factors of breast cancer will be 
given. Parts of it are quoted from KELSEY1 , and verif ied with data from the 
Nijmegen screening project. 
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In Western countries carcinoma of the breast is the most common cancer in 
females over age 40. The world's 10 highest annual incidence rates are quoted 
from the Statistics of the International Agency for Research on Cancer and 
presented in table 10.1. The estimated incidence in the Netherlands in 1977 is 
added to these figures. 
Table 10.1 World's 10 highes t b reas t cancer incidence r a t e s according to 
IARC s t a t s t i c s 2 and incidence r a t e in the Netherlands according to CBS/ 
SMR cancer r e g i s t e r 3 
1 
Age-adjusted"'·*" Crude incidence | 
Cancer registry* Period incidence per per 105 | 
105 woman-years woman years | 
Los Angeles (White) 
Switzerland (Geneva) 
Canada (Br Columbia) 
The Netherlands 
New Zealand (Non-Maori) 
Israel 
Uited Kingdom (Oxford) 
Denmark 
Brasil 
FR Germany (Hamburg) 
Sweden 
1972-77 
1973-77 
1973-77 
1977 
1972-76 
1972-76 
1974-77 
1973-76 
1973 
1973-77 
1971-75 
65.3 
76.1 
72.8 
72.0 
72.9 
59.9 
59.3 
58.8 
56.2 
55.7 
55.2 
( 1) 
( 2) 
( 3) 
( 4) 
( 5) 
( 6) 
( 7) 
( 8) 
( 9) 
(10) 
(11) 
118.9 ( 1) 
114.3 ( 2) 
86.6 ( 6) 
91.2 ( 4) 
62.6 (10) 
63.1 ( 9) 
81.7 ( 8) 
85.3 ( 7) 
44.0 (11) 
97.8 ( 3) 
88.3 ( 5) 
I 
* Only cancer r e g i s t r i e s with a t l eas t 1000 b reas t cancer cases diagnosed 
in the study per iod . (Rank order within pa ren theses ) . 
** World populat ion as s tandard . 
On the basis of these rates, the age-specific incidence rates of the Neth-
erlands in 1977, and the age-specific incidence rates of Arnhem in the period 
1975-1982, it is estimated that in the Netherlands 1 in 12 women will develop 
breast cancer at some point during her life. The incidence rates increase rap-
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idly with age up to 150 per 100,000 woman-years in the group of age 50, and 
then, at a slower rate, continue to increase to more than 350 per 100,000 
woman-years in the age-group 80+. 
I t is postulated that premenopausal and postmenopausal breast cancer have 
different etiologies. The former is believed to be associated with reproductive 
characteristics, which in turn are closely related to the function of the ovar-
ies. The latter seems to be more associated with exogenous factors, like 
nutrition and l i fe-style. Many epidemiologic studies have been done in this 
f ie ld. These have established that early age at f i rst bir th (<18) is a protec-
tive factor. The f i rst ful l - term delivery after age 35 is a risk factor for 
breast cancer. Early age at menarche (<12) and late age at menopause (>55) 
increase breast cancer r isk, while removal of the ovaries earlier than age 35 
lowers the risk to about one- th i rd . A combining role in all these factors is 
ascribed to the endogenous hormones, in particular to estrogens. However, 
special case-control studies doing biochemical analyses of plasma, ur ine, and 
(recently) saliva, failed to demonstrate significant differences in estrogen 
concentrations. On the other hand these results do not preclude the possibili-
t y that estrogens stimulate cancer growth. Maybe the estrogen levels at a 
younger age are more important for the development of breast cancer. If hor-
mone levels change during l ife-t ime, a case-control study is not the most 
suitable study design for etiologic investigations. The role of endogenous hor-
mones in breast cancer etiology has raised concern about the possibly harmful 
effect of 2 widely used exogenous hormones containing estrogens: oral contra-
ceptives and estrogen replacement medicines for perimenopausal complaints. 
The role of oral contraceptives will be more extensively discussed at the end 
of this chapter. Concerning the cancer promoting or inducing properties of 
estrogen replacement therapy, it is to be noted that many studies have meth-
odological limitations and do not show consistent results. The provisional 
conclusion is: no clear-cut effect. 
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Many epidemiologic studies have been done to determine the role of benign 
breast disease in the development of breast cancer. They show that an excess 
breast cancer risk is related to the presence of benign breast diseases. Most 
of these studies point to a doubled r isk. 
It has been suggested for many years that nutrition plays a role in breast 
cancer etiology. In countries where relevant data are available, there is a 
fair ly strong correlation between the per capita consumption of fats and oils 
and breast cancer mortality rates. The increase in breast cancer death rates 
among offspring of Japanese immigrants in the United States can be correlated 
with changes in their dietary habits. An upward trend in breast cancer inci-
dence in Iceland and England is correlated with an increased dietary fat 
intake. Because of the influence of many other factors it is difficult to detect 
causal relations. Several case-control studies that analysed nutrition and 
reproductive factors simultaneously could only demonstrate a weak association 
between high fat intake and breast cancer. It should be remarked here, that 
a retrospective study can hardly determine the dietary habits of years ago. 
Other studies among postmenopausal women show an association between obesi-
t y and breast cancer. In addition, age at menarche is influenced by nut r i -
t ion. Fat children become "mature" at an earlier age, and early menarche has 
already been mentioned as a risk factor. 
For the sake of completeness high socioeconomic status and family history 
of breast cancer have to be designated as risk factors too. It is still unknown 
to what extent environmental or genetic factors play a role. Many studies, 
however, indicate that women who have a f i rs t degree relative with breast 
cancer have a risk twice or 3 times the risk in the general population. If 
mother and sister are diagnosed for breast cancer, the relative risk ratio 
even increases to 8-10. All the factors discussed so far are presented in 
table 10 .2 . 
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Factor Elevated risk Reference Risk rat io* 
Table 10.2 Risk factors for breast cancer 
Age 
Age at 1st birth 
Parity 
Age at menarche 
Age at menopause 
Oophorectomy 
Benign breast disease 
Obesity 
Socioeconomic status 
Family history of 
breast cancer 
1 
65+ 
>35 
0 
<11 
>55 
no 
yes 
yes 
high 
yes 
<50 
<20 
>1 
>14 
<50 
yes 
no 
no 
low 
no 
>4 
>2 
<2 
<2 
<2 
>2 
<2 
1.5 
2 
2-4 
I 
* Breast cancer risk of women exposed to the risk factor rela-
tive to women of the reference category 
The associations are weak, and causal to an unknown degree only. The 
possibility of prevention is therefore restricted, all the more because too few 
women are exposed to these risk factors. Consider e.g. obesity as a causal 
factor. Women with a Quételet-index of at least 29 ( i .e . more than 15 kg 
above the ideal body weight) have a risk ratio of 1.5, compared with less 
obese women. Given the prevalence of women with such a high Quetëlet-
index, it can be estimated that the incidence of breast cancer could be 
reduced by 10% at most, provided dietary treatment were succesful in all 
these women. It can be concluded that primary prevention will hardly contrib-
ute to breast cancer incidence reduction. 
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High-r isk groups 
Some issues have to be taken into account when the value of risk factors 
in selective screening is assessed.11 5 Of these risk factors, age is obviously 
very important in every screening programme. If screening is concentrated on 
women of age 50 and over, instead of 40 and over, 25% of the cancers will be 
missed. On the basis of the Nijmegen screening data premenopausal and post-
menopausal women were separately studied to see whether high risk groups 
could be determined. For this purpose the prevalence in the population in the 
f i rst screening round was determined of the following dichotomized risk fac-
tors. See table 10.3. 
Table 10.3 Prevalence of seven r i sk fac tors in the Nijmegen 
screening populat ion 1975-76, age 35-64 
1 
Factor 
Marital status 
Obesity 
Parity 
Age at 1st birth 
Age at menarche 
Family with breast cancer 
Benign breast disease 
(according to mammogram) 
Risk indicator 
never married 
Quételet-index >31 
no children 
>30 years 
<11 years 
positive 
positive 
Prevalence 
11% 
12% 
18% 
2 Tk* 
η 
10% 
5% 
I 
* n u l l i p a r o u s women excluded 
Table 10.4 summarizes how many premenopausal and postmenopausal women 
actually have a combination of these risk factors. It displays the percentages 
of all cancers t h a t would be detected at the f i r s t screening if just these 
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women were screened. It can be derived from these f igures t h a t if a mere 50% 
of the total population -women with at least 1 risk factor- were screened, 70% 
of all cancers would be detected at the f i r s t screening. 
Table 10.4 D i s t r i b u t i o n of r i s k factors in p r e - and postmenopausal woman and 
proport ion of cancer cases if only h igh-r i sk groups had been screened for 
the f i r s t time 
Premenopausal Postmenopausal 
Screen-detec Screen-detec 
Number 
of risk 
factors 
>0 
>1 
>2 
>3 
>4 
W 
N 
9511 
4285 
1483 
265 
10 
этеп 
% 
100% 
45% 
16% 
3% 
0% 
ted 
N 
28 
20 
9 
2 
0 
cases 
% 
100% 
71% 
32% 
7% 
0% 
Number 
of risk 
factors 
>0 
>1 
>2 
>3 
>4 
Women 
N 
10003 
5642 
2036 
356 
28 
% 
100% 
56% 
20% 
4% 
0.3% 
ted 
N 
49 
34 
14 
5 
0 
cases 
% 
100% 
69% 
29% 
10% 
0% 
Table 10.5 gives the results on women screened for the second time. These 
results indicate that if half of the population were screened -again women 
with at least 1 risk factor- only 50-56% of the cancers would be detected at 
the second screening examination. Maybe these f igures can be used to deter­
mine how frequently certain women should be screened. It seems that at this 
moment little effect can be expected from selective screening. 
The assessment of high risk groups became topical again when WOLFE in 
1976 introduced his mammographie breast patterns as an index of risk of 
developing breast cancer. 8 As early as 1967 Wolfe had presented a classifica­
tion of xero-mammograms. Later on he made a classification into 4 groups with 
increasing breast cancer risk. He said that it would make it possible to deter-
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Table 10 5 D i s t r i bu t ion of r i sk fac tors in p re - and postmenopausal woman and 
proport ion of cancer cases if only h i g h - r i s k groups had been screened for 
the second time 
Premenopausal Postmenopausal 
Number 
of risk 
factors 
>0 
>1 
>2 
>3 
>A 
Women 
N 
7749 
3368 
1134 
200 
10 
% 
100% 
43% 
15% 
3% 
0 1% 
ted 
N 
16 
8 
2 
0 
0 
cases 
% 
100% 
50% 
13% 
0% 
0% 
Number 
of risk 
factors 
>0 
>1 
>2 
>3 
>4 
Women 
N 
7817 
4348 
1532 
259 
21 
% 
100% 
56% 
20% 
3% 
0 3% 
ted 
N 
28 
16 
7 
0 
0 
cases 
% 
100% 
57% 
25% 
0% 
0% 
mine high risk groups and apply the outcome to population screening. Wolfe's 
classification, in order of increasing r isk, is as follows: N 1 , parenchyma com-
posed primarily of fat with at most small areas of increased density; P I , par-
enchyma chiefly fat with prominent ducts in anterior portion up to a quarter 
of the breast volume; P2, severe involvement of prominent duct pattern occu-
pying more than one quarter of the breast volume; DY, severe involvement 
with dysplasia, which often obscures an underlying prominent duct pat tern . 
Wolfe presented the results of a retrospective cohort study among 5340 
women. The women were referred to hospital for a mammogram because of 
vague complaints involving the breasts. They were initially free of breast 
cancer and all were older than 30. The mammograms were classified into N 1 , 
P I , P2, and DY. The mean follow-up time was 3 years. Among these women 
76 breast cancers occured. In the DY group the incidence was 44.6 per 1000 
and m the N1 group 1,4 per 1000, yielding a risk ratio of 31 for the DY 
group. Such a high risk ratio seems implausible. If the prevalence of DY in 
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the population is set at 25%, this risk ratio would imply that 80% of all diag-
nosed breast cancers are to be found in the DY group, but this is not borne 
out by clinical experiences. 
The Nijmegen screening project also studied the relation between mammo-
graphie breast pattern according to Wolfe and breast cancer risk. The 
results were published in THE LANCET of 17 March, 1984; 591-593. 
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Summary Within the Nijmegen breast cancer screening 
programme a study was made of the relation 
between mammographie breast features according to Wolfe's 
classification and breast cancer risk. The time of follow-up 
was 6 years. The Nijmegen study challenged the strong 
relationship previously suggested. In comparison with 
women of N1 and PI breast type, the relative risk for women 
with P2 and DY breast type was estimated at 0-7, with 95% 
confidence limits of 0-2 and 2-4, after adjustment for the 
major risk factors. The results could not be explained by 
intra-observer variability or left-right difference. 
Introduction 
IN 1976 Wolfe, in a paper on mammographie parenchymal 
patterns and breast cancer risk, introduced a classification of 
the radiographic appearance of breast parenchyma into four 
groups with increasing breast cancer risk.' 
Wolfe's classification, in increasing order of risk, is as 
follows: N1, parenchyma composed primarily of fat with at 
most small areas of increased density; Ρ1, parenchyma chiefly 
fat with prominent ducts in anterior portion up to a quarter of 
the breast volume; P2, severe involvement with prominent 
duct pattern occupying more than a quarter of the breast 
volume; DY, severe involvement with dysplasia, which often 
obscures an underlying prominent duct pattern. 
As the results of other studies became available, the 
relationship found by Wolfe turned out to be less obvious and 
in some age-groups non-existent.2'8 The variation in these 
results may be due to different study designs (creps-sectional 
versus longitudinal), different study populations (hospital-
based or population-based), differences in risk factor 
patterns, or misclassification of the breast pattern. Data from 
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the breast cancer screening programme in Nijmegen, the 
Netherlands, enabled us to reassess the relation between 
mammographie breast features according to Wolfe and breast 
cancer risk with a follow-up time of 6 years. Other risk 
factors, intra-observer variability, and asymmetry of the 
breasts are considered. 
Subjects and Methods 
The data for this case-control study came from a breast cancer 
screening programme in which 19 532 women aged 35-64 had been 
screened since the programme started in 1975 ' Single-view 
mammography (initially lateromedial projection, since August, 
1981, mediolatero-obhque projection) had been earned out as the 
sole screening examination every 2 years, and in 1975-76 a standard 
questionnaire was used to obtain information about personal 
characteristics, medical history, and risk factors By 1982 four 
screening rounds had been done. 
Subjects 
The case series consisted of all women in whom breast cancer had 
first been diagnosed at their fourth screening examination in 
1981-82. It concerned 20 cases. A control group of 60 women was 
selected at random from all those who had been screened four times 
without diagnosis of breast cancer. 
Mammography 
The radiographs from the first screening examination in 1975-76 
were classified according to Wolfe by one of us (J. H ), who had no 
knowledge of the disease stage 6 years later. For controls the 
mammographie classification of the left breast was used after 
similarity of parenchymal pattern between the left and right breast 
had been confirmed. In cancer cases the mammographie 
classification of the breast subsequently involved was used. 
Data Analysis 
The sample size of 20 cases and 60 controls is sufficient to 
guarantee an 80% chance offinding a risk ratio of 5 at the 5% level of 
statistical significance under the assumption that 20% of the 
population have a P2 or DY breast 10 The risk ratio was estimated in 
terms of its odds ratio approximation. The confidence interval was 
computed by means of Miettinen's test-based method." To adjust 
for the possible confounding effects of risk factors, multiple logistic 
regression fitted by the method of maximum likelihood was applied 
Results 
The breast parenchymal patterns in left and right breasts 
are not necessarily the same. Most women have a somewhat 
larger left breast, and breast cancer is diagnosed a little more 
often in the left breast.12 Therefore the left-right differences 
in parenchymal patterns were studied. The 1975-76 
radiographs from 11 cases and 15 controls were classified, 
each side without reference to the other. There were hardly 
any left-right differences (table I). 
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Table II gives the distribution of parenchymal types in 
1975-76 among cases and controls. Cases had more N1 than 
DY patterns than controls. For the remaining analyses the N1 
was combined with the PI and the P2 group with the DY. 
The crude risk-ratio estimate for women with P2 + DY 
breast pattern compared with women with N1 + Ρ1 was 0 · 4 
with 95% confidence limits of 0 · 2 and 1 · 2 (table III). 
As potential confounding factors the following variables 
were included in the analysis: age, menopausal status, parity, 
age at first pregnancy, age at menarche, oral contraceptive 
use, family history of breast cancer, and obesity (Quetelet 
index, weight/height2). These factors were recorded at the 
first screening examination in 1975-76. Because only 2 cases 
and 3 controls had a family history ofbreast cancer, this factor 
was not included in the regression equation. The multivariate 
risk-ratio estimate for the data in table II is given in table III. 
TABLE 1-WOLFE CLASSIFICATION LEFT AND RIGHT IN CASES 
AND CONTROLS 
Cases (n= 11) 
Wolfe 
left 
N1 
PI 
P2 
DY 
Total 
Wolfe right 
N1 
2 
_ 
— 
— 
2 
PI 
1 
3 
— 
— 
4 
P2 
, 
1 
4 
— 
5 
DY 
_ 
_ 
— 
-
Total 
3 
4 
4 
_ 
11 
Controls(n«15) 
Wolfe 
left 
N1 
PI 
P2 
DY 
Total 
Wolfe right 
N1 
4 
_ 
— 
— 
4 
PI 
3 
1 
— 
4 
P2 
_ 
1 
3 
— 
4 
DY 
_ 
_ 
_ 
3 
3 
Toul 
15 
TABLE 1I-W0LFE CLASSIFICATION IN WOMEN WITH BREAST 
CANCER AND IN CONTROLS 
Wolfe classification in 1975 -76 
N1 
PI 
P2 
DY 
Breast cancer in 1981-82 
Yes ( n - 2 0 ) 
b(30%) 
6 (ЛМЬ) 
8 {40%) 
0(0%) 
No (η = 60) 
8 (IJ%) 
\b{27%) 
29 (*(%) 
7 (12%) 
TABLE Ill-RELATIVE-RISK ESTIMATES (ODDS RATIO) FOR P2 +DY 
(BASED ON DATA IN TABLE II) 
Wolfe 
classification 
N l + P l 
P2+DY 
No of 
cases 
12 
8 
No of 
controls 
24 
36 
Crude 
OR (95% CI) 
1 
0-4 (0-2, 1-2) 
Multivariate 
OR (95% CI) 
1 
0-7 (0-2, 2-4) 
OR"odds ratio CI = confidence interval 
- 162 -
RepToducibilny 
To test reproducibility 35 of the study subjects were 
selected at random For each of them the left radiographs 
taken at all four screening examinations were independently 
reclassified into the 4 categories by the radiologist without 
reference to the first classification 19 (13 7%) of the 140 
mammographs were classified differently, but into an 
adjacent category Spearman's correlation coefficient was 
0-88 
Discussion 
According to Wolfe the mammographie breast pattern is a 
strong predictor for breast cancer Others, however, report a 
risk ratio of only 5 or less 2 7 Wolfe's study was hospital-
based, and selection bias might explain the difference in 
results The mammographie density of breast tissue 
diminishes with age 60% of Wolfe's cancer series were under 
age 50, whereas in the total population breast cancer is mostly 
diagnosed over age 50 As a consequence of this DY cases may 
have been over-represented Furthermore, in Wolfe's study 
the follow-up time of the N1 +P1 and P2 + DY groups are not 
given If the latter group has longer follow-up it is likely to 
include more incident cases 
In the Nijmegen study there is no selection bias with 
respect to follow-up, because the period between the first and 
last mammographie examinations is always 6 years It is also 
unlikely that women with a specific breast pattern and risk of 
breast cancer are over-represented in our study, because all 
subjects were selected from an 80% sample of the female 
population of Nijmegen 
If breast cancer risk factors are related to parenchymal 
pattern, confounding bias may distort the risk ratio Seven 
risk factors appeared to be related to breast pattern and were 
taken into account in data analysis The intra-observer 
reproducibility of the classification of the mammographs was 
high (Spearman r=0-88) and unlikely to bias the ratio 
measure 
The Nijmegen study, with a retrospective design, 
challenged Wolfe's result there were more cases in the 
N1 + Ρ1 group than in the P2 + DY group In the population 
screening project in Kopparberg, Sweden, a strong relation 
was found between P2 + DY and existing breast cancer But 
for cases arising during the 1 year of follow-up the risk ratio of 
P2 + DY relative to N1 +P1 was 0·93 among women under 
age 55 7 
The growth rates of carcinomas detected at screening are 
thought to be lower than those of carcinomas diagnosed 
between screening examinations (length-biased sampling) " 
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Tumour growth rate might be related to breast parenchymal 
pattern. With early material from the Nijmegen screening 
project Holland et al showed that nearly 70% of cancers 
diagnosed between screenings were situated in dense breasts 
of the P2 and DY types 14'15 
Possibly our screen-detected case series was not 
representative with respect to growth rate and parenchymal 
pattern. To adjust for this, Wolfe's classification was applied 
to cases diagnosed between the third and fourth screenings. 
Adding this series to the screen-detected cancer series, we 
found an odds ratio of P2 + DY relative to N1 +P1 of 0-8. 
This ratio was adjusted for age with the Mantel-Haenszel 
procedure.16 The 95% confidence limits were 0-4 and 1 ·θ. 
We thank Ms Η Rijken and Dr E Muldenje, ofthe Radboud University 
Hospital, Nijmegen, and the personnel of the screening centre for their help, 
Mr H Straatman, of the Department of Social Medicine, Nijmegen, for the 
data analysis, and Dr L Tabar, of the breast cancer screening project in 
Kopparberg, Sweden, for reviewing the breast pattern of the Nijmegen 
interval-cancer cases 
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The results suggest that parenchymal patterns are not very useful in 
selective screening. Because of the small numbers, the Nijmegen study did 
not examine the age-specific effects. 
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ORAL CONTRACEPTIVE USE AND BREAST CANCER RISK 
Introduction 
The role of endogenous hormones in the etiology of breast cancer has 
raised the suspicion that oral contraceptive use is a breast cancer risk fac-
tor , but there is little evidence to that e f f e c t . 7 - 2 3 However, THE LANCET of 
22 October 1983 published a paper claiming there is a strong relation between 
long-term oral contraceptive (OC) use by young women and breast cancer 
r i sk . 2 * By means of a case-control study, the OC history of 314 young breast 
cancer patients (age <37) and 314 healthy neighbourhood controls were com-
pared. The f i rst group had used OCs longer and started using them at an 
earlier age than the control group. The most str iking result was that long-
term use before age 25 of a combination type of contraceptive with a high 
content of the progestogen component, proved to be associated with increased 
breast cancer r isk: the risk ratio after 5 years of OC use was 4 , with a low-
er 95% confidence limit > 1 . Many points of criticism were raised against this 
study, e . g . it was objected that the number of subjects that used "high pro-
gestogen" OCs before age 25 was too small (29 breast cancer cases and 6 con-
trols with more than 4 years' use) ; and that although the controls were indi-
vidually matched on age and neighbourhood, some more potential confounding 
risk factors should have been analysed. Moreover, no validation was given of 
the recalled use of OCs. The authors proposed a new hypothesis for the 
observed relation. A long and frequently anovular cycle was claimed to be 
less carcinogenic than an ovular cycle. If this cyclical pattern is broken by 
OCs (increasing mitotic activity in the breast tissue) the relative protection 
against breast cancer is reduced. 
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The Nijmegen screening data were used for a case-control study to investi­
gate the association between OC use and breast cancer development. Unfor­
tunately, data of women screened in 1975-76, 35-64 years old at t h a t time, 
had to be used. Only a minority could have used OCs before age 25, because 
they were not introduced in the Netherlands until the early '60s. 
Methods 
Cases: the case-group consists in principle of all patients diagnosed among 
participants in the Nijmegen screening programme in the period 1975-82 
(se ree η-detected cases, interval cases, and pseudo-interval cases). In addi­
t ion, to be eligible for the case-group, patients had to be younger than age 
55 at diagnosis. 
Controls: the control group is made up of women selected at random from 
the statistical tape of the screening programme, after it had been stratif ied 
according to attendance and age <55 at the time of the case's diagnosis. 
Additional criteria for all subjects of the case-control study were premeno­
pausal status at diagnosis and attendance of the f i r s t screening round in 
1975-76. In this round an extended questionnaire was offered to obtain infor­
mation on personal characteristics, medical history, and risk factors for 
breast cancer. To answer the question on OC exposure 3 periods (in calendar 
years) could be filled in on the questionnaire form. On the basis of these 
data an estimate of the total duration of contraceptive use can be calculated. 
The OC exposure was classified in 2 ways: never versus ever use and d u r a ­
tion of use ( D ) in D=0; 0<D<2; 2<D<4 and D>4 y e a r s . As potential confound­
ing factors the following variables were included in the study: age, mammo­
graphie breast pattern according to Wolfe, marital status, obesity (Quételet 
index, we igh t /he igh t 2 ) , par i ty , and age at f i rs t b i r t h . 
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Analysis: 119 breast cancer patients and 205 controls were studied in the 
analysis. The premenopausal subjects in this case-control study stemmed from 
a greater study including all Nijmegen breast cancer patients, for each of 
whom 2 controls were randomly sampled. The risk ratio was estimated in terms 
of its odds ratio approximation. The confidence interval was computed by 
means of Miettinen's test-based method. To adjust for the potential confound­
ing effects of the risk factors mentioned, the Mantel-Haenszel odds ratio was 
calculated, and the multiple logistic regression f i t ted by the method of maxi­
mum likelihood was appl ied. 2 5 In the analysis all r isk factors were dichotom­
ized. 
Results 
45% of the cases and 49% of the controls have at one time used OCs. The 
breast cancer risk ratio for the criterion ever-never use is 0.86 (95% confi­
dence interval 0.54; 1.35). The results are summarized in table 10.6. 
Table 10.6 Oral contracept ive use for premenopausal b r e a s t cancer cases and 
contro l s 
ι 1 
I 0C Case Control ОС-duration Case Control OR (95% CI) | 
| Ever use 54 101 D=0 years 65 104 1 (reference) | 
| Never use 65 104 0<D<2 13 20 1.04 (0.48 ; 2.24) | 
| Total 119 205 2<D<4 13 24 0.87 (0.41 ; 1.82) | 
| 4<D 28 57 0.79 (0.45 ; 1.36) | 
I OR=0.86; 95% CI=(0.54 ; 1.35) Total 119 205 | 
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This table also displays the effect of 2-year categories for duration of OC 
use. 24% of the cases and 28% of the controls used OCs for at least 4 years. 
No dose-response relation was found. The Mantel-Haenszel odds ratios of 
(n )ever use and breast cancer risk adjusted for 6 risk factors separately, are 
presented in table 10.7. 
Table 10.7 Crude and adjusted odds r a t i o s of OC use and breas t cancer 
1 
Factor adjusted 
None 
Mammographie breast 
pattern (Wolfe) 
Year of birth 
Marital status 
Quételet-index 
Parity 
Age at first birth 
Categories 
. 
Nl+Pl; P2+DY 
1910-29; 1930-39 
(n)ever married 
<26,29НЬё/ш2) 
0; 1+ child(ren) 
<28, 29+ years 
0R-MH 
0.86 
0.87 
0.93 
0.87 
0.86 
0.94 
0.96 
1 
(95% CI) | 
(0.54 ; 1.35) | 
(0.55 
(0.58 
(0.54 
(0.55 
(0.58 
(0.39 
1.38) | 
1.47) | 
1.38) | 
1-35) | 
1.51) | 
2.36) | 
I 
T h e multivariate risk ratio of ever OC use was 1.03. The coefficients and 
standard errors of the logistic models (upon successive inclusion of the β 
confounders) are given in appendix 1 0 . 1 . 
Conclusions 
The findings in this analysis did not show any association between oral 
contraceptive use and breast cancer r isk. 26% of the study subjects had used 
OCs for at least 4 years and 10% for at least 8 years. No dose-response rela-
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tionship was found. Because of the small numbers, this study could not eval -
uate the results of previous studies which claim certain groups of women to 
be at particular risk due to OC use, v iz . women with benign breast disease 
and women with a family history of breast cancer." 1 1 1* Nor could the f ind -
ings of a recent publication be reproduced suggesting OC use before age 25 
increases breast cancer r isk. Just 3 such cases were included in this study. 
Some fur ther statistical remarks about the observed odds ratio are presented 
in appendix 10.2 in terms of a power curve and a chi-square function. 
It was impossible to validate the OC use of the subjects. Recall bias may 
account for the absence of an association, although the OC exposure was 
determined before diagnosis. The controls were originally stratified according 
to attendance rates, to avoid problems like selection bias. It is possible that 
regular and irregular attenders differ with respect to OC use. 
None of the 6 confounding factors perceptibly altered the odds ratio est i -
mate. Logistic regression analysis controlling all 6 factors simultaneously, 
yielded similar results. 
Because there is not any relation between oral contraceptive use and 
breast cancer risk among premenopausal women, it would be pointless to apply 
OC use as a criterion to establish groups of women for selective screening. 
In the study presented here parenchymal pattern was put forward as a poten-
tial confounder. The data of the OC study were also used to reevaluate the 
relation between mammographie breast pattern according to Wolfe and breast 
cancer r isk, this time among premenopausal women. The rate ratio for women 
with P2 and DY breast type in comparison with women of N1 and PI breast 
type was now estimated at 1.85 (95% confidence interval 1.13 to 3 . 0 1 ) , after 
adjustment for the major risk factors. This result corresponds with the claim 
found in medical l i terature, that parenchymal patterns in young women are 
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predictive of breast cancer. In due time another study on this subject, and 
on the inter-observer variability in the classification of breast tissue will be 
conducted in Nijmegen. If the positive relation in younger women is con-
firmed, this can have implications for mammographica! screening. A policy 
could be devised offering young women with P2 and DY pattern more screen-
ing examinations. 
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Appendix 10.1 Logistic regression analyses for oral contraceptive use and breast cancer. All variables are dichotomised 
Variable Relative to Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 
Intercept - -0.470(0.158) -0.755(0.187) -1.279(0 272) -1.350(0.282) -1.352(0.283) -1.447(0.304) 
1.Ever use never use - 0 . 1 5 6 ( 0 . 2 3 1 ) - 0 . 0 7 8 ( 0 . 2 3 6 ) - 0 . 0 5 5 ( 0 . 2 3 9 ) 0 . 0 1 9 ( 0 . 2 5 1 ) 0 . 0 1 4 ( 0 . 2 5 2 ) 0 . 0 2 8 ( 0 . 2 5 3 ) 
ι 2.Born 1920-29 1930-39 0.766(0.249) 0.862(0.256) 0 . 8 7 4 ( 0 . 2 5 6 ) 0 . 8 8 5 ( 0 . 2 5 7 ) 0 . 8 6 1 ( 0 . 2 5 8 ) 
-»4 3 . M a m m o g r a p h i e 
W 
ι p a t t e r n (Wolfe) 
P2+DY Nl+Pl 0 .723(0.259) 0.680(0.265) 0 . 6 9 1 ( 0 . 2 6 4 ) 0 . 7 5 1 ( 0 . 2 7 4 ) 
4.No c h i l d r e n 1+ c h i l d r e n 0 . 3 0 4 ( 0 . 3 1 2 ) 0 . 5 5 3 ( 0 . 4 0 4 ) 0 . 5 7 8 ( 0 . 4 0 4 ) 
5 . ( E v e r ) m a r r i e d never m a r r i e d - 0 . 4 7 1 ( 0 . 4 8 6 ) - 0 . 4 6 2 ( 0 . 4 8 7 ) 
ô . Q u e t é l e t - i n d e x 
29+ £28 0 .311(0 .343) 
-2 log likelihood 425.60 416.12 407.99 407.04 406.10 405.28 
Appendix 10.2 Statistical comments on the observed relation between OC use 
and breast cancer risk 
The results of the case-control study evaluating the relation between oral 
contraceptive use and breast cancer risk are summarized in table 1. 
Table 1 
Total 
155 
169 
324 
ι 
54*104 
The odds ratio was estimated at .^^___ = Q 86 
65*101 
Assuming all the marginal totals (119, 205, 169, and 155) are fixed, one can 
test the hypothesis that 0R= 1 i.e. that there is not any association between 
OC use and breast cancer risk. Assuming this, the distribution of the expected 
number of A cases (see table 2) is approximately normal. 
OC 
Ever use 
Never use 
Total 
Case 'Control 
1 
54 I 101 
65 104 
119 205 
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I 
1 Ever use 
| OC 
| Never use 
1 
Table 
Case 
A 
С 
ni 
2 
Control 
1 
в I 
1 | 
D 1 
1 
nO 
1 
ml 
mO 
N 
ι 
The mean A(l) of this normal distribution is the positive root of the 
quadrat ic equat ion : 
A(l)*[mO-nl+A] 
[nl-A]*[mO-nl+A] 
= 1 •* A(l) = 56.93 
The var iance of A(l) of t h e approximately normal d i s t r i b u t i o n i s defined a s : 
Var(A(l))= 
1 1 1 1 
AU) B(l) C(l) D(l) J 
Var(A(l)) = 18.788 
These calculated values can be used to define an interval with lower limit a-1 
and upper limit a-u, such, that the probability of observing a "ever use 
cases" outside this interval is 
Pr (a <a-l)= 0.025 
Pr (a >a-u)= 0.025 
Whenever the outcome a (the observation a of A) lies in the interval (a-1; a-v.) 
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the hypothesis of no relation (0R= 1) is accepted, otherwise rejected. The 
acceptance region of this hypothesis is defined as: 
A(l) ± 1.9б/[Уаг (A(l))] 
56.96 ± 1.96V18.788 = (50.02 ; 63.89) 
which is the acceptance region of the test. The observed number of "ever use 
cases" in table 1 was 54, and of intermediate size in relation to the 
acceptance region just calculated •* the hypothesis 0R= 1 is not rejected. If 
an association between OC use and breast cancer risk (OR^l) is assumed, the 
left upper cell entry of table 2 is again normally distributed. The mean 
A(0R) of this distribution is the positive root of 
A(OR)»[m0-nl+A(OR)] 
[ml-A(0R)]*[nl-A(0R)] 
OR 
and the variance of A(0R) is defined as 
Var(A(0R)) 
1 1 1 1 
+ + + 
A(0R) B(0R) C(0R) D(0R) 
Acceptance of the hypothesis 0R= 1, when it is false (because ORi*!) is called 
a type II error. The size of a type II error is the probability that a type II 
error is made. The probability that a (ever use cases) lies outside the 
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acceptance region, the OR given, is called the power. For several ORs from the 
interval [0.2; 3.0] the probability Pr[reject the hypothesis of no association 
| given OR^l] was calculated. See figure 1. 
Power: chance of 
rejecting 0R= 1 
1.00-1 
0.80 • 
0.60 -
0.40 
0.20 
0.00 
-i 1 Γ-
0.Д 0.8 1.2 1.6 2.0 Odds ratio (hypothetical) 
Figure 1 Power (probability of not making a type II error) as a 
function of OR; 54 out of 119 cases and 101 out of 205 controls with 
OC use 
From figure 1 it can be derived e.g. that, given the marginals, the 
probability of detecting 0R= 2 at the 5% level of statistical significance is 
almost 85%. Given an actual 0R= 1.5, the power is + 40%, which means an 
almost 60% chance that, given the marginals, this OR is rejected in favour of 
0R= 1. 
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In the preceding paragraph it was checked whether the observed OR differs from 
OR equals 1. Recently MIETTINEN (Boston, unpublished manuscript 1962) has 
propagated a different approach to the observed effect measure. To what extent 
is the observed OR in cases and controls in agreement with a hypothetical OR 
in the population which the cases and controls were sampled from? He uses a 
function based on the difference between the estimated OR and the hypothetical 
OR. This function is X 2 (one degree of freedom) distributed, if the 
hypothetical value is valid in the population. This makes it possible to 
determine whether the observed OR corresponds with the hypothetical OR in the 
target population. The x2-function, constructed with the formulas of 
Miettinen's manuscript, is presented in figufe 2. 
I 
χ (OR): measure of disagreement 
of hypothetical OR and observed OR 
40.00 
30.00 . 
20.00 
(hypothetical) 
Figure 2 Chi-square as a function of OR; 54 out of 119 cases and 
101 out of 205 controls with OC use 
A X2(0R)= 3.84 corresponds with 0R= ±0.55 and 0R= ±1.35, suggesting that ORs 
between these 2 values are likely to yield the estimated 0R= 0.86 in the case-
control study. 
SUMMARY 
This thesis evaluates the estimates of the effect of screening with mammog-
raphy on the breast cancer mortality in Nijmegen in the period 1975-1982. The 
screening project started in Nijmegen in 1975. All Nijmegen women born 
before 1940 (N= 30,000, at that time age 35+ ) were invited to a biennial exam-
ination. The efficacy was analysed by means of a case-control design. A 
study was made of the screening histories of 62 breast cancer deaths and 310 
controls matched on year of b i r th . The breast cancer mortality in the 
screened group was 0.53 times as low as in the unscreened group (95% confi-
dence interval 0.26; 1 .08) . Residential district and marital status did not 
have any confounding influence on the effect measure. A stronger effect was 
observed in the group of women who had more screening examinations. 
Stratification according to bir th cohort showed there is not (ye t ) any effect 
in the youngest cohort, aged 35-49 at en t ry . It is unclear whether this can 
be explained by aggressive tumour growth, by too low a sensitivity of the 
mammographical test in this age-group, by too short a follow-up, or by 
chance. 
The survival analysis of participant and nonparticipant cases is likely to 
be subject to an as yet unknown degree of length time bias, selection bias, 
and overdiagnosis bias. The interpretation of the results of the survival anal-
ysis is therefore speculative. 
Although a strong efficacy was estimated there has not (yet ) been a fall in 
the total breast cancer mortality figure in Nijmegen. A large variance in the 
annual number of deaths is not unusual. I t is fur ther suggested that the 
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maximum effect in the total population, given a 2/3 attendance rate , is not 
expected until the late 1990s. 
Prolonged follow-up studies are required to prove that the screening pro-
gramme actually prevents breast cancer death. A study of the negative 
aspects of screening and a costs-effectiveness study must be initiated to 
gather sufficient and adequate data before a decision is made to implement a 
nation-wide screening programme. On the basis of a comparison with the inci-
dence rates in Arnhem the possibility of overdiagnosis in Nijmegen cannot be 
ruled out. 
The option of selective screening of h igh-r isk groups is concisely dis-
cussed. Little effect is expected. Finally the relation between oral contracep-
tive use and breast cancer risk in premenopausal women is studied. No asso-
ciation has been found. 
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SAMENVATTING 
Dit proefschrift beschrijft het effekt van screening met behulp van mam-
mografie op de borstkankersterfte in Nijmegen in de periode 1975-1982. Het 
bevolkingsonderzoek is in 1975 van start gegaan. Alle Nijmeegse vrouwen 
geboren voor 1940 (N= 30.000, destijds 35 jaar en ouder) werden voor een 
2-jaarlijks screeningsonderzoek uitgenodigd. De werkzaamheid van de screen-
ing werd geanalyseerd met behulp van een patient-kontrole onderzoek. Bij 62 
aan borstkanker overleden vrouwen en 310 op geboortejaar gematchte kon-
troles werd nagegaan of zij zich, na een uitnodiging daartoe, al of niet heb-
ben laten screenen. Aldus werd bepaald dat de sterfte aan borstkanker in de 
gescreende groep 0.53 maal zo laag was als in de niet gescreende groep (95% 
betrouwbaarheidsinterval 0.26; 1 .08) . De faktoren woonwijk en burgerl i jke 
staat hadden geen verstorende invloed op de effektmaat. Een sterker effekt 
werd waargenomen bij vrouwen die meerdere malen gescreend waren. Na 
opsplitsing volgens geboortekohort bleek in het jongste geboortekohort van 
vrouwen die bij het begin van het bevolkingsonderzoek 35-49 jaar oud waren 
geen effekt op de borstkankersterfte aantoonbaar te z i jn . Het is onduidelijk of 
dit te wijten is aan een agressieve groei van het carcinoom of een te lage 
sensitiviteit van de mammografie in deze leeftijdsgroep, door een te korte 
fol low-up periode of door toeval. 
De analyse van de overlevingskansen van patiënten die al dan niet deelna-
men aan het screeningsprogramma, werd bemoeilijkt door een nog niet te 
bepalen mate van invloed van "length time bias", "selection bias", en "over-
diagnosis bias". De interpretatie van de resultaten van deze analyse is bijge-
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volg arb i t ra i r . Ondanks de hoge mate van werkzaamheid die werd berekend, 
werd nog geen daling van de totale borstkankersterfte in Nijmegen waargeno-
men. Opgemerkt dient te worden dat het jaarlijks aantal sterfgevallen van 
borstkanker in Nijmegen een grote variatie kent , bovendien wordt bij een 
opkomst van 2/3 het maximale effekt voor de totale bevolking pas in de twee-
de helft van de jaren 90 verwacht. Een langerdurend vervolgonderzoek zal 
nodig zijn om aan te tonen dat het bevolkingsonderzoek daadwerkelijk het 
overlijden aan borstkanker kan voorkomen. Er zal met een uitgebreid onder-
zoek naar de neveneffekten van screening als mede een kosten-effektiviteits 
analyse begonnen moeten worden ter levering van voldoende en adekwate 
gegevens alvorens te besluiten tot al of niet starten van een landelijk bevolk-
ingsonderzoek. Op basis van een vergelijking met de incidentiecijfers in A r n -
hem kan het bestaan van overdiagnostiek in Nijmegen niet worden uitgesloten. 
Tot slot werd kort ingegaan op de mogelijkheid te komen tot afbakening 
van zogenaamde "high-r isk groups". Weinig effekt wordt hiervan verwacht. In 
dit kader werd tevens de relatie onderzocht tussen het gebruik van orale 
contraceptiva en het optreden van borstkanker bij premenopausale vrouwen. 
Er werd geen verband aangetoond. 
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Stellingen 
1 
Het is met juist bij de voorl icht ing in de media op het gebied van de kankerbestri j-
ding mededelingen aan het publiek te doen voordat de onderzoeksresultaten in een 
medisch t i jdschr i f t met een onafhankelijk referentensysteem gepubliceerd z i jn. 
Naar aanleiding van F.S.A.M. van Dam 
Voorlichting over kankerbehandeling en de media. Ned Tijdschr Geneeskd 1984; 128: 
35-36. 
2 
Dat het ziektestadium van intervalcarcmomen - carcmomen gediagnostiseerd tussen 
twee opeenvolgende screenmgsonderzoeken - minder vergevorderd is dan dat van 
met-gescreende borstkankerpatiënten, wordt eerder verklaard door het fe i t dat in-
tervalcarcmomen sneller groeien waardoor eerder verschijnselen optreden, dan door 
het e f fekt van voorl icht ing over borstzelfonderzoek zoals gesuggereerd m het 
2 Interimadvies van de Gezondheidsraad inzake de vroege opsporing van borstkan-
ker (1984, pagina 25). 
3 
De stell ing in het Nederlands Ti jdschri f t voor Geneeskunde 1983; 127: 2417 dat 
men, vanwege het vermijden van vertekening bij een oorzaak-gevolg relat ie, een 
aanzienlijk vertrouwen kan stellen m een gerandomiseerd onderzoek, een redelijk 
vertrouwen m een cohortonderzoek en slechts gering vertrouwen m een patiënt-kon-
t ro le onderzoek is met alleen m str i jd met de prakt i jk m de epidemiologie, maar 
ook een onderwaardering van de betekenis van het pat iënt-kontrole onderzoek. 
4 
Het opvragen van consultatiebureau gegevens is een beter diagnosticum voor re-
t ract ie le testes dan de toediening van LHRH via neusspray. 
Naar J.M. Borghans-Delvaux en J.K. Geeraedts-Feuerberg. Ned Tijdschr Geneeskd 
1985; 129: 35. 
5 
Alvorens de ethische toelaatbaarheid van bloeddoping te bespreken, is het gewenst 
eerst een gerandomiseerd onderzoek bij topsporters uit te voeren naar het ef fekt 
van bloeddoping op de sportprestatie. 
6 
Het in werking treden van de Mammoetwet in 1968 met onder andere het verplicht 
kiezen van een beperkt vakkenpakket heeft met geleid to t een hoger kennisniveau 
en betere studieprestaties van de studenten in het hoger wetenschappelijk onderwijs. 
7 
Zowel de goede voedingstoestand van de Nederlandse bevolking als het ontbreken 
van bewijsmateriaal over de relat ie tussen vi taminedef ic iënt ie en het optreden van 
neurale buisdefekten zetten vraagtekens bij het nut van preventieve toediening van 
vitaminepreparaten aan gravidae. 
8 
Opsplitsing van de epidemiologie m deelgebieden als kankerepidemiologie of hart-
vaatziektenepidemiologie heeft een nadelig ef fekt op de ontwikkel ing van de epide-
miologie als discipline. 
9 
Ter ver l icht ing van de f inanciële lasten dienen promovendi meer gebruik te maken 
van de mogelijkheid te promoveren op art ikelen. 
Nijmegen, 26 april 1985 
A.L .M. Verbeek 
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